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A B S T R A C T
Background
Hyperemesis gravidarum is a severe form of nausea and vomiting in pregnancy affecting 0.3% to 1.0% of pregnancies, and is one of the
most common indications for hospitalization during pregnancy. While a previous Cochrane review examined interventions for nausea
and vomiting in pregnancy, there has not yet been a review examining the interventions for the more severe condition of hyperemesis
gravidarum.
Objectives
To assess the effectiveness and safety, of all interventions for hyperemesis gravidarum in pregnancy up to 20 weeks’ gestation.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register and the Cochrane Complementary Medicine Field’s Trials
Register (20 December 2015) and reference lists of retrieved studies.
Selection criteria
Randomized controlled trials of any intervention for hyperemesis gravidarum. Quasi-randomized trials and trials using a cross-over
design were not eligible for inclusion.
We excluded trials on nausea and vomiting of pregnancy that were not specifically studying the more severe condition of hyperemesis
gravidarum.
Data collection and analysis
Two review authors independently reviewed the eligibility of trials, extracted data and evaluated the risk of bias. Data were checked for
accuracy.
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Main results
Twenty-five trials (involving 2052 women) met the inclusion criteria but the majority of 18 different comparisons described in the
review include data from single studies with small numbers of participants. The comparisons covered a range of interventions including
acupressure/acupuncture, outpatient care, intravenous fluids, and various pharmaceutical interventions. The methodological quality
of included studies was mixed. For selected important comparisons and outcomes, we graded the quality of the evidence and created
’Summary of findings’ tables. For most outcomes the evidence was graded as low or very low quality mainly due to the imprecision
of effect estimates. Comparisons included in the ’Summary of findings’ tables are described below, the remaining comparisons are
described in detail in the main text.
No primary outcome data were available when acupuncture was compared with placebo, There was no clear evidence of differences
between groups for anxiodepressive symptoms (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.73 to 1.40; one study, 36 women,
very low-quality evidence), spontaneous abortion (RR 0.48, 95% CI 0.05 to 5.03; one study, 57 women, low-quality evidence), preterm
birth (RR 0.12, 95% CI 0.01 to 2.26; one study, 36 women, low-quality evidence), or perinatal death (RR 0.57, 95% CI 0.04 to 8.30;
one study, 36 women, low-quality evidence).
There was insufficient evidence to identify clear differences between acupuncture and metoclopramide in a study with 81 participants
regarding reduction/cessation in nausea or vomiting (RR 1.40, 95% CI 0.79 to 2.49 and RR 1.51, 95% CI 0.92 to 2.48, respectively;
very low-quality evidence).
In a study with 92 participants, women taking vitamin B6 had a slightly longer hospital stay compared with placebo (mean difference
(MD) 0.80 days, 95% CI 0.08 to 1.52, moderate-quality evidence). There was insufficient evidence to demonstrate a difference in other
outcomes including mean number of episodes of emesis (MD 0.50, 95% CI -0.40 to 1.40, low-quality evidence) or side effects.
A comparison between metoclopramide and ondansetron identified no clear difference in the severity of nausea or vomiting (MD 1.70,
95% CI -0.15 to 3.55, and MD -0.10, 95% CI -1.63 to 1.43; one study, 83 women, respectively, very low-quality evidence). However,
more women taking metoclopramide complained of drowsiness and dry mouth (RR 2.40, 95% CI 1.23 to 4.69, and RR 2.38, 95%
CI 1.10 to 5.11, respectively; moderate-quality evidence). There were no clear differences between groups for other side effects.
In a single study with 146 participants comparing metoclopramide with promethazine, more women taking promethazine reported
drowsiness, dizziness, and dystonia (RR 0.70, 95% CI 0.56 to 0.87, RR 0.48, 95% CI 0.34 to 0.69, and RR 0.31, 95% CI 0.11 to
0.90, respectively, moderate-quality evidence). There were no clear differences between groups for other important outcomes including
quality of life and other side effects.
In a single trial with 30 women, those receiving ondansetron had no difference in duration of hospital admission compared to those
receiving promethazine (MD 0.00, 95% CI -1.39 to 1.39, very low-quality evidence), although there was increased sedation with
promethazine (RR 0.06, 95% CI 0.00 to 0.94, low-quality evidence) .
Regarding corticosteroids, in a study with 110 participants there was no difference in days of hospital admission compared to placebo
(MD -0.30, 95% CI -0.70 to 0.10; very low-quality evidence), but there was a decreased readmission rate (RR 0.69, 95% CI 0.50 to
0.94; four studies, 269 women). For other important outcomes including pregnancy complications, spontaneous abortion, stillbirth
and congenital abnormalities, there was insufficient evidence to identify differences between groups (very low-quality evidence for all
outcomes). In other single studies there were no clear differences between groups for preterm birth or side effects (very low-quality
evidence).
For hydrocortisone compared with metoclopramide, no data were available for primary outcomes and there was no difference in the
readmission rate (RR 0.08, 95% CI 0.00 to 1.28;one study, 40 women).
In a study with 80 women, compared to promethazine, those receiving prednisolone had increased nausea at 48 hours (RR 2.00, 95%
CI 1.08 to 3.72; low-quality evidence), but not at 17 days (RR 0.81, 95% CI 0.58 to 1.15, very low-quality evidence). There was no
clear difference in the number of episodes of emesis or subjective improvement in nausea/vomiting. There was insufficient evidence to
identify differences between groups for stillbirth and neonatal death and preterm birth.
Authors’ conclusions
On the basis of this review, there is little high-quality and consistent evidence supporting any one intervention, which should be taken
into account when making management decisions. There was also very limited reporting on the economic impact of hyperemesis
gravidarum and the impact that interventions may have.
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The limitations in interpreting the results of the included studies highlights the importance of consistency in the definitionof hyperemesis
gravidarum, the use of validated outcome measures, and the need for larger placebo-controlled trials.
P L A I N L A N G U A G E S U M M A R Y
Interventions for hyperemesis gravidarum
What is the issue and why is it important?
Although severe nausea and vomiting in pregnancy (hyperemesis gravidarum) rarely causes death, it is an important cause of ill
health with emotional, physical, and economic consequences. Women may need hospital treatment and may not be able to work
and it occasionally causes pregnancy complications and adverse outcomes for babies such as low birthweight. Many pharmaceutical,
complementary, and alternative therapies are available and the objective of this review was to examine the effectiveness and safety of
interventions for hyperemesis gravidarum.
What evidence did we find?
Twenty-five trials (involving 2052 women) were included examining 18 different comparisons covering a range of interventions
including acupressure/acupuncture, outpatient care, intravenous fluids, and various commonly used anti-sickness drugs. The quality
of included studies was mixed and for most outcomes findings were from single studies with low numbers of women taking part and
the evidence was assessed as being of low or very low quality. We have described findings for selected important comparisons below,
the remaining comparisons are described in detail in the main text.
There was no clear evidence of differences between acupuncture and placebo for symptoms of anxiety or depression, spontaneous
abortion, preterm birth or perinatal death.
There was insufficient evidence to identify clear differences between acupuncture and metoclopramide (an anti-nausea medication) for
reduction or cessation in nausea or vomiting.
Women taking vitamin B6 had a slightly longer hospital stay compared with placebo but there was no clear evidence of differences in
other outcomes including the average number of episodes of vomiting, hospital readmission rate, or side effects.
A comparison between two anti-nausea medications, metoclopramide and ondansetron, identified no clear difference in the severity
of nausea or vomiting, but more women taking metoclopramide complained of drowsiness and dry mouth. In a study comparing
metoclopramide with promethazine, more women taking promethazine reported drowsiness and dizziness but there were no clear
differences between groups for other important outcomes includingquality of life andother side effects. In a study looking at ondansetron
versus promethazine women spent similar lengths of time in hospital but there was increased sedation with promethazine.
Regarding corticosteroids, there was no difference in days of hospital admission compared to placebo, but there was a decreased
readmission rate. For other important outcomes including pregnancy complications, spontaneous abortion, stillbirth and congenital
abnormalities, preterm birth and side effects, there was insufficient evidence to identify differences between groups.
In a study comparing hydrocortisone (a corticosteroid) with metoclopramide, no data were available for primary outcomes, but there
was no difference in hospital readmission rate.
In a study comparing promethazine and prednisolone (a corticosteroid) those receiving prednisolone had increased nausea at 48 hours
but not at 17 days. There was no clear difference in the number of episodes of vomiting. There was insufficient evidence to identify
differences between groups for stillbirth and neonatal death and preterm birth
What does this mean?
Given that there was little evidence to support the superiority of one intervention over another in the treatment of hyperemesis, larger
controlled trials are needed on these therapies. More research should be done comparing the side effects and safety, as well as the
economic costs and benefits of these interventions to aid in the selection of the optimal treatment.
Reporting on adversematernal and infant outcomeswas limited andwe did not find any studies on dietary or other lifestyle interventions.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Acupuncture versus placebo
[Note: This table relates to the first comparison described in the abstract rather than the ’main’ or most important comparison presented in the review]
Patient or population: pregnant women with hyperemesis gravidarum
Setting: Studies in Croat ia (1) and UK (1)
Intervention: Acupuncture and acupressure
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Acupuncture
and acupressure
Quality of lif e: anxiode-
pressive symptomatol-
ogy
Study populat ion RR 1.01
(0.73 to 1.40)
36
(1 RCT)
⊕©©©
VERY LOW 12
Absolute ef fects calcu-
lated f rom results of
single study.800 per 1000 808 per 1000
(584 to 1000)
Spontaneous abort ion Study populat ion RR 0.48
(0.05 to 5.03)
57
(1 RCT)
⊕⊕©©
LOW 3
Absolute ef fects calcu-
lated f rom results of
single study.71 per 1000 34 per 1000
(4 to 359)
Preterm birth less than
37 weeks
Study populat ion RR 0.12
(0.01 to 2.26)
36
(1 RCT)
⊕⊕©©
LOW 3
Absolute ef fects calcu-
lated f rom results of
single study.154 per 1000 18 per 1000
(2 to 348)
St illbirth and neonatal
death
Study populat ion RR 0.57
(0.04 to 8.30)
36
(1 RCT)
⊕⊕©©
LOW 3
Absolute ef fects calcu-
lated f rom results of
single study.77 per 1000 44 per 1000
(3 to 638)
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1. Severity, reduct ion
or cessat ion in nausea/
vomit ing
2. Number of episodes
of emesis
3. Days of hospital ad-
mission
4. Intervent ion side ef -
fects
Not reported Not est imable Studies included in this
comparison did not re-
port these review out-
comes
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Single study with design lim itat ions contribut ing data
2 Small sample size and wide 95% CIs crossing the line of no ef fect
3 Small sample size, low event rate and wide 95% CIs crossing the line of no ef fect
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B A C K G R O U N D
Description of the condition
While nausea and vomiting in early pregnancy are very common,
affecting approximately 80% of pregnancies, hyperemesis gravi-
darum is a severe form affecting 0.3% to 1.0% of pregnancies
(Gadsby 1993; Niebyl 2010). The definition of hyperemesis gravi-
darum varies but generally includes intractable nausea/vomiting,
signs of dehydration such as ketonuria, high urine specific grav-
ity, electrolyte imbalances, and weight loss of at least 5% of pre-
pregnancy weight, excluding other diagnoses (ACOG2004;Mella
2011). The onset is generally in the first trimester at six to eight
weeks, peaking by 12 weeks, with most women having resolution
of symptoms by 20 weeks’ gestation (Jarvis 2011). The lack of
standard criteria has implications for inclusion criteria and out-
come measurements of controlled studies. For example, require-
ment of at least 5% weight loss is not always used as an inclusion
criteria in studies of interventions for hyperemesis gravidarum,
but one study found that the efficacy of corticosteroids may vary
depending on this criterion (Moran 2002).
It is important to exclude other causes of severe nausea and vom-
iting before arriving at the diagnosis of hyperemesis gravidarum.
Other causes include gastrointestinal (GI) etiologies such as infec-
tion, gastritis, cholecystitis, hepatitis, appendicitis, and pancreati-
tis. Neurological causes include migraines or other central nervous
system diseases. Genitourinary etiologies include urinary tract in-
fection/pyelonephritis. Metabolic or endocrine disturbances in-
clude hypercalcemia, Addisons’s disease, thyrotoxicosis. Psycho-
logical disorders include the spectrum of eating disorders. Finally,
other pregnancy-associated conditions such as molar pregnancy
must also be excluded (Ismail 2007; Mella 2011).
The epidemiology of hyperemesis gravidarum is generally young
women, primiparous, non-smokers, and non-Caucasian (Bailit
2005; Klebanoff 1985; Niebyl 2010). Other risk factors include
prior history of hyperemesis, pre-existing diabetes, hyperthyroid
disorder, depression or psychiatric illness, asthma, and GI disor-
ders (Fell 2006). Fetal abnormalities such as triploidy and hydrops
have also been associated with hyperemesis (Kelly 2009). The eti-
ology of hyperemesis gravidarum is poorly understood, although
it is generally thought to be associated with hormonal changes as-
sociated with pregnancy. Postulated mechanisms include human
chorionic gonadotropin stimulating secretory processes in the up-
per GI tract and/or stimulation of the thyroid stimulating hor-
mone receptor. Estrogen levels have also been positively associ-
ated with nausea and vomiting in pregnancy, perhaps through de-
layed GI motility and gastric emptying. Physiological stimulation
of the thyroid gland in early pregnancy causes a transient thyro-
toxicosis that may lead to hyperemesis. Several studies have found
a significant increase in Helicobacter pylori (H. pylori) infection
among women with hyperemesis, although whether this is a cause,
risk factor, or consequence of hyperemesis is not well established
(Ismail 2007; Kelly 2009).
Hyperemesis gravidarum has both maternal and fetal complica-
tions. Although hyperemesis gravidarum is rarely a source of mor-
tality, it is a significant source of morbidity. It is themost common
indication for hospitalization in early pregnancy, and the second
most common indication for hospitalization inpregnancy (ACOG
2004). Malnutrition and vitamin deficiencies may lead to anemia
and peripheral neuropathies, or more serious, but rare, compli-
cations such as Wernicke’s encephalopathy and central pontine
myelinolysis. Prolonged vomiting may lead to esophageal trauma
such as Mallory-Weiss tears. Nausea and vomiting in early preg-
nancy are associated with psychiatric morbidity. Although a causal
relationship is uncertain, the severity of nausea and vomiting has
been correlated with somatic symptoms, social dysfunction, anxi-
ety, insomnia, and severe depression (Ismail 2007; Kramer 2013;
Mella 2011; Swallow 2004). There may also be significant psy-
chosocial morbidity associated with hyperemesis. Multiple stud-
ies have demonstrated an association with decreased psychosocial
well-being, depression, and anxiety (ACOG 2004; Munch 2011;
Poursharif 2008). The physical and psychological/social burden
of hyperemesis gravidarum has also been associated with termina-
tion of pregnancy (ACOG 2004; Poursharif 2007). Fetal compli-
cations include preterm birth (delivery less than 37 weeks’ gesta-
tion), low birthweight (generally less than 2.5 kg), and small-for-
gestational age (less than the 10th percentile of expectedweight for
gestational age). There does not appear to be an increased risk of
spontaneous abortion (usually defined as less than 20 weeks), still-
birth (death of a fetus >= 20 weeks’ gestation or greater than 500
g), or neonatal death (death of a baby born live within 28 days of
birth) (Bailit 2005; Dodds 2006). The socioeconomic costs of hy-
peremesis are also significant, stemming from individual expense
in paying for treatment, lost job productivity from time off work,
and high healthcare costs related to provision of services and hos-
pital admissions.One study found that the cost of hyperemesis was
about $200,000,000 (USD) per year for the United States (Bailit
2005). Studies in Canada have estimated that severe nausea and
vomiting in pregnancy result in as many as 14 hospitalizations/
1000 births, and has a cost of $653/woman/week (CAD) (Neutel
2000; Piwko 2007).
Description of the interventions and how they
might work
A range of interventions are commonly used for the treatment
of hyperemesis gravidarum. These include dietary and lifestyle
modifications, complementary therapies (i.e. acupuncture, herbal
remedies), pharmaceutical therapies including a variety of classes
of antiemetics and corticosteroids, and enteral/parenteral nutri-
tion. The goals of therapy are generally to reduce nausea and vom-
iting, minimize hospitalization, prevent progression of symptom
severity, and improve quality of life. Prior studies examining in-
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tervention efficacy have used subjective measures of nausea/vom-
iting such as visual analogue scales (Sullivan 1996; Tan 2009) and
the Rhodes Index of Nausea, Vomiting, and Retching (Rhodes
1984; Rhodes 1999; Rosen 2003; Shin 2007), quantitative mea-
sures such as days of hospital admission and readmission rates,
and quality of life measures such as the General Health Question-
naire (Swallow 2004), and the Edinburgh Postpartum Depression
Screen (Bown 2008; Cox 1987; Kramer 2013). Secondary out-
comes often include adverse maternal and fetal outcomes. It can be
difficult to extrapolate safety data from trials designed to examine
efficacy because theymay not be powered to detect such outcomes,
and it is difficult to determine whether certain outcomes, such as
preterm delivery, are related to the intervention or the condition
of hyperemesis. However, given that some adverse outcomes, such
as congenital abnormalities, are not associated with hyperemesis,
data on some specific outcomes may be used to draw conclusions
on safety.
Non-pharmacological interventions
Dietary and lifestyle modifications
Dietarymodifications include recommendations to have small and
frequent meals, avoid spicy or fatty foods, and drink fluids reg-
ularly. Lifestyle modifications include avoiding noxious sensory
stimuli, eating crackers in the morning after waking, and increas-
ing rest. Although these are common recommendations, there are
few published studies evaluating the efficacy of these changes for
prevention or treatment of nausea/vomiting of pregnancy (ACOG
2004; Arsenault 2002; Matthews 2015).
Complementary therapies
There are a number of non-pharmacological therapies that have
been used for the treatment of nausea and vomiting in pregnancy
and hyperemesis gravidarum. Acupressure and electrical stimu-
lation wrist bands have been associated with benefit for nausea/
vomiting of early pregnancy, although the evidence is mixed and
limited (Heazell 2006; Ismail 2007; Matthews 2015; Mella 2011;
Rosen 2003; Shin 2007). Acupuncture has also been shown to
have some benefit in the treatment of nausea and vomiting in
pregnancy although again, the evidence is limited (ACOG 2004;
Carlsson 2000; Mella 2011). A Cochrane review evaluating its ef-
ficacy in nausea and vomiting in early pregnancy found one study
that demonstrated an improvement in severity of nausea and vom-
iting (Matthews 2015). These methods are based on traditional
Chinese medicine that specifies a point PC6 5 cm proximal to the
wrist crease that is associated with decreasing nausea. Acupuncture
and other stimulation at this point has been suggested to reduce
opioid-related post operative nausea as well as chemotherapy-as-
sociated nausea (Carlsson 2000).
Ginger
Ginger is another commonly recommended non-pharmacological
intervention for the treatment of nausea and vomiting in preg-
nancy. The active ingredient in ginger responsible for its thera-
peutic effect is not well understood but it has long been used as
a herbal medicine in Asian culture for the treatment of nausea
and vomiting in pregnancy. Several randomized controlled trials
have demonstrated a benefit of ginger in nausea and vomiting of
pregnancywithout any demonstrable adverse pregnancy outcomes
(Arsenault 2002; Matthews 2015; Mella 2011).
Intravenous fluids/enteral nutrition/parenteral nutrition
Hyperemesis gravidarum is commonly characterized by metabolic
and electrolyte disturbance requiring hospital admission, with the
initial therapy frequently being intravenous rehydration/repletion
of electrolytes. (ACOG 2004).
Both enteral and parenteral nutrition are used in refractory hy-
peremesis gravidarum. Complications of enteral nutrition can in-
clude infection, bleeding, tube dislodgement, preterm labor, and
discomfort for the woman (ACOG 2004; Saha 2009). Parenteral
nutrition is associated with a high incidence of complications in-
cluding infection, thrombosis, and mechanical failure, and there-
fore is recommended only in the failure of medical management
and enteral nutrition (ACOG 2004; Holmgren 2008).
Pharmacological interventions
A number of different classes of pharmaceutical agents have been
evaluated for the treatment of hyperemesis gravidarum.
Vitamin B6
Vitamin B6 or pyridoxine is commonly used as a first line treat-
ment for nausea and vomiting in pregnancy. It is a water soluble
vitamin used as a cofactor in a wide array of metabolic processes
and in the synthesis of nucleic acids and some neurotransmitters.
Used on its own, it is associated with a decrease in nausea but
not in vomiting (Mella 2011). Vitamin B6 has not been shown to
cause increased risk in major or minor congenital malformations
(Arsenault 2002; Mazzotta 2000).
Antihistamines
Antihistamines may act through different mechanisms. Doxy-
lamine is a H-1 receptor antagonist that had been used frequently
in combination with B6. When the combination B6 and doxy-
lamine was available in the United States, there was an associa-
tion with decreased admissions for hyperemesis, however it was
removed from the market secondary to safety concerns that were
later unfounded (ACOG2004; Ismail 2007). The combination of
doxylamine/B6 has been found to be both safe, with no evidence
of teratogenicity, and effective in the treatment of nausea and vom-
iting in pregnancy (Arsenault 2002; Mazzotta 2000; Mella 2011).
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H1-receptor antagonists such as doxylamine, hydroxyzine, and
diphenhydramine are thought centrally to reduce vestibular symp-
toms. There is one randomized controlled trial showing that
diphenhydrinate is as effective as ginger in the treatment of nausea
and vomiting of pregnancy (Pongrojpaw 2007).
H2-receptor antagonists such as famotidine and ranitidine act pe-
ripherally in reducing reflux, which may helpwith reducing symp-
toms of nausea and vomiting, although this has not been well
studied either.
A meta-analysis of antihistamines showed no increased risk of
congenital malformations, risk of miscarriage, or preterm delivery
(Gill 2009; Mella 2011).
Dopamine antagonists
Dopamine-2 antagonists such as metoclopramide stimulate GI
motility and have been shown to be effective in decreasing vom-
iting. Limited studies have demonstrated its safety in pregnancy
(Arsenault 2002; Mella 2011). Phenothiazines, such as promet-
hazine, are dopamine 2-receptor antagonists that act centrally to
suppress the chemoreceptor trigger zone (CTZ) that is responsible
for stimulating vomiting. These have been shown to be safe in
pregnancy with regards to teratogenicity (Arsenault 2002).
Benzodiazepines
Benzodiazepines such as diazepam are thought to be helpful in
the condition of hyperemesis gravidarum, presumably through
alleviating psychosomatic symptoms such as anxiety. However,
the safety of these medications in pregnancy is still controversial
with some studies demonstrating a positive association between
neonatal exposure to diazepam and prematurity and low birth
weight (Mella 2011; Tasci 2009).
Serotonin antagonists
Serotonin antagonists such as ondansetron also act centrally to
suppress the CTZ. Safety data are limited, animal studies and
small case studies have not demonstrated any teratogenic effect
(Mazzotta 2000). Recently, a large retrospective cohort study in
Denmark found no association between ondansetron and adverse
fetal outcomes (Pasternak 2013). Despite the limited safety and
efficacy data, its efficacy in treating chemotherapy-associated nau-
sea/vomiting has led to increased use of this medication (ACOG
2004).
Corticosteroids
Corticosteroids are often used as a last resort for treatment of
refractory hyperemesis. They have been used for the treatment of
chemotherapy-associated nausea and are postulated to modify the
CTZ. However, their use in early pregnancy has been associated
with oral cleft malformations, so it is generally reserved as a last
resort intervention (ACOG 2004; Arsenault 2002; Ismail 2007;
Mazzotta 2000).
Why it is important to do this review
Although a recent Cochrane review examined the efficacy and sa-
fety of many of these interventions for nausea/vomiting of early
pregnancy (Matthews 2015), there has not yet been a review as-
sessing interventions for the more severe condition of hyperemesis
gravidarum.
O B J E C T I V E S
To assess the effectiveness as well as maternal and fetal safety of all
published interventions for hyperemesis gravidarum.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomized controlled trials of any intervention
for hyperemesis gravidarum. We included randomized controlled
trials reported in abstract, provided that there was sufficient infor-
mation in the abstract or available from the author to allow us to
assess eligibility and risk of bias. We excluded quasi-randomized
trials and trials using a cross-over design. Multi-armed trials were
included and pair-wise comparison were conducted separately.
Types of participants
Pregnant women with a normal intrauterine pregnancy up to 20
weeks’ gestation diagnosed with hyperemesis gravidarum accord-
ing to the definition of the trials.
Types of interventions
We included all published interventions for hyperemesis gravi-
darum. Each intervention (i.e. acupressure or ondansetron) was
analyzed separately versus placebo or no treatment, and versus
other interventions. Compound interventions (i.e. ondansetron
and metoclopramide) were treated as single unique interventions.
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Types of outcome measures
For the sake of comparison, some outcomemeasures for this review
align with the outcome measures used in the previous Cochrane
review on interventions for nausea and vomiting in early preg-
nancy (Matthews 2015). The time frame for follow-up of out-
come measures, including maternal and neonatal safety data, was
defined by individual trials. The outcomes below are slightly dif-
ferent from what was initially published in the protocol for this
review. Severity of nausea/vomiting was added as a primary out-
come because it was found that this was often what was reported in
the included studies. Similarly, rather than reporting the number
of women requiring additional antiemetics, the outcome “number
of antiemetics required” was used instead as this was more often
reported.
Primary outcomes
Intervention efficacy
1. Severity, reduction, or cessation in nausea/vomiting
2. Number of episodes of emesis
3. Days of hospital admission
Secondary outcomes
Intervention efficacy
1. Hospital readmission
2. Number of women requiring additional antiemetics
3. Need for enteral or parenteral nutrition
Adverse maternal outcomes
1. Pregnancy complications (i.e. antepartum hemorrhage, pre-
eclampsia, gestational hypertension)
2. Weight loss
Adverse fetal/neonatal outcomes
1. Spontaneous abortion
2. Stillbirth and neonatal death
3. Congenital abnormalities
4. Low birthweight
5. Preterm birth
Quality of life
1. Quality of life outcomes including emotional,
psychological, and physical well-being
2. Intervention side effects
3. Decision to terminate the pregnancy
Economic costs
1. Direct financial costs to women
2. Productivity costs
3. Healthcare system costs
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s
(PCG) Trials Register by contacting the Trials Search Co-ordina-
tor (20 December 2015).
The Register is a database containing over 20,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate the PCG Trials Register including the
detailed search strategies forCENTRAL,MEDLINE,Embase and
CINAHL; the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current awareness
service, please follow this link to the editorial information about
the Cochrane Pregnancy and Childbirth Group in The Cochrane
Library and select the ‘Specialized Register ’ section from the op-
tions on the left side of the screen.
Briefly, the Cochrane PCG Trials Register is maintained by the
Trials Search Co-ordinator and contains trials identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a specific
PCG review topic (or topics), and is then added to the Register.
The Trials Search Co-ordinator searches the Register for each re-
view using this topic number rather than keywords. This results
in a more specific search set which has been fully accounted for in
the relevant review sections (Included, Excluded, Awaiting Clas-
sification or Ongoing).
In addition, we contacted the Cochrane Complementary
Medicine Field to search their Trials Register (20 September 2014)
and checked again via The Cochrane Register of Studies (CRSO)
(20 December 2015) (see: Appendix 1).
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Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
Selection of studies
Two review authors (RB and SB) independently assessed for in-
clusion all the potential studies we identify as a result of the search
strategy. We resolved any disagreement through discussion or, if
required, we consulted a third review author (AK).
Data extraction and management
We designed a form to extract data. For eligible studies, three
review authors (RB, SB, GS) extracted the data using the agreed
form.We resolved discrepancies through discussion or, if required,
we consulted a fourth author (AK). We entered data into Review
Manager software (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors (RB and SB) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreement by discussion or by involving an
additional assessor (AK).
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered studies to be
low risk of bias if they were blinded, or if we judged that the lack of
blinding would be unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomized participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or supplied by the trial
authors, we re-included missing data in the analyses.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomization);
• unclear risk of bias.
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(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
Wemade explicit judgements aboutwhether studies are at high risk
of bias, according to the criteria given in the Cochrane Handbook
(Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it likely to impact on the findings.
Assessment of the quality of the evidence using the
GRADE approach
For this update the quality of the evidence has been assessed using
the GRADE approach as outlined in the GRADE handbook in
order to assess the quality of the body of evidence relating to the
following outcomes.
1. Severity, reduction or cessation in nausea/vomiting
2. Number of episodes of emesis
3. Days of hospital admission
4. Intervention side effects
5. Quality of life outcomes including emotional,
psychological, and physical well-being
6. Pregnancy complications (i.e. antepartum hemorrhage, pre-
eclampsia, gestational hypertension)
7. Adverse fetal/neonatal outcomes (i.e. spontaneous abortion,
stillbirth and neonatal death, congenital abnormalities, low
birthweight, preterm birth)
We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
’Summary of findings’ tables. A summary of the intervention effect
and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Where reported, the above seven outcomes have been set out in
’Summary of findings’ tables. Other important outcomes such
as hospital readmission, pregnancy termination and the use of
additional antiemetics have been described in full in the results
section.
A broad range of interventions for hyperemesis gravidarum were
examined in the included trials and so to summarize findings, we
selected those non-pharmacological and pharmacological compar-
isons that we considered to be most clinically relevant. Findings
for nine different comparisons have been set out in the ’Summary
of findings’ tables.
1. Acupuncture versus placebo
2. Acupuncture versus metoclopramide
3. Pyridoxine versus placebo
4. Metoclopramide versus ondansetron
5. Hydrocortisone versus metoclopramide
6. Metoclopramide versus promethazine
7. Ondansetron versus promethazine
8. Corticosteroids versus promethazine
9. Corticosteroids versus placebo
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we planned to use the mean difference if
outcomes were measured in the same way between trials and the
standardized mean difference to combine trials that measured the
same outcome, but used different methods. We were unable to
pool continuous data becausemost trials had a unique comparison,
thus only the mean difference was used.
Unit of analysis issues
Cluster-randomized trials
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We planned to include cluster-randomized trials in the analyses
along with individually-randomized trials, however all included
studies were individually-randomized trials.
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensitiv-
ity analysis, however because most trials had a unique comparison
and we were unable to group most included studies, therefore a
sensitivity analysis was not performed.
For all outcomes, we will carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomized to each group in the analyses, and all partici-
pants were analyzed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomized minus any participants whose outcomes are known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either the T² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged to be sufficiently similar. If there was
clinical heterogeneity sufficient to expect that the underlying treat-
ment effects differ between trials, or if substantial statistical het-
erogeneity was detected, we used random-effects meta-analysis to
produce an overall summary, if an average treatment effect across
trials was considered clinically meaningful. The random-effects
summary was treated as the average range of possible treatment
effects and we discussed the clinical implications of treatment ef-
fects differing between trials. If the average treatment effect was
not clinically meaningful, we did not combine trials.
Where we used random-effects analyses, we presented the results
as the average treatment effect with 95% confidence intervals, and
the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
The majority of our analyses are based on data from single stud-
ies with small numbers of participants. If we had identified sub-
stantial heterogeneity, we planned to investigate it using subgroup
analyses and sensitivity analyses. In future updates, if more tri-
als are included, we will consider whether an overall summary is
meaningful, and if it is, use random-effects analysis to produce it.
We planned to carry out the following subgroup analyses:
1. women with weight loss of at least 5% of pre-pregnancy
weight versus women with weight loss of less than 5% of pre-
pregnancy weight;
2. singleton gestation versus twin gestations;
3. primiparous versus multiparous.
We planned to use the primary outcomes in subgroup analysis.
1. Severity, reduction, or cessation in nausea/vomiting. We
will examine outcomes measured by all commonly used
instruments to assess nausea and vomiting.
2. Number of episodes of emesis.
3. Days of hospital admission.
We planned to assess subgroup differences by interaction tests
available within RevMan (RevMan 2014). However there were
insufficient data to conduct a subgroup analysis.
Sensitivity analysis
We planned to perform sensitivity analysis in trials found to have
a high or unclear risk of attrition bias, and high or unclear risk of
other biases. However, because most trials were unique compar-
isons we did not carry out a sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
See: Figure 1).
12Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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The search strategy identified 78 total reports representing 67 dis-
tinct studies (some studies were resulted inmore than one publica-
tion). Of these 67 studies, 25 met inclusion criteria for the review,
35 were excluded, two are awaiting translation (and are listed in
Characteristics of studies awaiting classification) and five studies
are ongoing (see Characteristics of ongoing studies).
Included studies
Twenty-five studies (involving 2052 women) met inclusion crite-
ria. The included studies examined a range of interventions.
Non-pharmacological interventions
Acupuncture or acupressure at the P6 (or Neigun) point was ex-
amined in seven studies; in five studies it was compared with
placebo (Habek 2004; Heazell 2006; Mamo 1995; Miller 2001;
Shin 2007); in one study it was compared with metoclopramide
(Neri 2005); and in one study it was compared with Western
medicine (intravenous fluids, electrolyte repletion and phenobar-
bital) and Chinese medicine (Mao 2010). One study compared
the efficacy of progressivemuscle relaxationwith pharmacotherapy
versus pharmacotherapy alone (Gawande 2011). Pharmacother-
apy in this case consisted of the progressive use of doxylamine
succinate, ondansetron, metoclopramide, and promethazine. One
study evaluated intravenous hydration with dextrose saline versus
normal saline (Tan 2013). One study compared midwife-led out-
patient care versus routine carewith inpatient admission (McParlin
2008). One study examined holistic assessment with individual-
ized care plan and support and advice from nurses versus stan-
dard care (Fletcher 2015). There were no randomized controlled
trials on hyperemesis gravidarum that examined other dietary or
lifestyle modifications, or the use of ginger.
Pharmacological interventions
All studies recruited women with hyperemesis gravidarum or se-
vere nausea and vomiting of pregnancy, as defined by the authors.
The spectrum of severe symptoms necessary for inclusion in these
studies varied but included failure of outpatient therapy, need for
inpatient admission, ketonuria, weight loss, electrolyte imbalance.
The gestational age of pregnancy at which women were recruited
was generally in the first and second trimester (less than 20 weeks),
although one study included women up to 30 weeks, however
none of the women recruited were beyond 12 weeks (Shin 2007).
Most studies collected data on the severity, reduction, or cessation
in nausea and vomiting. However, pooling data was complicated
by variations in reporting and the individual time frames used.
Most studies used a 10-point visual analogue scale (VAS) for the
severity of nausea and/or vomiting, where a higher number repre-
sented more severe symptoms (Abas 2014; Ditto 1999; Kashifard
2013; Nelson-Piercy 2001; Sullivan 1996; Tan 2009; Tan 2010;
Tan 2013; Ziaei 2004). Other studies used individualized mea-
sures such as a scale of zero to two for nausea/vomiting/food in-
take/functioning (Neri 2005), and a “severity” and “relief ” scoring
system developed by the authors of Ylikorkala 1979. Other scales
such as the “Hyperemesis Impact of Symptoms Questionnaire”
(Fletcher 2015), the “Pregnancy Unique Quantification of Emesis
and Vomiting” (McParlin 2008), and the “Rhodes Index of Nau-
sea, Vomiting, and Retching” (Miller 2001; Shin 2007) were also
used. A number of studies reported on the number of episodes of
vomiting (Abas 2014; Bondok 2006; Kashifard 2013; Tan 2009;
Tan 2010; Tan 2013; Ziaei 2004). Other measures of nausea and
vomiting that we did not analyze included recurrence of vomiting
(Duggar 2001), number of antiemetics required and days required
to achieve no vomiting (Gawande 2011), lack of need for med-
ication (Habek 2004), number of antiemetic doses and need for
additional antiemetics (Heazell 2006), need for antiemetic med-
ication (Mamo 1995), and therapy failure defined by persistent
vomiting (more than five times/day), inability to tolerate liquids
bymouth, or the impression that the woman was not better (Safari
1998). In this review we chose to describe outcomes relating to
women’s nausea and vomiting at the time points reported by the
study. In addition to the severity of nausea/vomiting and num-
ber of episodes of emesis, our primary outcomes also included
the number of days of hospital admission, which was reported in
several studies (Abas 2014; Ditto 1999; Heazell 2006; McParlin
2008; Nelson-Piercy 2001; Sullivan 1996; Tan 2009; Tan 2010;
Tan 2013; Yost 2003).
Our secondary outcomes included intervention efficacy, which
included the number of women requiring additional antiemetics,
hospital readmission rate, and the need for enteral or parenteral
nutrition. The number of women requiring additional antiemetics
was reported in a few studies (Ditto 1999; Habek 2004; Nelson-
Piercy 2001; Safari 1998). Hospital readmission was reported by
several studies (Bondok 2006; Ditto 1999; Duggar 2001; Nelson-
Piercy 2001; Safari 1998; Tabatabaii 2008; Tan 2009; Ylikorkala
1979; Yost 2003). Only Bondok 2006 reported on the need for
enteral or parenteral nutrition.
Other secondary maternal and neonatal outcomes included ad-
verse pregnancy outcomes, pregnancy complications, and mater-
nal weight loss. A number of studies reported on adverse preg-
nancy outcomes and complications (Ditto 1999, Nelson-Piercy
2001, Heazell 2006, McParlin 2008, Safari 1998, Yost 2003).
A few studies reported change in weight (Nelson-Piercy 2001;
Sullivan 1996; Tan 2009; Ylikorkala 1979). Another secondary
outcome was quality of life, which included measures of qual-
ity of life, intervention side effects, and the decision to termi-
nate the pregnancy. A few studies that evaluated quality of a
life with a variety of measures including a Clinical Global Im-
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provement score (Gawande 2011), Anxiodepressive Symptom In-
dex (Habek 2004), pregnancy-unique quantification of emesis
and nausea (PUQE) score (McParlin 2008), well-being rating
(Nelson-Piercy 2001; Tan 2009; Tan 2010; Tan 2013), well-be-
ing verbal numeric rating scale (VNRS) (Abas 2014), and Short
Form (36) Health Survery (McParlin 2008). Several studies re-
ported on the number of women who decided to terminate the
pregnancy (Ditto 1999; Gawande 2011; Heazell 2006; McParlin
2008; Nelson-Piercy 2001; Safari 1998). Several studies also re-
ported on intervention side effects (Abas 2014; Duggar 2001;
Kashifard 2013; Sullivan 1996; Tan 2009; Tan 2010; Tan 2013;
Ziaei 2004). The final secondary outcome was economic costs,
which were only reported in one study (McParlin 2008).
Studies awaiting further assessment and ongoing
studies
There are two studies awaiting further classification. Translations
were not available for He 2009 or Eftekhari 2013.
There are five ongoing studies. Cyna 2008 is a randomized con-
trolled trial examining the efficacy of hypnosis on hyperemesis and
is still recruiting. One randomized controlled trial (Mehrolhasani
2012) evaluated demitron versus promethazine in the treatment
of hyperemesis gravidarum; according to the trial registry, recruit-
ment has been completed, but no results were found. We have
contacted the authors for information. Guttuso 2014 is a random-
ized trial comparing gabapentin and metoclopramide that is cur-
rently recruiting. Mitchell-Jones 2014 is a randomized controlled
trial comparing inpatient versus outpatient management of severe
nausea and vomiting of pregnancy that is also currently recruit-
ing. Finally, Koren 2014 is an ongoing multicenter randomized
controlled trial evaluating the safety and efficacy of doxylamine
succinate and pyridoxine hydrochloride (trade name Diclegis) in
nausea and vomiting of pregnancy; the inclusion criteria does not
specify hyperemesis gravidarum but there is no exclusion of severe
nausea and vomiting so the final study results may include a sub-
group of women with hyperemesis.
Excluded studies
After assessment of study eligibility, we excluded 35 studies. The
main reasons for exclusion were that the study was on nausea and
vomiting of pregnancy and not hyperemesis gravidarum (19 stud-
ies), or the study used a cross-over design (five studies). Two studies
were quasi-randomized, and in one study it was unclear whether
the study was randomized or quasi-randomized. Two studies were
not randomized controlled trials. Three studies were not reports
on trials. Finally, three studies were on prophylactic treatment for
prevention rather than treatment of the condition and as suchwere
excluded.
Risk of bias in included studies
Sequence generation (selection bias)
In 10 of the included studies, the methods used to random-
ize women were not described or were unclear (Duggar 2001;
Gawande 2011; Habek 2004; Mamo 1995; Mao 2010; McParlin
2008; Miller 2001; Sullivan 1996; Tabatabaii 2008; Ylikorkala
1979). The remainder of the studies were assessed to have ade-
quate randomization methods. Eight studies used computer-gen-
erated randomization list (Bondok 2006; Fletcher 2015; Kashifard
2013; Nelson-Piercy 2001; Neri 2005; Safari 1998; Tan 2013;
Yost 2003). Two studies used a random number table (Ditto 1999;
Ziaei 2004). Only one study used coin toss (Shin 2007) as a
method of randomization. Three studies used block randomiza-
tion (Abas 2014; Tan 2009; Tan 2010), and one study used exter-
nal randomization services (Heazell 2006).
Allocation
Fourteen of the included studies were unclear on allocation con-
cealment (Ditto 1999; Duggar 2001; Habek 2004; Kashifard
2013; Mamo 1995; Mao 2010; McParlin 2008; Miller 2001;Shin
2007; Sullivan1996;Tabatabaii 2008; Ylikorkala 1979; Yost 2003;
Ziaei 2004). One study was deemed to have a high risk of bias
in allocation concealment - Gawande 2011 reported treating ob-
stetricians were blinded to whether the women received a mus-
cle relaxation session, however there was no report on conceal-
ment of allocation, and the control group received no placebo in-
tervention. The remaining studies were judged to have adequate
allocation concealment. Four studies used a code that was held
by a third party: Bondok 2006 described using a withheld code
and identical appearing interventions. Nelson-Piercy 2001 used
sequentially numbered trial packs with the copy of the allocation
schedule held by the pharmacy, Neri 2005 used a code that was
held under the control of a midwife, Safari 1998 used envelopes
that were prepared in advance by a third party, although the en-
velopes were not specified to be opaque. Four studies described
using opaque, sealed envelopes (Abas 2014; Tan 2009; Tan 2010;
Tan 2013). One study described drawing ticket from an opaque
bag (Heazell 2006).One study reported random allocation done
remotely via telephone (Fletcher 2015).
Blinding
Blinding of participants was unclear or not described in 12 studies
(Ditto 1999; Duggar 2001; Kashifard 2013; Mamo 1995; Mao
2010; McParlin 2008; Miller 2001; Safari 1998; Tabatabaii 2008;
Tan 2009; Ylikorkala 1979; Ziaei 2004). There was a high risk of
bias in three studies. Gawande 2011, as mentioned previously, had
a control group of women called into the office but they received
no kind of placebo muscle relaxation intervention. Similarly, in
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Fletcher 2015 participants were not blinded. Neri 2005 had a
comparison group but no placebo intervention for acupuncture
or acupressure. The remainder of the studies were deemed to have
adequate participant blinding with masking of participants and
similar appearing interventions.
Blinding of outcome assessors was unclear or not described in
seventeen studies (Ditto 1999; Duggar 2001; Gawande 2011;
Heazell 2006; Mamo 1995; Mao 2010; McParlin 2008; Miller
2001; Neri 2005; Shin 2007; Sullivan 1996; Tabatabaii 2008; Tan
2010; Tan 2013; Ylikorkala 1979; Yost 2003; Ziaei 2004). Fletcher
2015 primary outcomes were self reported and the participants
were not blinded, thus was deemed to have a high risk of bias. The
remainder of the studies were deemed to have adequately described
blinding of investigators.
Incomplete outcome data
Attrition was either unclear or not reported in 13 studies (Bondok
2006; Ditto 1999; Duggar 2001; Habek 2004; Kashifard 2013;
Mamo 1995;McParlin 2008;Miller 2001; Neri 2005; Shin 2007;
Sullivan 1996; Tabatabaii 2008; Tan 2009). The remainder of the
studies were deemed to have a low risk of attrition bias, with a
low rate of attrition, accompanying reasons provided, and similar
numbers lost to follow-up in each comparison group.
Selective reporting
The risk of reporting bias was unclear or not described in six stud-
ies, five of which were abstracts in which there was not enough in-
formation to adequately judge the presence of bias (Duggar 2001;
Mamo 1995;McParlin 2008;Miller 2001; Tabatabaii 2008).Mao
2010 reported outcomes as described in the methods, however it
was unclear how the outcomes were measured, whether standard
tools were used or not, as such, we considered the risk of reporting
bias to be unclear. The remainder of the studies were deemed to
be low risk of reporting bias with expected outcomes reported, or
outcomes specified as being predetermined.
Other potential sources of bias
Most studies did not have enough information to adequately as-
sess the presence other forms of bias and as such were deemed
to have an unclear risk of bias. There was a high risk of bias in
one study. Nelson-Piercy 2001 reported that their trial was prema-
turely ended due to a combination of factors including departure
of key staff members and “the erroneous belief that steroids had
such a dramatic beneficial effect that continued randomization
was not justified”.
Figure 2 and Figure 3 provides a summary of our ’Risk of bias’
assessment.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Effects of interventions
See: Summary of findings for the main comparison
Acupuncture versus placebo; Summary of findings 2
Acupuncture versus metoclopramide; Summary of findings
3 Pyridoxine versus placebo; Summary of findings 4
Metoclopramide versus ondansetron; Summary of findings 5
Metoclopramide versus promethazine; Summary of findings
6 Ondansetron versus promethazine; Summary of findings 7
Corticosteroids versus promethazine; Summary of findings 8
Corticosteroids versus placebo
We included 25 studies (involving 2052 women) in this review but
the majority of our analyses are based on data from single studies
with small numbers of participants.
Acupunture/Acupressure
Acupuncture and acupressure versus placebo
Three studies (involving 182 women) compared P6 acupressure
or acupuncture versus placebo and were included in the analysis.
Two additional studies were in abstract form only and did not have
data that could be entered into the analysis. Miller 2001 compared
nerve stimulation with a watch-like device at P6 versus placebo
and reported lower symptoms in the intervention group, without
specific data reported. Mamo 1995 compared acupressure Sea-
band applied to each wrist versus control with no acupressure and
reported more women required additional antiemetics than in the
control group, again without specific data reported.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
With regards to this primary outcome, only one study (Shin 2007)
reported a decreased mean nausea score (using Rhodes index of
nausea vomiting or retching), however, no standard deviation was
reported so this could not be entered into our data and analysis
tables.
Number of episodes of emesis
None of the studies reported on the number of episodes of emesis.
Days of hospital admission
None of the studies reported on the number days of hospital ad-
mission.
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Secondary outcomes
Regarding the secondary outcomes. The number of women re-
quiring additional antiemetics was lower in the acupuncture/
acupressure group compared to placebo (risk ratio (RR) 0.20, 95%
confidence interval (CI) 0.08 to 0.50, one study (Habek 2004),
36 women (Analysis 1.1)). However, there was no difference be-
tween the treatment group and placebo control with regard to
spontaneous abortion (RR 0.48, 95%CI 0.05 to 5.03, one study
(Heazell 2006), 57 women (Analysis 1.2), low-quality evidence),
preterm birth less than 37 weeks (RR 0.12, 95% CI 0.01 to
2.26, one study (Heazell 2006), 36 women (Analysis 1.3), low-
quality evidence), stillbirth or neonatal death (RR 0.57, 95% CI
0.04 to 8.30, one study (Heazell 2006), 36 women (Analysis 1.4),
low-quality evidence), decision to terminate the pregnancy (RR
0.72, 95% CI 0.18 to 2.95 (Heazell 2006), 57 women (Analysis
1.5)), or anxiodepressive symptomology (RR 1.01, 95%CI 0.73
to 1.40, one study (Habek 2004), 36 women (Analysis 1.6), very
low-quality evidence). (Findings for this comparison are set out in
Summary of findings for the main comparison.)
Acupuncture versus metoclopramide
One study (Neri 2005, involving 81 women), evaluated the ef-
ficacy of acupuncture twice weekly versus metoclopramide infu-
sion in the treatment of hyperemesis gravidarum. Findings for this
comparison are set out in Summary of findings 2.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Regarding the primary outcome, after the cessationof the last treat-
ment, the rate of women who experienced a reduction of nausea in
the acupuncture group was no different from the metoclopramide
group (RR 1.40, 95% CI 0.79 to 2.49 (Analysis 2.1), very low-
quality evidence) neither was the rate of women who experienced
a reduction in vomiting (RR 1.51, 95% CI 0.92 to 2.48 (Analysis
2.2), very low-quality evidence).
Number of episodes of emesis
There were no data available on number of episodes of emesis.
Days of hospital admission
There were no data available on the number of days of hospital
admission.
Secondary outcomes
There were no data available on any of this review’s secondary
outcomes.
Acupuncture versus Western medicine (phenobarbital)
There was one study (Mao 2010), involving 90 women that evalu-
ated acupuncture versus Western medicine. Both groups received
fluid hydration and electrolyte repletion, Acupuncture was per-
formed at BL11, ST37, PC6, SP4, RN12, and ST36, as deter-
mined by symptoms. The Western medicine group received 30
mg phenobarbital three times a day.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Results were reported as Complete Recovery: cessation of nausea
and vomiting, normal appetite; Obvious Effects: reduction by at
least 50% in frequency of nausea and vomiting, appetite improved;
Effects Showed: reduction by 25% to 50% in nausea and vomit-
ing, somewhat improved appetite; and Ineffective: reduction less
than 25% in nausea/vomiting, no improvement in appetite. Total
effectiveness rate was defined as the number of women with ei-
ther Complete Recovery, Obvious Effects, or Effects Showed. At
the end of one week of treatment, there were significantly more
women with complete recovery and less women with ineffective
therapy in the acupuncture versus the phenobarbital group (RR
6.75, 95% CI 2.69 to 16.94 (Analysis 3.1) and (RR 0.06, 95% CI
0.01 to 0.44 (Analysis 3.4)). Acupuncture was more likely to have
any effectiveness (total effective rate) compared to phenobarbital
(RR 2.07, 95% CI 1.40 to 3.05, (Analysis 3.5)).
Number of episodes of emesis
There were no data available on number of episodes of emesis.
Days of hospital admission
There were no data available on the number of days of hospital
admission.
Secondary outcomes
There were no data available on any of this review’s secondary
outcomes.
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Acupuncture versus Chinese medicine
There was one study (Mao 2010, involving 90 women) that evalu-
ated acupuncture versus Chinese medicine. Both groups received
fluid hydration and electrolyte repletion, Acupuncture was per-
formed at BL11, ST37, PC6, SP4, RN12, and ST36, as deter-
mined by symptoms. Women in the Chinese medicine group re-
ceived a selection of traditional Chinese medication according to
the dialectical classification.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Results were reported as Complete Recovery: cessation of nausea
and vomiting, normal appetite; Obvious Effects: reduction by at
least 50% in frequency of nausea and vomiting, appetite improved;
Effects Showed: reduction by 25% to 50% in nausea and vomit-
ing, somewhat improved appetite; and ’Ineffective’: reduction less
than 25% in nausea/vomiting, no improvement in appetite. Total
effectiveness rate was defined as the number of women with ei-
ther Complete Recovery, Obvious Effects, or Effects Showed. At
the end of one week of treatment, there were significantly more
women with complete recovery and less women with ineffective
therapy in the acupuncture versus Chinese medicine group (RR
9.00, 95% CI 3.06 to 26.51(Analysis 4.1) and (RR 0.08, 95% CI
0.01 to 0.60 (Analysis 4.4)). Acupuncture was more likely to have
any effectiveness (total effective rate) than Chinese medicine (RR
1.61, 95% CI 1.19 to 2.17, (Analysis 4.5))
Number of episodes of emesis
There were no data available on number of episodes of emesis.
Days of hospital admission
There were no data available on the number of days of hospital
admission.
Secondary outcomes
There were no data available on any of this review’s secondary
outcomes.
Chinese medicine versus Western medicine
(phenobarbital)
There was one study (Mao 2010, involving 90 women) that eval-
uated Chinese medicine versus Western medicine. The Chinese
medicine group received a selection of traditional Chinese medi-
cation according to the dialectical classification and the “Western
Medicine” group received phenobarbital 30 mg orally three times
daily.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Results were reported as Complete Recovery: cessation of nausea
and vomiting, normal appetite; Obvious Effects: reduction by at
least 50% in frequency of nausea and vomiting, appetite improved;
Effects Showed: reduction by 25% to 50% in nausea and vomit-
ing, somewhat improved appetite; and Ineffective: reduction less
than 25% in nausea/vomiting, no improvement in appetite. Total
effectiveness rate was defined as the number of women with either
Complete Recovery, Obvious Effects, or Effects Showed. At the
end of one week of treatment, there was no significant difference
between the two groups in number of women with either com-
plete recovery (RR 0.75, 95% CI 0.18 to 3.07 (Analysis 5.1)) or
any effectiveness (total effective rate) (RR 1.29, 95% CI 0.79 to
2.08, (Analysis 5.5)).
Number of episodes of emesis
There were no data available on number of episodes of emesis.
Days of hospital admission
There were no data available on the number of days of hospital
admission.
Secondary outcomes
There were no data available on any of this review’s secondary
outcomes.
Progressive muscle relaxation and pharmacotherapy
versus pharmacotherapy
One study (Gawande 2011, involving 30 women) compared pro-
gressive muscle relaxation with pharmacotherapy versus phar-
macotherapy alone. Pharmacotherapy included the progressive
use of doxylamine succinate, ondansetron, metoclopramide, and
promethazine.
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Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Regarding the primary outcome, Gawande 2011 reported a Clin-
ical Global Improvement Score, a significant improvement in
muscle relaxation with pharmacotherapy compared to pharma-
cotherapy alone (mean difference (MD) -0.54 points, 95% CI -
1.04 to -0.04 (Analysis 6.1)).
Number of episodes of emesis
None of the studies reported on the number of episodes of emesis.
Days of hospital admission
None of the studies reported on the number of days of hospital
admission.
Secondary outcomes
Regarding secondary outcomes, there were no women in either
group who decided to terminate the pregnancy.
No data were reported for any of this review’s other secondary
outcomes.
Midwife-led outpatient care versus routine care
We found one study (involving 53 women) that examined
midwife-led outpatient care versus routine care with admission
(McParlin 2008). Data were obtained from communication with
the authors.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
There was no clear differences in the mean PUQE (pregnancy-
unique quantification of emesis and nausea) score between the
group of women who received midwife-led outpatient care and
women who received routine care with admission (MD -0.70
points, 95% CI -3.17 to 1.77 (Analysis 7.1)).
Number of episodes of emesis
No data were reported for this outcome.
Days of hospital admission
Women who received midwife-led care remained in the hospital
for fewer hours (MD -33.20 hours, 95% CI -46.91 to -19.49
(Analysis 7.2).
Secondary outcomes
Regarding secondary outcomes, there was no clear difference in
the rate of women who decided to terminate the pregnancy (RR
2.89, 95%CI0.12 to 67.96 (Analysis 7.3)). Therewas also no clear
difference in spontaneous miscarriage (RR 0.96, 95% CI 0.15
to 6.34 (Analysis 7.4)), or in the rate ofsmall-for-gestational-age
infants (RR 1.44, 95%CI 0.26 to 7.96) (Analysis 7.5)).In terms of
economic costs there was also no evidence of a difference between
groups in relation to the rate of women who lost time from paid
employment (RR 1.04, 95% CI 0.28 to 3.87 (Analysis 7.6)).
Data were not available for any other secondary outcomes in this
review.
Holistic assessment with standard care versus
standard care
One study (Fletcher 2015, involving 273women) compared holis-
tic assessment with an individualized care plan in addition to stan-
dard medical care versus standard medical care alone. The holis-
tic assessment involved a Hyperemeis impact of symptoms (HIS)
questionnaire (Power 2009) that was used to tailor a care package
comprising practical and supportive care. Standard care was intra-
venous rehydration and antiemetic therapy.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
There was no significant difference in the severity of nausea and
vomiting as measured by PUQE (MD -0.20, 95% CI -1.10 to
0.70, (Analysis 8.1)).
Number of episodes of emesis
None of the studies reported on the number of episodes of emesis.
Days of hospital admission
Fletcher 2015 reported days of hospital admission for the two
groups but did not include a standard deviation so this data could
not be entered for analysis. Per the authors’ report, there was a
significantly shorter length of stay in the holistic assessment group
(4.97 days versus 6.14 days, P = 0.05).
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Secondary outcomes
Fletcher 2015 reported on quality of life by assessing both social
functioning and client satisfaction and found no clear difference
between holistic assessment with standard care versus standard care
alone (MD 2.00, 95% CI -6.70 to 10.70 (Analysis 8.2)); (MD -
0.50, 95% CI -1.90 to 0.90 (Analysis 8.3)).
Fletcher 2015 reported on economic costs by looking at both
productivity costs fromdays lost at work andhealth system costs
but did not report standard deviations so this data could not be
entered for analysis. Per the authors report the total healthcare costs
were higher in the standard care arm (£1360.50 versus 1185.90),
however the holistic assessment group was associated with more
days lost fromwork (£1930.50 versus £1468.80), thus the holistic
assessment group had a higher societal cost than the standard care
alone group (£3174.90 versus £2977.50).
Dextrose saline versus normal saline
One study (Tan 2013, involving 203 women) randomized women
to either rehydration with dextrose saline versus normal saline.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Regarding the primary outcome, improvement in nausea/vomit-
ing and number of episodes of emesis was reported in median (in-
terquartile range), so that data could not be used for analysis in
the RevMan tables. Tan 2013 reported a reduction in the median
nausea visual numerical rating scale score at eight and 16 hours
favoring dextrose saline, however this difference dissipated at 24
hours.
Number of episodes of emesis
No data were reported for this outcome.
Days of hospital admission
There was no difference identified in the length of hospital stay
between the two groups (MD -5.00 hours, 95% CI -10.78 to 0.78
(Analysis 9.1)).
Secondary outcomes
Regarding secondary outcomes,quality of lifewas reported, but as
a median so the data could not be used for analysis in our RevMan
tables, however the authors reported no significant difference in
median well-being score at 24 hours.
There were no data available on any other secondary outcomes.
Vitamin B6
Pyridoxine versus placebo
One study (Tan 2009, involving 94 women) randomized women
to receive pyridoxine 20mg orally three times a day versus placebo,
in addition to all women receiving standard care with intravenous
rehydration, metoclopramide, and oral thiamine. Interventions
were continued for two weeks, outcomes examined a the one- and
two-weekmark, results reported here are at the one-weekmark due
to significant attrition by two weeks. Findings for this comparison
are set out in Summary of findings 3.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Tan 2009, reported nausea score as a median rather than a mean
score - so the data could not be used for the RevMan tables, how-
ever the trialist reported no significant difference in nausea scores.
Number of episodes of emesis
There was no strong evidence of a difference in the daily mean
vomiting episodes (MD 0.50 vomiting episodes, 95% CI -0.40 to
1.40, 66 women (Analysis 10.1), low-quality evidence)
Days of hospital admission
There was a slightly longer hospital stay associated with B6 com-
pared with placebo (MD 0.80 day, 95% CI 0.08 to 1.52, 92
women (Analysis 10.2, moderate-quality evidence).
Secondary outcomes
Regarding the secondary outcomes, there was no clear difference
in hospital readmission (RR 1.78, 95% CI 0.85 to 3.71, 78
women (Analysis 10.3) or in weight loss after one week (MD
0.00 kg, 95% CI -0.93 to 0.93) (Analysis 10.4). Quality of life
was reported as a median and therefore could not be included
in the analysis, however Tan 2009 reports no difference between
groups in well-being score. Tan 2009 did report on intervention
side effects, and there was no differences in the rate of dizziness
(RR 1.67, 95% CI 0.85 to 3.26, 66 women, low-quality evidence
(Analysis 10.5)), headaches, (RR 1.33, 95% CI 0.52 to 3.42, 66
women, low-quality evidence (Analysis 10.6)), diarrhea (RR 3.00,
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95% CI 0.13 to 71.07, 66 women (Analysis 10.7)), palpitations
(RR 1.00, 95% CI 0.22 to 4.60, 66 women, low-quality evidence
(Analysis 10.8)) and dry mouth (RR 0.82, 95% CI 0.49 to 1.38,
66 women, low-quality evidence (Analysis 10.9)) in the pyridoxine
group compared to placebo after one week of treatment. There
were also no cases of rash or photosensitivity in either group.
There were no data available on any other secondary outcomes.
Antihistamines
No studies that examined antihistamines were identified.
Dopamine antagonists
Metoclopramide versus acupuncture
One study (Neri 2005) evaluated the efficacy of acupuncture twice
weekly versus metoclopramide infusion in the treatment of hyper-
emesis gravidarum - the results have already been reported under
the comparison of acupuncture versus metoclopramide (see above
and Comparison 2 in Data and analyses).
Metoclopramide versus ondansetron
There were two studies (involving 243 women) that compared
metoclopramide with ondansetron (Abas 2014; Kashifard 2013).
Abas 2014 used 10 mg intravenous metoclopramide every eight
hours for four doses versus 4 mg ondansetron intravenous every
eight hours for four doses, while Kashifard 2013 used oral med-
ications in the same doses for two weeks and assessed severity of
nausea and vomiting during the treatment period and two days
one week after completion of therapy. Results for this comparison
have been set out in Summary of findings 4.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Regarding this primary outcome, Abas 2014 reported nausea score
as a median so it could not be analyzed in combination with the
other study (Kashifard 2013), but Abas 2014 reports no significant
difference between groups. Kashifard 2013 reported no significant
difference between the metoclopramide and ondansetron groups
in terms of the severity of nausea (MD 1.70 point, 95% CI -0.15
to 3.55, one study, 83 women (Analysis 11.1), very low-quality
evidence), or in the severity of vomiting according to a 10-point
VAS rating score on the second day one week after completion of
therapy (MD -0.10 points, 95% CI -1.63 to 1.43, one study, 83
women (Analysis 11.2), very low-quality evidence).
Number of episodes of emesis
No data were reported for this outcome.
Days of hospital admission
No data were reported for this outcome.
Secondary outcomes
Regarding secondary outcomes, Abas 2014 provided data (from
160 women) in relation to intervention side effects. The num-
ber of women who felt drowsy (RR 2.40, 95% CI 1.23 to 4.69
(Analysis 11.3) moderate-quality evidence), and who had a dry
mouth (RR 2.38, 95% CI 1.10 to 5.11 (Analysis 11.4), moderate-
quality evidence) was higher in the metoclopramide group com-
pared to the group of women who received ondansetron. There
were no clear differences in the rate of women unable to sleep (RR
1.29, 95% CI 0.50 to 3.28 (Analysis 11.5), felt dizzy (RR 2.33,
95% CI 0.94 to 5.77, low-quality evidence (Analysis 11.6)), had
diarrhea (RR 9.00, 95% CI 0.49 to 164.46 (Analysis 11.7)), had
headache (RR 1.22, 95% CI 0.54 to 2.79 (Analysis 11.8)), expe-
rienced palpitations (RR 2.50, 95% CI 0.50 to 12.51 (Analysis
11.9)), or noticed skin rash (RR 1.00, 95% CI 0.06 to 15.71
(Analysis 11.10)); no cases of dystonia in both groups were re-
ported (Analysis 11.11). Kashifard 2013 reported no side effects in
either themetoclopramide or the ondansetron group, although the
side effects examined were not specified. In addition, Abas 2014
reported no difference in the well-being VNRS score about qual-
ity of life outcome (MD -0.40 points, 95% CI -0.83 to 0.03, one
study 160 women, moderate-quality evidence (Analysis 11.12)).
There were no data available on any other secondary outcomes.
Hydrocortisone versus metoclopramide
There was one study (Bondok 2006, involving 40 women) that
compared women receiving 300 mg intravenous hydrocortisone
daily for three days, tapered over the week, versus 10 mg of meto-
clopramide intravenously three times daily for one week. We had
intended to produce a ’Summary of findings’ table for this com-
parison but none of the pre-specified outcomes were reported.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
There were no data on the subjective severity, reduction, or cessa-
tion of nausea.
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Number of episodes of emesis
Meannumber of daily episodes of emesis were reported by Bondok
2006 as significantly decreased in the hydrocortisone group, al-
though the actual numbers were not available to be included into
the analysis.
Days of hospital admission
No data were reported for this outcome.
Secondary outcomes
Regarding secondary outcomes, there was no difference in the rate
of hospital readmission between themetoclopramide and hydro-
cortisone groups (RR 0.08, 95% CI 0.00 to 1.28 (Analysis 12.1)
moderate-quality evidence). Similarly, there was no clear difference
in the number of women requiring enteral or parenteral nu-
trition between the two groups (RR 0.33, 95% CI 0.01 to 7.72
(Analysis 12.2)).
No other secondary outcomes were reported.
Metoclopramide versus promethazine
One study (Tan 2010) compared 10 mg intravenous metoclo-
pramide versus 25 mg intravenous promethazine given eight
hourly for 24 hours. (See Summary of findings 5.)
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Nausea score was reported by Tan 2010 as a median so data could
not be included in our analysis, but the trialist reported no signif-
icant difference in nausea score between groups.
Number of episodes of emesis
The number of vomiting episodes were reported by Tan 2010
as a median so these data could not be included in our analysis,
but the trialist reported no significant difference in the number of
vomiting episodes between groups.
Days of hospital admission
No data were reported for this outcome.
Secondary outcomes
In relation to quality of life, themeanwell-being VNRS score was
similar in themetoclopramide group and the promethazine groups
(MD 0.50 points, 95% CI -0.22 to 1.22, low-quality evidence,
(Analysis 13.1)). Tan 2010, provided data on the intervention
side effects - there was no strong evidence showing any differences
in the number of women unable to sleep (RR 0.78, 95% CI 0.40
to 1.53, (Analysis 13.2)), had a dry mouth (RR 0.91, 95%CI 0.62
to 1.34 (Analysis 13.3)), had diarrhea (RR 1.39, 95% CI 0.32 to
5.99 (Analysis 13.4)), had headache (RR 0.81, 95% CI 0.47 to
1.38 (Analysis 13.5)) (low-quality evidence for the aforementioned
side effects), experienced palpitations (RR 0.61, 95% CI 0.25 to
1.46 (Analysis 13.6)), and noticed skin rash (RR 1.39, 95% CI
0.32 to 5.99 (Analysis 13.7) . However, the number of women
who felt drowsy (RR 0.70, 95% CI 0.56 to 0.87, moderate-quality
evidence (Analysis 13.8), the number of women who felt dizzy (RR
0.48, 95% CI 0.34 to 0.69, moderate-quality evidence (Analysis
13.9)) and the number of women who experienced dystonia (RR
0.31, 95% CI 0.11 to 0.90 (Analysis 13.10)) was lower in the
metoclopramide group compared to the group of women who
received promethazine.
No other secondary outcomes were reported.
Benzodiazepines
Parenteral fluid with diazepam versus without diazepam
There was one study (Ditto 1999, involving 50 women) that eval-
uated the treatment of hyperemesis gravidarum with or without
10 mg intravenous diazepam twice daily while admitted, and with
5 mg oral diazepam twice daily versus placebo on discharge.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
The trial authors did not report a MD in nausea score, but did
report a significantly decreased number of women with severe
nausea in the diazepam group.
Number of episodes of emesis
Ditto 1999 didnot report the specific number of episodes of emesis
but reported a similar number of women with decreased emesis in
both groups.
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Days of hospital admission
The mean hospital stay was shorter in the diazepam group com-
pared to placebo (MD -1.10, 95% CI -2.07 to -0.13 (Analysis
14.1)).
Secondary outcomes
Regarding secondary outcomes, there were no clear differences
in hospital readmission (RR 0.17, 95% CI 0.02 to 1.29
(Analysis 14.2)), or the number of women requiring additional
antiemetic drugs (RR 0.50, 95%CI 0.05 to 5.17 (Analysis 14.3))
between the group of women who received parenteral fluid with
diazepam group and those who received parenteral fluid without
diazepam. Similarly, there was no differences identified between
the two groups in terms of the number of women who had con-
genital abnormalities (the trialist authors reported no congeni-
tal abnormalities in either group, Analysis 14.4), the incidence of
preterm delivery (RR0.50, 95%CI 0.05 to 5.17 (Analysis 14.5)),
or in the rate of women who decided to terminate the pregnancy
due to the hyperemesis (RR 3.00, 95%CI 0.13 to 70.30) (Analysis
14.6).
No other secondary outcome data were available for analysis.
Serotonin antagonist
Ondansetron versus promethazine
One study (Sullivan 1996, involving 30 women) randomized
women to receive either 10 mg intravenous ondansetron or 50 mg
intravenous promethazine for one dose then every eight hours as
needed. (See Summary of findings 6.)
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Specific subjective nausea scores were not reported by Sullivan
1996 and could not be entered into our RevMan tables. However,
the trialist reported no significant difference in the severity of
nausea between the two groups.
Number of episodes of emesis
There were no data available on number of episodes of emesis.
Days of hospital admission
There was no difference between the ondansetron and promet-
hazine groups in terms of the number of days of hospital admis-
sion (MD 0.00 days, 95% CI -1.39 to 1.39 (Analysis 15.1), very
low-quality evidence).
Secondary outcomes
Regarding secondary outcomes, the rate of sedation (adverse ef-
fect) was decreased with ondansetron (RR 0.06, 95% CI 0.00 to
0.94 (Analysis 15.2), low-quality evidence), no other side effects
were observed.
No other secondary outcomes were reported.
Ondansetron versus metoclopramide (two studies with 243
women)
Two studies (involving 243 women) compared ondansetron with
metoclopramide - the results have already been reported under
the comparison of metoclopramide versus ondansetron (see above
and Comparison 11 in Data and analyses).
Phenothiazines
Promethazine versus metoclopramide
One study (Tan 2010, involving 149 women) compared 10 mg
intravenous metoclopramide to 25 mg intravenous promethazine
given every 8 hours for 24 hours - the results have already been
reported under the comparison of metoclopramide versus promet-
hazine (see above and Comparison 13 in Data and analyses).
Ondansetron versus promethazine
One study (Sullivan 1996, involving 30 women) randomized
women to receive either 10 mg intravenous ondansetron or 50 mg
intravenous promethazine for one dose then every eight hours as
needed. The results have already been reported under the compar-
ison of promethazine versus ondansetron (see above and Compar-
ison 15 in Data and analyses).
Corticosteroids versus promethazine (two studies with 120
women)
Two studies (involving a total of 120 women) were involved in
this comparison. One study (Safari 1998) evaluated oral methyl-
prednisolone 16 mg three times daily versus oral promethazine 25
mg three times daily, while another one (Ziaei 2004) compared 5
mg oral prednisolone with 75 mg oral promethazine daily for 10
days. (See Summary of findings 7.)
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Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
In one study (Ziaei 2004), the number of women with severe nau-
sea at 48 hours was higher in the prednisolone group compared to
the promethazine group (RR 2.00, 95% CI 1.08 to 3.72 (Analysis
16.1), low-quality evidence) and at day 17 was not significantly dif-
ferent between groups (RR 0.81, 95% CI 0.58 to 1.15 (Analysis
16.2), very low-quality evidence). We did not find any difference in
the number of episodes of vomiting at 48 hours (RR 3.00, 95%
CI 0.33 to 27.63 (Analysis 16.3)) and at 17 days (RR 1.00, 95%
CI 0.21 to 4.65 (Analysis 16.4), very low-quality evidence).
In another study, Safari 1998 reported on therapy failure as defined
by persistence of vomiting more than five times/day, inability to
tolerate liquids, and the women’s impression that they were not
better, and there was no difference between groups (RR 1.50, 95%
CI 0.28 to 8.04 (Analysis 16.5)).
Number of episodes of emesis
Ziaei (Ziaei 2004) reported increased number of episodes of emesis
in the prednisolone group at 48 hours, but no difference at day
17; however data were reported as a median so were not able to be
analyzed.
Days of hospital admission
There were no data available on the number of days of hospital
admission.
Secondary outcomes
Regarding secondary outcomes, there was no strong evidence of
differences in the rate of hospital readmission (RR 0.09, 95%
CI 0.01 to 1.53 (Safari 1998, 34 women) (Analysis 16.6)), in the
number of women requiring additional antiemetics (RR 1.50,
95%CI 0.28 to 8.04 (Safari 1998, 40 women) (Analysis 16.7)), or
in the rate of stillbirth/neonatal death (RR 3.00, 95% CI 0.13
to 69.52 (Safari 1998, 40 women, low-quality evidence) (Analysis
16.8), in the rate of preterm birth (RR 3.00, 95% CI 0.13 to
69.52 (Safari 1998, 40 women, low-quality evidence) (Analysis
16.9)), or in the rate of women who decided to terminate the
pregnancy (RR 3.00, 95% CI 0.13 to 69.52 (Safari 1998, 40
women) (Analysis 16.10)). In terms of side effects, there was no
difference in the rate of women who felt abdominal pain during
the first 48 hours (RR 0.33, 95% CI 0.07 to 1.55 (Ziaei 2004, 80
women) (Analysis 16.11)), and between the third and 10th day
(RR 0.11, 95%CI 0.10 to 2.00 (Ziaei 2004, 80 women) (Analysis
16.12)). The rate of drowsiness was also not substantially different
(RR 0.08, 95% CI 0.00 to 1.32 (Ziaei 2004, 80 women), low-
quality evidence (Analysis 16.13)). Regarding quality of life, the
number of women who reported becoming well or partially well
by 48 hours was lower in the prednisolone group compared to
promethazine (RR 0.67, 95% CI 0.47 to 0.95 (Analysis 16.14)),
while no difference was identified in the number of women who
reported becoming well or partially well by 17 days (RR 1.67,
95% CI 0.95 to 2.92 (Analysis 16.15)) (Ziaei 2004).
No other secondary outcomes were reported.
Steroid hormones
Corticosteroids versus placebo
There were four studies (involving 271 women) that evaluated
the efficacy of steroids versus placebo in hyperemesis gravidarum
(Duggar 2001; Nelson-Piercy 2001; Tabatabaii 2008; Yost 2003).
The women in Duggar 2001 received oral methylprednisone 12
tablets of 4 mg methylprednisone daily for three days followed
by a 10-day taper. The women in Nelson-Piercy 2001 received
20 mg of oral prednisolone every 12 hours for one week; they
also received additional antiemetics as deemed necessary by the
providers. The women in Tabatabaii 2008 and Yost 2003 received
125 mg of intravenous methylprednisolone followed by an oral
prednisone taper; in the former study the women also received B6,
in the latter study the women also received metoclopramide and
promethazine as standard of care. Results for this comparison are
set out in Summary of findings 8.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Nelson-Piercy 2001 reported a non-significant reduction in sever-
ity of nausea in the steroid versus placebo group, however this was
reported as a median and could not be included into the analysis.
Number of episodes of emesis
There were no data available on number of episodes of emesis.
Days of hospital admission
Days of hospital admission were available from Yost 2003, there
was no clear difference (MD -0.30 day, 95% CI -0.70 to 0.10, very
low-quality evidence) in the number of days of hospital admission
between groups (Analysis 17.1).
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Secondary outcomes
Regarding secondary outcomes, the rate of hospital readmission
was lower in the steroid hormone group compared to the placebo
group of women (RR 0.69, 95% CI 0.50 to 0.94, four studies,
269 women (Analysis 17.2)) (Duggar 2001; Nelson-Piercy 2001;
Tabatabaii 2008; Yost 2003). There was no difference in the rate
of pregnancy complications (pregnancy hypertension or gesta-
tional diabetes (RR 0.61, 95% CI 0.26 to 1.47, very low-quality
evidence (Analysis 17.3)) based on data reported in Yost 2003 (110
women). There was no significant difference in the rate of sponta-
neous abortion (RR 0.64, 95% CI 0.11 to 3.70 (Yost 2003, 110
women, very low-quality evidence) (Analysis 17.4)). There was no
difference in the rate of stillbirth or neonatal death (RR 0.70,
95% CI 0.09 to 5.29, two studies, 134 women, very low-quality
evidence) (Analysis 17.5)). Only one study (Yost 2003) reported on
congenital abnormalities, and there was no difference between
groups (RR 0.32, 95% CI 0.01 to 7.73, one study 110 women,
very low-quality evidence (Analysis 17.6)). One study (Yost 2003)
reported on low birthweight (RR 1.35, 95% CI 0.46 to 4.00,
110 women (Analysis 17.7), very low-quality evidence) and another
study (Nelson-Piercy 2001) reported on small-for-gestational-
age infants (RR 1.00, 95% CI 0.07 to 14.21, 24 women (Analysis
17.8)) and there was no significant difference between groups for
either outcome. One study (Yost 2003) reported on preterm birth
less than 36 weeks and Nelson-Piercy 2001 reported on preterm
birth less than 37 weeks, when we combined these data using a
random-effects analysis (due to substantial statistical heterogene-
ity) therewas nodifference between groups (averageRR1.01, 95%
CI 0.31 to 3.28; two studies, 134 women, Tau² = 0.27, I² = 37%
(Analysis 17.9), very low-quality evidence). Duggar 2001 reported
intervention side effects (specifics side effects not reported) and
found no difference in the rate of side effects (RR 0.79, 95%
CI 0.06 to 11.20, 25 women, very low-quality evidence (Analysis
17.10)).One study (Nelson-Piercy 2001) reported on thenumber
of women requiring additional antiemetics and there was no
clear difference between groups for this outcome (RR 0.56, 95%
CI 0.26 to 1.17, 24 women (Analysis 17.11)) and there was also
no difference in the number of women who decided to terminate
the pregnancy (RR 0.33, 95% CI 0.01 to 7.45, (Nelson-Piercy
2001) 24 women (Analysis 17.12)).
There were no data available on any other secondary outcome.
Corticosteroids versus promethazine (two studies with 120
women)
Two studies (involving a total of 120 women) were involved in
this comparison. One study (Safari 1998) evaluated oral methyl-
prednisolone 16 mg three times daily versus oral promethazine 25
mg three times daily, while another one (Ziaei 2004) compared 5
mg oral prednisolone with 75 mg oral promethazine daily for 10
days. The results have already been reported under the compari-
son of corticosteroids versus promethazine above (see above and
Comparison 14 in Data and analyses).
Hydrocortisone versus metoclopramide (one study with 40
women)
One study (Bondok 2006, involving 40 women) compared
women receiving 300 mg intravenous hydrocortisone daily for
three days, tapered over the week, versus 10 mg of intravenous
metoclopramide three times daily for one week. The results have
already been reported under the comparison of hydrocortisone
versus metoclopramide (see above and Comparison 12 in Data
and analyses).
Adrenocorticotropic hormone (ACTH) versus placebo
One study (Ylikorkala 1979, involving 32 women) randomized
women to 0.5 mg intramuscular ACTH versus placebo for four
days. There were no data available on number of episodes of emesis
or days of hospital admission.
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
In terms of mean relief score, there was no difference between
the group of women who received intramuscular ACTH and the
group of women who received a placebo (MD 0.60 points, 95%
CI -1.65 to 2.85 (Analysis 18.1)).
Number of episodes of emesis
There were no data available on number of episodes of emesis.
Days of hospital admission
There were no data available on the number of days of hospital
admission.
Secondary outcomes
Regarding secondary outcomes, the group of women who received
intramuscular ACTH had a higher mean weight gain than the
women in the placebo group (MD 1.0 kg, 95% CI 0.34 to 1.66
(Analysis 18.2)). There was no difference between groups in terms
of the rate of hospital readmission (RR 1.00, 95% CI 0.16 to
6.25 (Analysis 18.3)), rate of spontaneous abortion (RR 1.00,
95% CI 0.07 to 14.64 (Analysis 18.4), or rate of preterm birth
(RR 3.00, 95% CI 0.13 to 68.57 (Analysis 18.5)).
Data on other secondary outcomes were not available.
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Subgroup analysis
Subgroup analysis on primary outcomes was planned to be per-
formed on the following subgroups: singleton versus multiple ges-
tation, prime versusmultiparous, andwomenwith over 5%weight
loss versus women without less than 5% weight loss. Unfortu-
nately, there were insufficient data to carry out these subgroup
analyses. No studies that included multiple gestations or multi-
parous women reported data separately for those groups. Eight
studies included only singleton gestations, but they were all also
the only study in their comparison group (Bondok 2006; Ditto
1999; Gawande 2011; Neri 2005; Sullivan 1996; Tan 2009; Tan
2010; Tan 2013). Both Kashifard 2013, which included only sin-
gletons, and Abas 2014, which included multiple gestations, com-
pared metoclopramide and ondansetron, however Kashifard 2013
did not have data available on primary outcomes for analysis.
Three studies included weight loss over 5% as an inclusion cri-
teria (Bondok 2006; Ditto 1999; Neri 2005), one study required
women to have more than 2.25 kg weight loss (Sullivan 1996),
and one study required women to have had weight loss of at least
3 kg (Kashifard 2013), but again they were the only studies in
their comparison group or did not have data on primary outcomes
available for analysis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Acupuncture versus metoclopramide
Patient or population: pregnant women with hyperemesis gravidarum
Setting: Study in Italy
Intervention: Acupuncture
Comparison: Metoclopramide
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with metoclo-
pramide
Risk with Acupuncture
Reduct ion or cessat ion
in nausea
Study populat ion RR 1.40
(0.79 to 2.49)
81
(1 RCT)
⊕©©©
VERY LOW 12
Absolute ef fects calcu-
lated f rom results of
single study.316 per 1000 442 per 1000
(249 to 786)
Reduct ion or cessat ion
in vomit ing
Study populat ion RR 1.51
(0.92 to 2.48)
81
(1 RCT)
⊕©©©
VERY LOW 12
Absolute ef fects calcu-
lated f rom results of
single study.368 per 1000 556 per 1000
(339 to 914)
1. Number of episodes
of emesis
2. Days of hospital ad-
mission
3. Intervent ion side ef -
fects
4. Quality of lif e out-
comes
5. Pregnancy complica-
t ions
6. Adverse fetal/ neona-
tal outcomes
Not reported Not est imable The study included in
this comparison did not
report these review out-
comes
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Single study with design lim itat ions contribut ing data
2 Small sample size and wide 95% CIs crossing the line of no ef fect
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Pyridoxine versus placebo
Patient or population: pregnant women with hyperemesis gravidarum
Setting: Study in Malaysia
Intervention: Pyridoxine
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Pyridoxine
Number of episodes of
emesis
Mean episodes 1.4 Mean episodes 1.9 The mean number of
episodes of emesis in
the intervent ion group
was 0.5 more (0.4 fewer
to 1.4 more)
66
(1 RCT)
⊕⊕©©
LOW 1
The absolute ef fects
were f rom a single
study
Days of hospital admis-
sion
The mean days of hos-
pital admission was 3.
1
The mean days of hos-
pital admission was 3.
9.
The mean days of hos-
pital admission in the
intervent ion group was
0.8 days more (0.08
more to 1.52 more)
92
(1 RCT)
⊕⊕⊕©
MODERATE 2
The absolute ef fects
were f rom a single
study
Intervent ions side ef -
fects: dizziness
Study populat ion RR 1.67
(0.85 to 3.26)
66
(1 RCT)
⊕⊕©©
LOW 1
The absolute ef fects
were calculated f rom a
single study273 per 1000 455 per 1000
(232 to 889)
Intervent ions side ef -
fects: headaches
Study populat ion RR 1.33
(0.52 to 3.42)
66
(1 RCT)
⊕⊕©©
LOW 1
The absolute ef fects
were calculated f rom a
single study182 per 1000 242 per 1000
(95 to 622)
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Intervent ions side ef -
fects: diarrhoea
Study populat ion RR 3.00
(0.13 to 71.07)
66
(1 RCT)
3 The absolute ef fects
were calculated f rom a
single study0 per 1000 0 per 1000
(0 to 0)
Intervent ions side ef -
fects: palpitat ions
Study populat ion RR 1.00
(0.22 to 4.60)
66
(1 RCT)
⊕⊕©©
LOW 3
The absolute ef fects
were calculated f rom a
single study91 per 1000 91 per 1000
(20 to 418)
Intervent ions side ef -
fects: dry mouth
Study populat ion RR 0.82
(0.49 to 1.38)
66
(1 RCT)
⊕⊕©©
LOW 1
The absolute ef fects
were calculated f rom a
single study515 per 1000 422 per 1000
(252 to 711)
1. Severity, reduct ion
or cessat ion in nausea/
vomit ing
2. Quality of lif e out-
comes
3. Pregnancy complica-
t ions
4. Adverse fetal/ neona-
tal outcomes
Not reported Not est imable The studies included
in this comparison did
not include these re-
view outcomes
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Small sample size and wide 95% CIs crossing the line of no ef fect
2 Estimate based on single study with small sample size32
In
te
rv
e
n
tio
n
s
fo
r
tre
a
tin
g
h
y
p
e
re
m
e
sis
g
ra
v
id
a
ru
m
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
3 Small sample size, low event rate and wide 95% CIs crossing the line of no ef fect
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Metoclopramide versus ondansetron
Patient or population: pregnant women with hyperemesis gravidarum
Setting: Studies in Iran (1) and Malaysia (1)
Intervention: Metoclopramide
Comparison: Ondansetron
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with ondansetron Risk with M etoclo-
pramide
Severity of nausea The mean severity
score with ondansetron
was 3.4
The mean severity
score with metoclo-
pramide was 5.1
The mean severity of
nausea in the interven-
t ion group was 1.7 more
(0.15 less to 3.55 more)
83
(1 RCT)
⊕©©©
VERY LOW 12
Absolute ef fects f rom
single study
Severity of vomit ing The mean severity of
vomit ing score with on-
dansetron was 4.8
The mean severity
score with metoclo-
pramide was 4.7.
The mean severity of
vomit ing in the interven-
t ion group was 0.1 less
(1.63 less to 1.43 more)
83
(1 RCT)
⊕©©©
VERY LOW 12
Absolute ef fects f rom
single study
Quality of lif e The mean quality of lif e
score with ondansetron
was 8.7.
The mean quality of
lif e score with metoclo-
pramide was 8.3.
The mean quality of
lif e in the intervent ion
group was 0.4 less (0.
83 less to 0.03 more)
160
(1 RCT)
⊕⊕⊕©
MODERATE 3
Absolute ef fects f rom
single study
Intervent ion side ef -
fects: felt drowsy
Study populat ion RR 2.40
(1.23 to 4.69)
160
(1 RCT)
⊕⊕⊕©
MODERATE 3
Absolute ef fects calcu-
lated f rom single study
125 per 1000 300 per 1000
(154 to 586)
Intervent ion side ef -
fects: unable to sleep
Study populat ion RR 1.29
(0.50 to 3.28)
160
(1 RCT)
⊕⊕©©
LOW 2
Absolute ef fects calcu-
lated f rom single study
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88 per 1000 113 per 1000
(44 to 287)
Intervent ion side ef -
fects: dry mouth
Study populat ion RR 2.38
(1.10 to 5.11)
160
(1 RCT)
⊕⊕⊕©
MODERATE 3
Absolute ef fects calcu-
lated f rom single study
100 per 1000 238 per 1000
(110 to 511)
Intervent ion side ef -
fects: felt dizzy
Study populat ion RR 2.33
(0.94 to 5.77)
160
(1 RCT)
⊕⊕©©
LOW 2
Absolute ef fects calcu-
lated f rom single study
75 per 1000 175 per 1000
(71 to 433)
1. Severity, reduct ion
or cessat ion in nausea/
vomit ing
2.Days of hospital ad-
mission
3. Pregnancy complica-
t ions
4. Adverse fetal/ neona-
tal outcomes
Not reported Not est imable The studies included in
this comparison did not
report these review out-
comes
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Single study with design lim itat ions contribut ing data
2 Small sample size and wide 95% CIs crossing the line of no ef fect
3 Estimate based on single study with small sample size
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Metoclopramide versus promethazine
Patient or population: Pregnant women with hyperemesis gravidarum
Setting: Study in Malaysia
Intervention: Metoclopramide
Comparison: Promethazine
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with promet-
hazine
Risk with M etoclo-
pramide
Quality of lif e The mean quality of lif e
score was 7.1
The mean quality of lif e
score was 7.6
The mean quality of lif e
score in the interven-
t ion group was 0.5 more
(0.22 less to 1.22 more)
149
(1 RCT)
⊕⊕©©
LOW 1
Absolute ef fects f rom
single study.
Intervent ion side ef -
fects: drowsy
Study populat ion RR 0.70
(0.56 to 0.87)
143
(1 RCT)
⊕⊕⊕©
MODERATE 2
Absolute ef fects calcu-
lated f rom single study.
836 per 1000 585 per 1000
(468 to 727)
Intervent ion side ef -
fects: unable to sleep
Study populat ion RR 0.78
(0.40 to 1.53)
143
(1 RCT)
⊕⊕©©
LOW 1
Absolute ef fects calcu-
lated f rom single study.
219 per 1000 171 per 1000
(88 to 335)
Intervent ion side ef -
fects: dry mouth
Study populat ion RR 0.91
(0.62 to 1.34)
143
(1 RCT)
⊕⊕©©
LOW 1
Absolute ef fects calcu-
lated f rom single study.
438 per 1000 399 per 1000
(272 to 587)
Intervent ion side ef -
fects: felt dizzy
Study populat ion RR 0.48
(0.34 to 0.69)
143
(1 RCT)
⊕⊕⊕©
MODERATE 2
Absolute ef fects calcu-
lated f rom single study.
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712 per 1000 342 per 1000
(242 to 492)
Intervent ion side ef -
fects: diarrhea
Study populat ion RR 1.39
(0.32 to 5.99)
143
(1 RCT)
⊕⊕©©
LOW 3
Absolute ef fects calcu-
lated f rom single study.
41 per 1000 57 per 1000
(13 to 246)
Intervent ion side ef -
fects: headache
Study populat ion RR 0.81
(0.47 to 1.38)
143
(1 RCT)
⊕⊕©©
LOW 1
Absolute ef fects calcu-
lated f rom single study.
301 per 1000 244 per 1000
(142 to 416)
1. Severity, reduct ion
or cessat ion in nausea/
vomit ing
2. Number of episodes
of emesis
3. Days of hospital ad-
mission
4. Pregnancy complica-
t ions
5. Adverse fetal/ neona-
tal outcomes
Not reported Not est imable The study included in
this comparison did not
report these review out-
comes
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Small sample size and wide 95% CIs crossing the line of no ef fect
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2 Estimate based on single study with small sample size
3 Small sample size, low event rate and wide 95% CIs crossing the line of no ef fect
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Ondansetron versus promethazine
Patient or population: Pregnant women with hyperemesis gravidarum
Setting: Study in the USA
Intervention: Ondansetron
Comparison: Promethazine
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with promet-
hazine
Risk with Ondansetron
Days of hospital admis-
sion
The mean days of hos-
pital admission was 4.
47 with promethazine
The mean days of hos-
pital admission was
4.47 days with on-
dansetron
The mean dif ference in
days of hospital admis-
sion in the intervent ion
group was 0 (1.39 fewer
to 1.39 more)
30
(1 RCT)
⊕©©©
VERY LOW 12
Absolute ef fect f rom
one study
Intervent ion side ef fect:
sedat ion
Study populat ion RR 0.06
(0.00 to 0.94)
30
(1 RCT)
⊕⊕©©
LOW 13
Absolute ef fects calcu-
lated f rom one study
533 per 1000 32 per 1000
(0 to 501)
1. Severity, reduct ion
or cessat ion in nausea/
vomit ing
2. Number of episodes
of emesis
3. Quality of lif e out-
comes
4. Pregnancy complica-
t ions
5. Adverse fetal/ neona-
tal outcomes
Not reported Not est imable The study included in
this comparison did not
report these review out-
comes
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Single study with design lim itat ions contribut ing data
2 Small sample size and wide 95% CIs crossing the line of no ef fect
3 Estimated based on single study with small sample size
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Cort icosteroids versus promethazine
Patient or population: Pregnant women with hyperemesis gravidarum
Setting: Studies in the USA (1) and Iran (1)
Intervention: Cort icosteroids
Comparison: Promethazine
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with promet-
hazine
Risk with Corticos-
teroids
Severe nausea 48 hours Study populat ion RR 2.00
(1.08 to 3.72)
80
(1 RCT)
⊕⊕©©
LOW 12
Absolute est imates cal-
culated f rom single
study250 per 1000 500 per 1000
(270 to 930)
Severe nausea 17th day Study populat ion RR 0.81
(0.58 to 1.15)
78
(1 RCT)
⊕©©©
VERY LOW 13
Absolute est imates cal-
culated f rom single
study692 per 1000 561 per 1000
(402 to 796)
Episodes of vomit ing
48 hours
Study populat ion RR 3.00
(0.33 to 27.63)
80
(1 RCT)
⊕©©©
VERY LOW 14
Absolute est imates cal-
culated f rom single
study25 per 1000 75 per 1000
(8 to 691)
Episodes of vomit ing
17th day
Study populat ion RR 1.00
(0.21 to 4.65)
78
(1 RCT)
⊕©©©
VERY LOW 14
Absolute est imates cal-
culated f rom single
study77 per 1000 77 per 1000
(16 to 358)
In-
tervent ion side ef fects:
drowsiness 48hrs and
3-10 days
Study populat ion RR 0.08
(0.00 to 1.32)
80
(1 RCT)
⊕⊕©©
LOW 15
Absolute est imates cal-
culated f rom single
stud
4
1
In
te
rv
e
n
tio
n
s
fo
r
tre
a
tin
g
h
y
p
e
re
m
e
sis
g
ra
v
id
a
ru
m
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
150 per 1000 12 per 1000
(0 to 198)
St illbirth and neonatal
death
RR 3.00
(0.13 to 69.52)
40
(1 RCT)
⊕⊕©©
LOW 12
Low event rate. Abso-
lute est imate not calcu-
lated
Preterm birth RR 3.00
(0.13 to 69.52)
40
(1 RCT)
⊕⊕©©
LOW 4
Low event rate. Abso-
lute est imate not calcu-
lated
1. Days of hospital ad-
mission
2. Quality of lif e out-
comes
3. Pregnancy complica-
t ions
Not reported Not est imable The studies included in
this comparison did not
report these review out-
comes
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Single study with design lim itat ions contribut ing data
2 Estimate based on single study with small sample size
3 Small sample size and wide 95% CIs crossing the line of no ef fect
4 Small sample size, low event rate and wide 95% CIs crossing the line of no ef fect
5 Estimate based on single study with small sample size and low event rate
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Cort icosteroids versus placebo
Patient or population: Pregnant women with hyperemesis gravidarum
Setting: Studies in the USA (2) and UK (1)
Intervention: Cort icosteroids
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Corticos-
teroids
Days of hospital admis-
sion
The mean days of hos-
pital admission was 2.
2 days
The mean days of hos-
pital admission was 1.
9 days
The mean days of hos-
pital admission in the
intervent ion group was
0.3 days fewer (0.7
fewer to 0.1 more)
110
(1 RCT)
⊕©©©
VERY LOW 12
Absolute ef fects f rom a
single study
Pregnancy complica-
t ions
Study populat ion RR 0.61
(0.26 to 1.47)
110
(1 RCT)
⊕©©©
VERY LOW 12
Absolute ef fects cal-
culated f rom a single
study204 per 1000 124 per 1000
(53 to 299)
Spontaneous abort ion Study populat ion RR 0.64
(0.11 to 3.70)
110
(1 RCT)
⊕©©©
VERY LOW 13
Absolute ef fects cal-
culated f rom a single
study56 per 1000 36 per 1000
(6 to 206)
St illbirth and neonatal
death
Study populat ion RR 0.70
(0.15 to 3.34)
134
(2 RCTs)
⊕©©©
VERY LOW 13
Absolute ef fects cal-
culated f rom a single
study45 per 1000 32 per 1000
(7 to 152)
Congenital abnormali-
t ies
Study populat ion RR 0.32
(0.01 to 7.73)
110
(1 RCT)
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VERY LOW 13
Absolute ef fects cal-
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19 per 1000 6 per 1000
(0 to 143)
Intervent ion side ef -
fects
Study populat ion RR 0.79
(0.06 to 11.20)
25
(1 RCT)
⊕©©©
VERY LOW 13
Absolute ef fects cal-
culated f rom a single
study91 per 1000 72 per 1000
(5 to 1000)
Preterm birth Study populat ion RR 1.01
(0.31 to 3.28)
134
(2 RCTs)
⊕©©©
VERY LOW 245
Absolute ef fects based
on inconsistent f ind-
ings in 2 studies121 per 1000 122 per 1000
(38 to 398)
1. Severity, reduct ion
or cessat ion in nausea/
vomit ing
2. Number of episodes
of emesis
3. Quality of lif e out-
comes
Not reported Not est imable The studies included in
this comparison did not
report these review out-
comes
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Single study with design lim itat ions contribut ing data
2 Small sample size and wide 95% CIs crossing the line of no ef fect
3 Small sample size, low event rate and wide 95% CIs crossing the line of no ef fect
4 Data f rom studies with design lim itat ions
5 Inconsistent ef fect in the two studies contribut ing data
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D I S C U S S I O N
Summary of main results
This review included 25 studies (involving 2052 women), but
the majority of our analyses are based on data from single studies
with small numbers of participants. The included studies covered
a range of interventions (both pharmacological and non-pharma-
cological, such as acupressure/acupuncture, outpatient care, intra-
venous fluids, and various pharmaceutical interventions) for treat-
ing hyperemesis gravidarum. There were no studies of dietary or
other lifestyle interventions. However, the majority of interven-
tions were evaluated in small, often unique, trials, making strong
clinical recommendations impossible.
1. Acupuncture/acupressure was associated with fewer women
requiring additional antiemetics compared to placebo. There was
no clear difference in miscarriage, preterm birth, stillbirth or
neonatal death, decision to terminate the pregnancy, or
anxiodepressive symptoms compared to placebo. There was no
difference in the rate of women who experienced a reduction in
nausea or vomiting compared to metoclopramide. Acupuncture
was associated with greater improvement in nausea/vomiting
compared to phenobarbital and Chinese medicine.
2. Chinese medicine compared to phenobarbital had no
difference in improvement in nausea and vomiting.
3. There were no studies solely on dietary or lifestyle
modification, although, midwife-led outpatient care was
associated with fewer hours of hospital admission than routine
inpatient admission with no difference in pregnancy-unique
quantification of emesis and nausea (PUQE) score, decision to
terminate the pregnancy, miscarriage, small-for-gestational age
infants, or time off work when compared with routine care.
4. Tailored care based on a holistic assessment in addition to
standard care compared to standard care alone did not
demonstrate any difference in improvement of nausea and
vomiting or quality of life.
5. There was greater degree of subjective improvement found
with muscle relaxation therapy and pharmacotherapy compared
to pharmacotherapy alone with no clear difference in decision to
terminate the pregnancy.
6. There was no difference in duration of hospital stay with
dextrose saline fluids versus normal saline for rehydration.
7. Vitamin B6 showed a slightly longer hospital admission
compared with placebo, but no difference in the number of
episodes of emesis. There was also no difference found in the rate
of hospital readmission, weight loss, or medication side effects
compared to placebo.
8. Parenteral fluid with diazepam compared to parenteral fluid
alone had a decreased mean duration of hospital admission, but
there was no difference in the hospital readmission rate, number
of women requiring additional antiemetics, number of women
choosing to terminate the pregnancy, or in the rate of preterm
delivery. Neither group had any cases of congenital anomalies.
9. Metoclopramide compared to ondansetron had similar
nausea and vomiting severity, but increased rate of drowsiness
and dry mouth. Compared to hydrocortisone, metoclopramide
had similar rates of hospital readmission and need for enteral/
parenteral nutrition. Compared to promethazine, there was no
difference in quality of life measures, but there were decreased
rates of drowsiness, dizziness and dystonia with metoclopramide.
10. Ondansetron compared to promethazine had no clear
difference in days of hospital admission but decreased rate of
sedation, and compared to metoclopramide, had a lower rate of
drowsiness and dry mouth with no difference in nausea/
vomiting severity.
11. Promethazine compared to metoclopramide had similar
mean well-being outcomes with increased rate of drowsiness,
dizziness and dystonia. Promethazine compared with
ondansetron showed no difference in days of hospital admission
but had an increased rate of sedation. Promethazine compared
with corticosteroids had improved well-being scores and
improved nausea at 48 hours, but not by day 17. Compared with
corticosteroids, there was no difference episodes of emesis, in the
number of women who had persistent vomiting, inability to
tolerate oral intake, or participant perceived improvement. There
was also no significant difference in readmission rate, women
requiring additional antiemetics, rate of stillbirth, neonatal
death, preterm delivery, decision to terminate the pregnancy, or
medication side effects.
12. Corticosteroids compared to placebo had a lower rate of
hospital readmission, but otherwise demonstrated no difference
in days of hospital admission, medication side effects, number of
women requiring additional antiemetics, decision to terminate
the pregnancy or adverse pregnancy outcomes including
hypertension, diabetes, stillbirth or neonatal death, congenital
anomalies, and low birthweight. Compared to promethazine,
steroids were associated with lower well-being, and had more
severe nausea at 48 hours, although this did not persist by day
17. There was also no significant difference in readmission rate,
women requiring additional antiemetics, rate of stillbirth,
neonatal death, preterm delivery, decision to terminate the
pregnancy, or medication side effects. Compared to
metoclopramide, treatment with corticosteroids demonstrated
no difference in hospital readmission.
13. Treatment with ACTH compared to placebo had no strong
evidence of difference in mean relief score, but did demonstrate
increased mean weight gain. There was also no clear difference
found in rate of readmission, miscarriage, or preterm delivery.
Overall completeness and applicability of
evidence
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We attempted to be as inclusive as possible in the search strat-
egy and have included studies in languages other than English.
Nonetheless, the studies reported are predominantly from Euro-
pean and North American journals, which may limit the external
validity of these result.
Interpreting and comparing the findings of the studies included
was difficult because of the variation in the reporting of the sub-
jective outcome of severity of nausea and vomiting, thus the meta-
analysis component of this review is limited. In addition, even
within a comparison, often dosages or route of administration var-
ied between studies, we treated them as equivalent which is not
necessarily clinically true.
Limited data were available regarding adversematernal and neona-
tal outcomes, thus the lack of report on adverse events or the lack
of statistical significance does not necessarily mean no harm is
present. Larger studies on individual interventions need to be ex-
amined to determine the safety of these many interventions.
There was also very limited reporting on the economic impact of
hyperemesis gravidarum and the impact on this economic burden
that interventions may have. Although studies often reported an
overall well-being score, this does not necessarily equate with abil-
ity to return to work.
Quality of the evidence
We were unable to pool findings for most interventions reviewed
here because of heterogeneity in intervention and comparison
groups and in outcomes measured, thus most results presented
are from individual studies. Additionally, inclusion and exclusion
criteria varied between studies. Studies were included on the basis
of their own definition of hyperemesis gravidarum, which may
or may not have included objective criteria like weight loss. The
methodological quality of the included studies varied. A number
of studies were published in abstract form only, and not enough
methodological detail was provided to appropriately assess any
type of risk of bias. For studies published in full, the quality was
generally good with adequate quality in randomization, outcome
reporting, and limited attrition. However, for a number of stud-
ies were there was not enough information to appropriately assess
blinding of either participants or investigators. Additionally, no
study reported on the quality of their blinding, thus it is possi-
ble that, for example, sham acupuncture was not believable. Ap-
propriate blinding is especially important in this condition be-
cause the primary outcomes are often subjective and self-reported.
There was one study on outpatient versus inpatient management
where blinding was inherently impossible. Another limitation is
that studies with a placebo comparison often included standard
care for both groups which involved one or a combination of other
antiemetic medications, which varied by study, and the details
of which were not reported. Finally, there was heterogeneity in
the way in which outcomes were measured. Most studies used a
10-point visual analogue scale, without providing support of its
validation in nausea and vomiting of pregnancy. Other studies
used the Rhodes Index of Nausea, Vomiting, and Retching, which
was originally developed to measure symptoms of chemotherapy,
but has been validated in pregnancy (Rhodes 1984; Zhou 2001).
Other studies used pregnancy specific questionnaires, either of the
author’s creation, without support of validation, or the more com-
monly used PUQE, which has been validated (Koren 2005).
For important outcomes and comparisons we graded the quality of
the evidence using the GRADE approach. When outcomes were
reported, at best the evidence was graded as being of moderate
quality, while formost outcomes the evidence was assessed as being
of low or very low quality. The main reasons for downgrading
the evidence were design limitations in the studies contributing
data, but most importantly the imprecision of effect estimates. For
most outcomes, single studies with relatively small sample sizes
contributed data. Studies were mainly under-powered to identify
differences between comparison groups and most effect estimates
had wide 95% CIs crossing the line of no effect.
See Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6; Summary of
findings 7; Summary of findings 8.
Potential biases in the review process
There is potential for bias in every step of the review process. We
attempted to limit the bias by having at least two review authors
independently carry out the evaluation of studies for inclusion,
data extraction, and quality assessment, with any discrepancies be-
ing resolved by a third review author. However, such an assessment
is still by nature subjective and a different team of review authors
may have had a different assessment.
Agreements and disagreements with other
studies or reviews
There are several other reviews and overviews on hyperemesis
gravidarum, with varying degrees of support from the literature
(Eliakim 2000; Goodwin 1998; Ismail 2007; Jarvis 2011;Maltepe
2013;McCarthy 2014a; Philip 2003; Sonkusare 2008). Goodwin
1998 mentions randomized trials on both nausea and vomiting of
pregnancy as well as hyperemesis gravidarum and acknowledges
the limited support from trials of various interventions. The au-
thors do mention studies reviewed here (Sullivan 1996; Ylikorkala
1979), as well as a study we excluded based on cross-over design,
on the effect of ginger (Fischer-Rasmussen 1991). Their review
also supports the use of steroids in reducing the need for hospi-
talization, although does not include the more recent studies re-
viewed here.
Eliakim and colleagues (Eliakim 2000) mention a few interven-
tions in their review, but with limited data supporting their con-
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clusion. In contrast to our review, they mention benefit of vitamin
B6, although the study they cite is for the treatment of nausea and
vomiting in pregnancy, rather than hyperemesis gravidarum. They
mention beneficial results for a number of antiemetics including
Bendectin, meclizine, metoclopramide, promethazine, hydrox-
yzine, trimethobenzamine, thielpyrazin, mepryramine, dimenhy-
drinate, droperidol, diphenhydramine, ondansetron, methylpred-
nisolone, and ginger, but cites other reviews on nausea and vom-
iting of pregnancy as their sources rather than specific studies.
Philip2003 provides a review that includes randomized trials,most
of whichwe have also included, as well as retrospective studies. The
authors have similarly found no benefit with ACTH (Ylikorkala
1979), no benefit of ondansetron over promethazine (Sullivan
1996), and possible benefit of corticosteroids (Duggar 2001; Safari
1998). They also conclude no benefit with vitamin B6. In contrast
to our review, they found no benefit from P6 acupressure where we
have found that there may be some benefit compared to placebo.
A review by Ismail and colleagues (Ismail 2007) similarly con-
cludes limited benefit acupuncture/acupressure; they recommend
use of antiemetics, but do not provide data to support their efficacy
in hyperemesis gravidarum, and, in contrast to our review, found
no benefit with corticosteroids, while we did find a decreased rate
of hospitalization compared to placebo. Sonkusare 2008 examines
a number of different interventions, however includes trials on
nausea and vomiting of pregnancy along with hyperemesis gravi-
darum, and is not limited to randomized controlled trials. In con-
trast to our review, they found benefit with vitamin B6 and ginger.
They found no benefit with corticosteroids, based on only one
study, also included in this review (Yost 2003), and finally, they
concluded there was benefit with diazepam, nerve stimulation,
erythromycin, and cannabis (Sonkusare 2008).
The review by Jarvis in 2011 (Jarvis 2011) mentions trials for both
nausea and vomiting and pregnancy as well as hyperemesis, and
is not limited to randomized controlled trials. The authors simi-
larly found little benefit of one antiemetic over another, describe
similar side-effect profiles to our review, although they conclude
drowsiness is most common with phenothiazines, which is not
something supported by evidence in our review. They also recom-
mend normal saline over dextrose saline, for the risk of Wernicke’s
encephalopathy, although our review found no difference between
the two. They also found that corticosteroids may reduce hospi-
tal admissions. Maltepe 2013 provides a review primarily on nau-
sea and vomiting of pregnancy with some mention of antiemetics
for hyperemesis gravidarum, without specific recommendations
or conclusions on their benefit. McCarthy 2014a provides a brief
overview on treatment for hyperemesis gravidarum, citing, how-
ever, the previously published Cochrane review on nausea and
vomiting of pregnancy, which specifically excludes hyperemesis
gravidarum (Matthews 2015). They similarly conclude limited ev-
idence regarding the benefit of one antiemetic over another.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although there have been a number of reviews on the manage-
ment of hyperemesis gravidarum, as described above, they often
have limited evidence to support their conclusions, and combine
interventions for nausea and vomiting of pregnancy with themore
severe condition of hyperemesis gravidarum.
On the basis of this review, there is little high-quality and con-
sistent evidence supporting any one intervention, which should
be taken into account when making management decisions. Ad-
ditionally, in evaluating various interventions, we have combined
various forms of a specific therapy for the purpose of the meta-
analysis, such as intravenous and oral forms and different dosages,
so we cannot provide guidelines on specific doses or routes of the
antiemetics examined here.
Implications for research
The difficulty in interpreting the results of this review highlights
the importance of having a specific definition of hyperemesis gravi-
darum for use in trials, conducting randomized controlled trials in
comparing interventions, and using validated instruments for the
measurement of severity of nausea and vomiting. There should be
an agreed-upon set of clearly-defined and measurable outcomes
in trials of interventions for hyperemesis gravidarum, so that out-
comes of trials can be combined in future meta-analyses.
The vast majority of the trials evaluating interventions for hyper-
emesis gravidarum were evaluated in only small, often unique, tri-
als, so almost all interventions deserve to be evaluated further in
much larger, well-designed trials.We found little data on the use of
ginger, antihistamines, and dietary and lifestyle modifications in
the treatment of hyperemesis gravidarum, which is an area of fur-
ther research. There was only one study on outpatient-led care that
found reduced hospital stay compared with routine care, which
certainly warrants further study. There were a number of stud-
ies comparing the commonly used antiemetics metoclopramide,
ondansetron, and promethazine, although data on primary out-
comes were limited and the main differences found were in side-
effect profiles. There were also a number of studies on corticos-
teroids, but the heterogeneity in inclusion criteria, specific medi-
cations, and comparison groups in these studies makes it difficult
to draw conclusions from our results. Placebo-controlled trials on
steroids included other antiemetics in both groups as standard of
care, which varied by study, but the finding of decreased hospital
readmission rate warrants further study.
Finally, given that there was little evidence to support the superi-
ority of one intervention over another in the treatment of hyper-
emesis, more research should be done comparing the side-effect
profiles and safety, as well as the economic costs and benefits of
these interventions to aid in the selection of the optimal regimen.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abas 2014
Methods Randomized controlled trial.
Participants Pregnant women with singleton gestations of 16 weeks or less with clinical diagnosis
of HG with clinical dehydration and ketonuria (2+ or greater) hospitalized for the first
time with this diagnosis. 80 women randomized to interventions and 80 to controls
Interventions 4 mg ondansetron IV infused over 10 minutes every 8 hours for 4 doses versus 10 mg
metoclopramide IV infused over 10 minutes every 8 hours for 4 doses
Outcomes Vomiting episodes, well-being (10-point visual numeric rating scale), nausea intensity
(10-point visual numeric rating scale), ketonuria all at 24 hours, treatment curtailment,
open-label use of IV metoclopramide after the study, length of hospital stay
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It is stated that randomization was carried out in blocks
of 4 or 8 with sequence generated by computer
Allocation concealment (selection bias) Low risk Numbered, sealed, opaque envelopes were used to allo-
cate treatment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 1 author prepared and labeled the solutions. Study drug
packs were identical. Labeling of drugs was swapped pe-
riodically to prevent inadvertent elucidation of alloca-
tion from adverse effects
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Person self-reported number of emesis episodes and
recorded nausea in a diary. Maintenance of masking was
high and person unlikely to be aware of treatment allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of women lost to follow-up was low, and
accompanying reasons are reported. 4/80 and 3/80 from
each group did not complete the trial drug
Selective reporting (reporting bias) Low risk Methods state that predetermined outcomes were used
and reported, all expected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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Bondok 2006
Methods Randomized controlled trial.
Participants Pregnant women at less than 16 weeks’ gestation with diagnosis of intractable HG
(severe persistent vomiting, ketonuria, and weight loss > 5% of prepregnancy weight)
necessitation ICU admission. 20 women randomized to interventions and 20 to controls
Interventions 300 mg IV hydrocortisone daily with taper versus 10 mg metoclopramide IV every 8
hours
Outcomes Number of vomiting episodes, readmission to ICU.
Notes 1 participant required TPN.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization conducted with a computer-generated
randomized list
Allocation concealment (selection bias) Low risk The code was held and syringes used for both groups
were identical in appearance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study is described as a double-blind study. It is
stated that the personnel administering the drugs was
masked to treatment. The description of the adminis-
tration schedule is a little ambiguous but it seems that
people in each group received a 10 mL injection every
8 hours. The syringes were identical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Nurses recording the number of episodes of emesis were
blinded to the treatment, main investigators were also
blinded to which participants were in which group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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Ditto 1999
Methods Randomized controlled trial.
Participants Women with HG at less than 16 weeks’ gestation, defined by persistent nausea and
vomiting for 1 week with at least 1 of the following: weight loss > 5% since beginning of
symptoms, ketonuria (3% increase), serum potassium less than 3.4 mEq/L. 25 women
randomized to interventions and 25 to controls
Interventions IV saline, glucose, multivitamins with 10 mg IV twice daily and PO 5 mg bid diazepam
on discharge versus IV saline, glucose, multivitamins without diazepam
Outcomes Severity of nausea (VAS 0-10), number of episodes of vomiting, hospital admission
length, number of readmissions, pregnancy outcome, neonatal outcome. lack of im-
provement defined by persistent (> 5 x/day) vomiting
Notes Lack of improvement defined as persistent (> 5 x/day) vomiting. Primary outcome
reported as number of participants with improvement in figure form, specific numbers
not reported. No response from authors in request for additional data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table used to allocate participants.
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient reporting to determine presence of other
forms of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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Duggar 2001
Methods Randomized controlled trial.
Participants Pregnant women with admission diagnosis of HG. 14 women randomized to interven-
tions and 11 to controls
Interventions Methylprednisone PO versus placebo.
Outcomes Recurrence of vomiting after randomization, readmission, medication tolerance
Notes Abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study is described as randomized, but details on method
of randomization not available
Allocation concealment (selection bias) Unclear risk Details on methods of allocation concealment not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is described as double-blind and it is stated
that treatment in the placebo group “looked like” that in
the methylprednisolone group. However, it is not stated
who was masked to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of people randomized to each group not re-
ported. It is unclear whether anyone withdrew from
treatment or was lost to follow-up
Selective reporting (reporting bias) Unclear risk As a conference abstract, insufficient information re-
ported to determine presence of selective reporting
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
Fletcher 2015
Methods Randomized controlled trial.
Participants Pregnant women at least 16 years old diagnosed with HG defined as need for admission
with nausea and vomiting early in pregnancy, admitted within the previous 24 hours,
excluded women if nausea/vomiting commenced after 14 weeks
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Fletcher 2015 (Continued)
Interventions Intervention comprised creation of a bespoke treatment plan for each patient based on
their response to the Hyperemesis Impact of Symptoms questionnaire. Scale based on 10
questions, scoring 0-3. A score of 2 or more indicates woman needs support in that area.
Treatment plan included practical and supportive care (dietary advice, practical advice
on symptom management and advice on psychological impact of symptoms). These
Women also received standard care (IV hydration plus antiemetic therapy). Comparison
group received standard care alone
Outcomes Womens’ health status assessed using SF-36 and EQ-5D.
PUQE score recorded.
Client Satisfaction Questionnaire used to evaluate satisfaction with health care. Hospital
readmission rate. Cost-effectiveness. Primary outcome is social functioning, as assessed
using the SF-36
Notes Data for analysis taken from the 2-week time point because this point had the highest
response rate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It is stated that randomization was carried out remotely
by the York Trials Unit, using computer-generated sim-
ple allocation
Allocation concealment (selection bias) Low risk Allocation randomized remotely via telephone.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded. Unclear whether research
personnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Participants were not blinded. Unclear whether research
personnel were blinded.Outcomeswere reported by par-
ticipants, thus the fact that they were not blinded may
influence outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of women lost to follow-up was low, and
accompanying reasons are reported. The proportion of
women lost to follow-up from each group was similar
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes, given the objective of the trial,
are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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Gawande 2011
Methods Randomized controlled trial.
Participants Pregnant women at less than 12 weeks’ gestation with HG defined by severe vomiting,
dehydration, acidosis and hypokalemia. 15 women randomized to interventions and 15
to controls
Interventions Progressive muscle relaxation daily for 2 weeks and pharmacotherapy versus pharma-
cotherapy alone
Outcomes Number of antiemetics required, number of days to achieve complete response (no
vomiting 24 hours), number of participants with recurrence after complete response,
clinical global improvement at the end of 2 weeks (CGI score)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study is described as randomized, but details on the
method of randomization are not reported
Allocation concealment (selection bias) High risk Treatment group received progressive muscle relaxation
sessions, placebo group were called to psychiatric OPD
but received no intervention. Treating obstetricians were
reported to be blinded, details not specified, risk of com-
promise given that participants were not blinded. Meth-
ods used to conceal allocation not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treating obstetricians were reportedly blinded but par-
ticipants were not, participants were called to psychiatric
OPD sessions but did not receive a placebo interven-
tion, so there is a high risk treating providers would still
be able to determine group allocation by speaking with
participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is stated that the “observer” was masked to treatment.
It is unclear whether the observer is the person assessing
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data analyzed on all people randomized.
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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Habek 2004
Methods Randomized controlled trial.
Participants Pregnant women with HG. 22 women randomized to interventions and 15 to controls
Interventions 2 active interventions:
1: bilateral manual acupuncture of Pc6 acupoints (30 mins a day for 7 days);
2: bilateral acupressure of Pc6 acupoints (self-applied for 30 mins when feeling nausea
throughout the day)
2 placebo groups:
1: superficial acupuncture;
2: superficial acupressure.
Outcomes Resolution of symptoms of nausea and vomiting, and lack or need for medication for
treatment of symptoms
Notes Outcome criteria were defined as disappearance of symptoms and no requirement for
additional medication. However, efficacy was based on participant report and indepen-
dent evaluation of the participant’s clinical condition. No further details reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study is described as randomized, but details on the
method of randomization are not reported
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as a double-blind study. It is stated that the
women and the clinician assessing therapeutic efficacy
weremasked to treatment. Sham treatment used tomask
key personnel to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The clinician assessing therapeutic efficacy was masked
to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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Heazell 2006
Methods Randomized controlled trial.
Participants Women with nausea and vomiting on their first inpatient admission and between 5 and
14 weeks’ gestation. Women also had to have at least 2+ of ketonuria on urinalysis, an
inability to tolerate oral fluids and a requirement for antiemetic medication. 40 women
randomized to interventions and 40 to controls
Interventions Acupressure at the P6 meridian point (wristbands worn for 8 hours a day) versus placebo
acupressure at a point on the dorsal aspect of the forearm (wristbands worn for 8 hours
a day)
Outcomes Days of hospital admission, number of participants requiring 4 or more days, require-
ment of additional antiemetic treatment, amount of IV fluids required within 24 hours,
and number of additional antiemetics required. Pregnancy outcome (SAB, TAB, PTD,
IUFD, term delivery, congenital anomalies)
Notes No response from authors for request for additional data.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It is stated that women were randomly allocated to ei-
ther the treatment or placebo group by an independent
remote researcher with no prior knowledge of the par-
ticipant
Allocation concealment (selection bias) Low risk It is stated that a ticket that indicated either placebo or
treatment group was drawn from an opaque bag
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded to their assignment, identical
bead was placed at an acupressure versus alternate fore-
arm site
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
was masked to treatment. However, the outcomes as-
sessed are predominantly objective outcomes (e.g., num-
ber of days of hospital stay) and at a low risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of women lost to follow-up was low, and
accompanying reasons are reported. The proportion of
women lost to follow-up from each group was similar
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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Kashifard 2013
Methods Randomized controlled trial.
Participants 18-35 years, gestational age less than 16 weeks, vomiting 3 times a day with weight
loss more than 3 kg and ketonuria. 34 women randomized to interventions and 49 to
controls
Interventions 10 mg metoclopramide PO 3 times daily versus ondansetron 4 mg PO 3 times daily
Outcomes Severity of nausea (VAS 1-10), number of vomiting episodes within 2 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It is stated that the randomized list was computer-gen-
erated
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is described as a double-blind study, with in-
vestigators and participants masked to treatment. It is
unclear whether the treatments were of similar appear-
ance and, thus, whether masking could have been com-
promised
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators reported to be blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
Mamo 1995
Methods Randomized controlled trial.
Participants Pregnant women in first trimester with severe pregnancy vomiting. 19 women random-
ized to interventions and 19 to controls
Interventions Sea-band acupressure versus placebo.
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Mamo 1995 (Continued)
Outcomes Need for antiemetic medication, need for hospitalization.
Notes Abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study is described as randomized, but details on the
method of randomization are not reported
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details reported on level of masking.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up
Selective reporting (reporting bias) Unclear risk As a conference abstract, insufficient information re-
ported to determine presence of selective reporting
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
Mao 2010
Methods Randomized controlled trial.
Participants Pregnant women age 20-36 years with frequent vomiting, inability to tolerate food, de-
hydration, electrolyte abnormalities, diagnosed with HG by the Obstetrics and Gynae-
cology department; based on definition in a medical textbook. Study included women
with gestation up to 12 weeks, although this was not a specified inclusion criterion
Interventions Acupuncuncture - standard care (hydration, electrolytes) plus acupuncture at BL11,
ST37, PC6, SP4, RN12, ST36; ORWestern medicine - 30 mg luminal (phenobarbital)
orally 3 times daily in addition to standard care; OR Chinese medicine based according
to dialectical classification
Outcomes Ketone bodies, CO2-CP decline, electrolyte imbalance and severity of nausea and vom-
iting
Severity of nausea and vomiting defined as:
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Mao 2010 (Continued)
Complete Recovery: Nausea and vomiting ceased and normal appetite returned.
Obvious Effects: The frequency of nausea and vomiting reduced by over 50% and the
appetite has increased.
Effects Showed: The frequency of nausea and vomiting was reduced by 25%-50% and
the appetite has some slight increase.
Ineffectiveness: Frequent vomiting continued, the reduction of vomiting frequency was
below 25% and there was no change in appetite
Notes Data for analysis taken from day 7 time point as that was the completion of therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study is described as randomized, but details on the
method of randomization are not reported
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Details on level of masking unclear.
Possibly an open-label trial as it is likely to be diffi-
cult to mask the intervention (acupuncture versus oral
medicine)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Details on level of masking unclear.
Incomplete outcome data (attrition bias)
All outcomes
Low risk It is not stated whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up. How-
ever, results are reported based on all women analyzed
(total 30 women in each group at the 2 time points as-
sessed)
Selective reporting (reporting bias) Unclear risk Although outcomes captured were described and abso-
lute event rates for some clinical outcomes are reported,
methods to measure said outcomes were not specified,
so it is unclear whether key or expected outcomes were
measured appropriately and reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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McParlin 2008
Methods Randomized controlled trial.
Participants Pregnant women with severe nausea and vomiting in pregnancy. 27 women randomized
to interventions and 26 to controls
Interventions Outpatient care: rapid IV rehydration (3 liters over 6 hours), and IV cyclizine, followed
by discharge home with oral cyclizine, and an advice leaflet. Participants also received
ongoing midwifery support through 2 follow-up telephone calls versus inpatient admis-
sion and routine care
Outcomes Physical symptoms evaluated by the pregnancy unique quantification of emesis and
vomiting score on admission and at 7 days. Quality of life measured on days 1 and 7
using the SF36.v2 score. Readmission rate and admission time
Notes Abstract only. Outcomes were not pre-specified.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study is described as randomized, but details on the
method of randomization are not reported
Allocation concealment (selection bias) Unclear risk Details on method used to conceal allocation not avail-
able, given nature of intervention not possible to blind
those who participated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Details on method used to conceal allocation not avail-
able, given nature of intervention not possible to blind
those who participated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Itis unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up. There
was only 69% protocol adherence in the intervention
group; effect on outcome unclear
Selective reporting (reporting bias) Unclear risk As a conference abstract, insufficient information re-
ported to determine presence of selective reporting
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
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Miller 2001
Methods Randomized controlled trial.
Participants Pregnant women at 6-12 weeks’ gestation with severe nausea and vomiting. 45 women
randomized to interventions and 28 to controls
Interventions Nerve stimulation therapy (with a watch-like device) over the volar aspect of the wrist
at the P6 point (Reliefband) versus placebo
Outcomes Rhodes index of nausea, vomiting, and retching and 1, 2, and 3 weeks. Medication use,
weight gain, urinary ketones
Notes Abstract only, specific data not reported, unable to contact author for additional data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study described as randomized, but details on method
of randomization not reported
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Details on level of masking unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Details on level of masking unclear.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Conference abstract only, unclear whether any person
was lost to follow-up or withdrew from treatment
Selective reporting (reporting bias) Unclear risk Abstract only, unclear whether all outcomes reported.
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
Nelson-Piercy 2001
Methods Randomized controlled trial.
Participants Pregnant women with severe or prolongedHG, with onset of symptoms before 12 weeks’
gestation. Women were also dependent on IV fluids for at least 1 week (first admission
for HG) or for 24 hours (second or subsequent admission for HG), were receiving
regular treatment with at least 1 antiemetic, had ketonuria on admission, no infection
(as evidence by mid-stream urine sample), normal random blood glucose (unless known
diabetic), vomiting at least twice a day, or nausea so severe they were unable to eat or
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Nelson-Piercy 2001 (Continued)
drink, and were receiving thiamine. 12 women randomized to interventions and 13 to
controls
Interventions Prednisolone 20 mg orally every 12 hours for 1 week. If after 72 hours, a woman was still
vomiting and was dependent on IV fluid, the regimen was changed to an IV equivalent
versus placebo at same dosing regimen as prednisolone (either oral tablet or saline)
Outcomes Frequency of vomiting (vomiting score measured on a scale from 0 to 4), dependence on
IV fluids after 1 week of treatment, length of hospital stay, duration of IV fluid therapy
after randomization, severity of nausea (measured on a scale from 0 to 10), need for
antiemetics, presence of ptyalism, well-being rating (measured on a scale from 0 to 10),
intake of oral fluids and food, change in thyroid function tests, change in liver function
tests, weight gain. Pregnancy outcomes: birthweight, preterm delivery, gestational age of
delivery, birthweight < 5th percentile, stillbirth, multiple gestation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It is stated that women were randomly allocated individ-
ually using a computer-generated allocation schedule
Allocation concealment (selection bias) Low risk It is stated that each center was allocated sequentially
numbered trial packs held in the pharmacy, and each
pharmacy held a copy of the allocation schedule
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is stated that the clinicians (assessors), nurses, mid-
wives and participants were blinded to the study med-
ication. The prednisolone tablets were identical in ap-
pearance to the placebo tablets. The local pharmacists
were blinded until the need for IV therapy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The clinician assessing outcomes was masked to treat-
ment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 woman withdrew from the study due to preg-
nancy termination on day 1
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias High risk Per the authors’ report, this studywas prematurely halted
due to “a combination of different factors in different
centers, including the departure of keymembers of staff,
and the erroneous belief that steroids had had such a
dramatic beneficial effect that continued randomization
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Nelson-Piercy 2001 (Continued)
of women was not justified”
Neri 2005
Methods Randomized controlled trial.
Participants Women with HG and who had a singleton pregnancy, were at less than 12 weeks’
gestation, and had a diagnosis of HG based on the commonly accepted criteria of nausea
and vomiting leading to clinical symptoms of dehydration and weight loss > 5%. 43
women randomized to interventions and 38 to controls
Interventions Acupuncture (includes stimulation at 5 acupoints) twice a week for 2 weeks. Women
were also advised to wear a device giving acupressure at the Pc6 point (worn for 6-8
hours per day) versus metoclopramide infusion (20 mg/500 mL saline infused over 60
mins) twice a week for 2 weeks. Oral treatment was supplemented with vitamin B12 (30
mg/day)
Outcomes Number of participants with improved intensity of nausea, improved episodes of vom-
iting, improved rate of food intake, daily functioning. Pregnancy outcome (gestational
age at delivery, birthweight, rate of cesarean section)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It is stated that a computer-generated random list was
used to allocate women to treatment group: odd and
evennumbers formed the basis of allocation to treatment
Allocation concealment (selection bias) Low risk Allocation code held under the control of a midwife.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo used, participants not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Results are based on 81 out of 88 women randomized.
The number of women lost from the metoclopramide
group was considerably higher than that from the acu-
pressure group (6 women versus 1 woman, respectively)
. 1 woman withdrew from acupuncture group due to
perceived inefficacy. 4 women refused to take metoclo-
pramide, and 2 had spontaneous abortions at 10 weeks.
The influence of this imbalance on estimate of effect is
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Neri 2005 (Continued)
unclear
Selective reporting (reporting bias) Low risk Although the protocol of the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
Safari 1998
Methods Randomized controlled trial.
Participants Women with an intrauterine pregnancy of gestation of 16 weeks or less and diagnosis of
HG (persistent vomiting, large ketonuria, and weight loss). If nausea and vomiting did
not resolve after IV hydration, or if a woman had been previously admitted to hospital
for hyperemesis, they were offered participation in the study. 20 women randomized to
interventions and 20 to controls
Interventions Methylprednisolone 16mg orally 3 times a day for 3 days, followed by a tapering regimen
(halving of dose every 3 days) to none during the course of 2 weeks versus promethazine
25 mg tablets 3 times a day for 2 weeks
Outcomes Improvement of symptoms within 2 weeks of starting therapy. Lack of improvement was
defined as persistent vomiting (> 5 times a day), inability to tolerate liquids by mouth,
or participant’s impression that she was not better, readmission to hospital
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It is stated that a computer-generated random list was
used to allocate women to treatment group
Allocation concealment (selection bias) Low risk It is stated that “Envelopes containing the study assign-
ment were prepared in advance and sequentially labeled
by a third party not involved in the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The primary investigators, attending physicians, and the
participants weremasked to treatment.However,Nurses
dispensing the medication were able to observe the dif-
ference in the shape of the pills but were not informed
which pills corresponded to which medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Attending physician was masked to treatment.
69Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Safari 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of women lost to follow-up was low, with
the same number of women lost from each group (3
women, 6 women in total)
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine the presence of other
forms of bias
Shin 2007
Methods Randomized controlled trial.
Participants Women diagnosed with HG, defined as consistent nausea and vomiting, electrolyte
imbalance, more than 5% loss of weight, dehydration, positive ketonuria, and increased
urine specific gravity. Women were also aged 20 to 40 years and at gestation of 5 to 30
weeks. Women were receiving only conventional IV fluid therapy. Women had no other
complications of pregnancy. 23 women randomized to interventions and 22 to controls
Interventions Acupressure at the P6 meridian point. Pressure was applied for 7 seconds with 2-second
pauses, 3 times daily before breakfast, lunch and dinner. Each session lasted 10 minutes
versus placebo acupressure (as for acupressure but pressure applied at a bony part around
the radial pulse) versus control (no treatment other than conventional IV therapy)
Outcomes Degree of nausea and vomiting (measured using a modified version of the Rhodes Index;
score between 6 and 30), ketonuria
Notes Insufficient reporting to determine the presence of other forms of bias
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by coin toss.
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study is described as double-blind. The nurses ad-
ministering treatment were not aware of treatment allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported to be double-blind, however unclear whether
or how the person assessing outcomes was blinded
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Shin 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine the presence of other
forms of bias
Sullivan 1996
Methods Randomized controlled trial.
Participants Women with severe HG during the first and second trimesters of pregnancy that had not
been previously treated by IV medication or hospitalization. Women also had to have
2 of: at least a 5-pound weight loss compared with the initial prenatal visit or previous
record; ketonuria > 80 mg/dL in a random urine specimen; hypokalemia (potasium < 3.
0 mEq/dL) or hyponatremia (sodium < 134 mEq/dL requiring IV replacement; positive
test result for serum acetone; or more than 2 visits to the obstetric emergency depart-
ment requiring IV hydration or promethazine suppositories. 15 women randomized to
interventions and 15 to controls
Interventions Ondansetron 10 mg IV every 8 hours (infused over 30 minutes) versus promethazine
50 mg IV every 8 hours (infused over 30 minutes)
Outcomes Severity of nausea (assessed on a VAS; 10 cm scale), duration of hospital stay, treatment
failure, daily weight gain, antiemetic usage, and adverse effects
Notes Unclear how many women were randomized. Seems to be 30, but states that 30 were
evaluable, which suggests more women were randomized than analyzed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study is described as randomized, but details on
method of randomization are not reported
Allocation concealment (selection bias) Unclear risk Details on method used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study is described as double-blind, but it is unclear
who was masked to treatment. Although it is unclear
who was masked to treatment, maintenance of masking
seems adequate: the infusion solution was marked as
“hyperemesis study drug” and the infusion bag covered
with a plain brown bag
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Sullivan 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether personnel assessing outcomes
was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
Tabatabaii 2008
Methods Randomized controlled trial.
Participants Pregnant women with HG in first half of pregnancy. 48 women randomized to inter-
ventions and 48 to controls
Interventions Methylprednisolone (125 mg) IV infusion followed by an oral prednisone taper (40 mg
for 1 day, 20 mg for 3 days, 10 mg for 3 days, 5 mg for 7 days) versus placebo. Both
groups also received 100 mg vitamin B6 daily
Outcomes Number of women requiring rehospitalization for HG.
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study is described as randomized, but details on the
method of randomization are not reported
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study is described as double-blind but details on who
wasmasked, or howmaskingwasmaintained (other than
that the placebo infusion was identical in appearance to
the methylprednisolone infusion), are not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether personnel assessing outcomes
were masked to treatment
72Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tabatabaii 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up
Selective reporting (reporting bias) Unclear risk As a conference abstract, insufficient information re-
ported to determine the presence of selective reporting
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
Tan 2009
Methods Randomized controlled trial.
Participants Women with singleton gestation at less than 20 weeks and with presumed HG (severe
nausea and vomiting during pregnancy with clinical features warranting hospitalization)
. Women were experiencing their first hospital admission for HG and were enrolled
within 12 hours of admission. 47 women randomized to interventions and 45 to controls
Interventions Oral pyridoxine (20 mg 3 times daily from admission to 2 weeks after hospital discharge)
versus placebo
Outcomes Readmission rate for HG in the 2 weeks after hospital discharge, daily vomiting episodes
at home by diary, and nausea score at enrollment, hospital discharge and week 1 and 2
reviews, adverse effects
Other outcomes were admission to discharge interval, compliance, body weight, ke-
tonuria, dry retching episodes by diary and an overall well-being score using a 10-point
VAS (higher score denotes greater well-being)
Nausea evaluated with a 10-point VAS (higher score denotes more severe nausea)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The allocation sequence was randomly generated in
blocks of 10. Randomization was carried out by opening
the next available envelope
Allocation concealment (selection bias) Low risk Envelopes were sealed and opaque. Treatment allocation
was not revealed to the participants or providers
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Treatment allocationwas not revealed to the participants
or the providers. At hospital discharge, womenwere sup-
plied their allocated medication in identical packaging.
Pyridoxine tabletswerewhite. Placebo tabletswerewhite
“tic tacs”, which have a mint flavor. It is unclear whether
tic tacs are sufficiently similar in appearance or taste to
73Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tan 2009 (Continued)
pyridoxine tablets to maintain the masking of treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk It is not stated whether the personnel assessing outcomes
was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of women lost to follow-up was low with
similar rates of attrition between groups at week 1, <
20%, similar rate of attrition between groups at week 2,
> 20%
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine the presence of other
forms of bias
Tan 2010
Methods Randomized controlled trial.
Participants Womenwith singleton gestation at 16weeks or less and with presumedHG (dehydration
and detectable ketonuria by urine dipstick test). Women were experiencing their first
hospital admission for HG. 73 women randomized to interventions and 76 to controls
Interventions Metoclopramide 10 mg IV (infused over 1 to 2 mins)
Treatment given just after randomization and again at 8, 16 and 24 hours
versus
Promethazine 25 mg IV (infused over 1 to 2 mins)
Treatment given just after randomization and again at 8, 16 and 24 hours
Outcomes Vomiting episodes, severity of nausea (as measured using a 10-point VAS), well-being
(as measured using a 10-point VAS), ketonuria, treatment curtailment, total doses of
IV antiemetic during admission, interval of admission, time needed for IV rehydration,
adverse effects
Notes Contact authors regarding the numbers for each group for primary outcome
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The allocation sequence was computer-generated in ran-
dom blocks of 4 or 8. Women were assigned randomly
by the sequential opening of numbered, sealed, opaque
envelopes stating “Drug A” or “Drug B”
Allocation concealment (selection bias) Low risk Envelopes were sealed and opaque.
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participant allocation was concealed and study drugs
were in identical vials
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing the out-
comes was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 6 out of 149 did not complete symptom profile
questionnaire, the proportion of women lost from each
group was similar
Selective reporting (reporting bias) Low risk Preset primary and secondary outcomes.
Other bias Unclear risk Insufficient reporting to determine the presence of other
forms of bias
Tan 2013
Methods Randomized controlled trial.
Participants Women aged 18 years or older, with singleton gestation at 16 weeks or less and with
presumed HG (intractable nausea and vomiting of pregnancy with dehydration and
starvation clinically judged to require hospitalization for IV rehydration and antiemetic
drug administration)
Women also had ketonuria by urine dipstick of at least 1+ on admission, plasma glucose
110 mg/dL or less, and sodium 125 mmol/L or greater
Womenwere experiencing their first hospital admission forHG and were enrolledwithin
2 hours of admission to the ward. 111 women randomized to interventions and 111 to
controls
Interventions 5% dextrose-0.9% saline (IV infusion at a rate 125 mL/h over 24 hours) versus 0.9%
saline (IV infusion at a rate 125 mL/h over 24 hours)
All women also received oral thiamine daily plus IV antiemetic
Outcomes Severity of nausea (as measured using a 10-point VAS), well-being (as measured using a
10-point VAS), ketonuria, frequency of vomiting, hyponatremia (135 mmol/L or less),
hypokalemia (3.5 mmol/L or less), hypochloremia (99 mmol/L or less), hyperglycemia
(8 mmol/L or greater), duration of IV antiemetic and IV rehydration during admission,
interval of admission, time to oral intake
Notes Women already under IV rehydration therapy were not eligible for enrollment
All women also received a multivitamin containing thiamine and IV antiemetic
Risk of bias
Bias Authors’ judgement Support for judgement
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Tan 2013 (Continued)
Random sequence generation (selection
bias)
Low risk It is stated that the allocation sequence was computer-
generated
Allocation concealment (selection bias) Low risk Envelopes were sealed and opaque.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was double-blind. Participants and healthcare
providers were masked to treatment. IV solutions were
prepared in 500 mL containers with the manufacturer’s
label removed and the container relabeled as solution
A or B. The solutions and containers were identical in
appearance, with the exception of labels (A or B)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
were masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of women lost to follow-up was low and
similar between groups. 2/111 and 1/111 in each group
withdrew, 7/111 and 9/111 in each group excluded for
pre-specified criteria
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine presence of other
forms of bias
Ylikorkala 1979
Methods Randomized controlled trial.
Participants Women admitted to hospital because ofHG and whose vomiting did not stop or decrease
significantly during their first 2 days in hospital. 16 women randomized to interventions
and 16 to controls
Interventions Synthetic ACTH (tetracosactid) 0.5 mg IM on 4 consecutive days versus placebo IM on
4 consecutive days
Outcomes Symptom severity, daily number of vomiting attacks, weight gain/loss, serum cortisol
and urine steroids
Notes Symptom severity was evaluated using a scoring system designed by the authors. Scoring
system differed across symptoms
Risk of bias
Bias Authors’ judgement Support for judgement
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Ylikorkala 1979 (Continued)
Random sequence generation (selection
bias)
Unclear risk The study is described as randomized, but details on
method of randomization are not reported
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is described as double-blind, however details
on who was masked to the treatment are not reported.
It is stated that treatments were numbered and similar
in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is stated that nurses counted the daily number of
episodes of emesis. It is unclear whether the nurses were
masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No-one withdrew from the study.
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Insufficient reporting to determine the presence of other
forms of bias
Yost 2003
Methods Randomized controlled trial.
Participants Women at less than 20 weeks’ gestation with HG, and who had not responded to outpa-
tient therapy and who had 3+ or 4+ dipstick urinary ketones (evidence of dehydration).
64 women randomized to interventions and 62 to controls
Interventions Methylprednisolone 125 mg IV, followed by a tapering regimen of oral prednisone (40
mg for 1 day, 20 mg for 3 days, 10 mg for 3 days, and 5 mg for 7 days)
Standard of care also included IV fluids, metoclopramide, and promethazine versus
placebo IV followed by oral placebo tablets (tapering regimen)
Standard of care also included IV fluids, metoclopramide, and promethazine
Outcomes Number of ER visits, hospital readmission, number of hospital admissions, hospital
length of stay, total hospital days for all admissions in pregnancy, pregnancy outcomes
(SAB, gestational diabetes, pregnancy hypertension, preterm delivery < 26 weeks, ce-
sarean delivery), neonatal outcomes (gender, anomalies, birthweight, IUGR, stillbirth,
neonatal death)
Notes Study was under powered to detect a difference between groups
Risk of bias
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Yost 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It is stated that randomization was performed by com-
puter-generated blocks of 20
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation are not
available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Women were reported to be blinded and the interven-
tion and placebo were identical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
was masked to the treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk A similar number of women, < 15%, was lost to follow-
up in each group, accompanying reasons are reported
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Based on the reported power calculations, the study may
have been underpowered to identify a statistically signif-
icant difference, unclear what effect this may have had.
Insufficient reporting to determine presence of other
forms of bias
Ziaei 2004
Methods Randomized controlled trial.
Participants Women at between 6 and 12 weeks’ gestation and vomiting more than 3 times per day
during the last 72 hours or ketonuria that did not respond to dietary manipulation and
caused weight loss. 39 women randomized to interventions and 39 to controls
Interventions Prednisolone 5 mg/day orally in the morning for 10 days versus promethazine 25 mg 3
times daily (oral) for 10 days
Outcomes Severity of nausea (VAS 10-point scale), number of vomiting episodes per day, response
to treatment, adverse effects (abdominal pain, drowsiness). Participants were also asked
to rate how ill they felt (became completely or partially well, no change or became worse)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Ziaei 2004 (Continued)
Random sequence generation (selection
bias)
Low risk It is stated that randomization was carried out using a
random number table
Allocation concealment (selection bias) Unclear risk Details on methods used to conceal allocation not avail-
able.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is stated that themain investigators did not which par-
ticipants were placed in each group. It is unclear whether
the participants were masked to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the personnel assessing outcomes
was masked to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of women lost to follow-up was low, and
accompanying reasons are reported. The proportion of
women lost to follow-up was similar in each group, 1/
40 women in each group were lost to follow-up on the
17th day
Selective reporting (reporting bias) Low risk Although the protocol for the trial is not available, ex-
pected clinical outcomes are reported
Other bias Unclear risk Based on the reported power calculations, the study may
have been underpowered to identify a statistically signif-
icant difference, unclear what effect this may have had.
Insufficient reporting to determine presence of other
forms of bias
ACTH: adrenocorticotropic hormone
CGI: clinical global improvement
ER: emergency room
HG: hyperemesis gravidarum
ICU: intensive care unit
IM: intramuscular
IUFD: intrauterine fetal demise
IUGR: intrauterine growth restriction
IV: intravenous
OPD: outpatient department
PO: oral administration
PTD: preterm delivery
PUQE: pregnancy-unique quantification of emesis and nausea
SAB: spontaneous abortion
SF-36v2: Short form 36, version 2
TAB: therapeutic/elective abortion
TPN: total parenteral nutrition
VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adamczak 2007 Not a study on hyperemesis gravidarum.
Carlsson 2000 Cross-over design.
Dehkordi 2013 Study excluded participants with severe nausea and vomiting, not a study on hyperemesis gravidarum
Erez 1971 Not a study on hyperemesis gravidarum.
Ferruti 1982 Not a study on hyperemesis gravidarum.
Fischer-Rasmussen 1991 Cross-over design.
Ghahiri 2011 Not randomized. Not a study on hyperemesis gravidarum.
Gordon 2013 Letter to editor, not a study.
Kadan 2009 Cross-over design. Not a study on hyperemesis gravidarum.
Koren 2006 Study on pre-emptive treatment or prophylaxis, not for treatment of diagnosed hyperemesis gravidarum
Koren 2010 Not a study on hyperemesis gravidarum.
Koren 2013 Study on pre-emptive treatment or prophylaxis, not for treatment of diagnosed hyperemesis gravidarum
Koren 2015 Not a study specifically on hyperemesis gravidarum.
Lask 1953 Not clearly a study on hyperemesis gravidarum.
Ling 1994 Quasi-randomized.
Liu 1994 Not clear whether study was randomized or quasi-randomized
Madegard-Linh 2004 Cross-over design.
Magee 1996 Case report, not randomized controlled trial
Maina 2012 Cross-over design.
Maina 2014 Cross-over design.
Maltepe 2012 Study on pre-emptive treatment or prophylaxis, not for treatment of diagnosed hyperemesis gravidarum
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(Continued)
Matok 2013 Not a randomized controlled trial
Matok 2014 Not a randomized controlled trial
McCarthy 2014b Not a study on hyperemesis gravidarum.
Nguyen 2008 Not a study on hyperemesis gravidarum.
Oliveira 2014 Not a study on hyperemesis gravidarum.
Ozgoli 2009 Not a study on hyperemesis gravidarum.
Ozgoli 2011 Not a study on hyperemesis gravidarum.
Price 1964 Not a study on hyperemesis gravidarum.
Rad 2010 Not a study on hyperemesis gravidarum.
Rosen 2003 Not a study on hyperemesis gravidarum.
Shin 2005 Quasi-randomized.
Weiner 1990 Letter, not a trial.
Wibowo 2012 Not a study on hyperemesis gravidarum.
Willetts 2003 Not a study on hyperemesis gravidarum.
Characteristics of studies awaiting assessment [ordered by study ID]
Eftekhari 2013
Methods Randomized controlled trial
Participants Pregnant women under 20 weeks gestation diagnosed with hyperemesis gravidarum
Interventions Ondansetron and promethazine.
Outcomes Treatment response and side effects, further details of outcomes not able to be determined
Notes Full translation not available.
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He 2009
Methods
Participants
Interventions
Outcomes
Notes Translation not available.
Characteristics of ongoing studies [ordered by study ID]
Cyna 2008
Trial name or title Hypnosis for nausea and vomiting in early pregnancy: a randomized controlled trial
Methods Randomized controlled trial.
Participants Pregnant women suffering from nausea and vomiting of pregnancy
Interventions Usual care (supportive and pharmacological medication and/or intravenous fluids as required) plus audio CD
on hypnosis lasting 1/2 hour for 7 consecutive days versus usual care
Outcomes Suffering associated with nausea and vomiting as measured by a 5-point Likert scale, incidence of nausea in
previous 24 hours, incidence of vomiting in previous 24 hours, anxiety as measured by Spielberger, number
of days off work
Starting date February 2007.
Contact information Dr. A. M. Cyna: allan.cyna@cywhs.sa.gov.au
Notes Still recruiting, results not yet published, authors contacted for further information
Guttuso 2014
Trial name or title Comparison of gabapentin and metoclopramide for treating hyperemesis gravidarum
Methods Randomized controlled trial.
Participants Women 18years or older at less than 16 weeks gestation who have required at least 2 administrations of IV
hydration 1 week apart, or daily emesis for the last 14 days and 1 administration of IV hydration, with at
least 1 of the following: 3-4+ ketonuria, serum potassium < 3.4 mmol, or > 5% weight loss from initial
antenatal weight, having failed therapy with at least 1 antiemetic, excluding other medical problems that
could contribute to symptoms, with a PUQE score of >=12 for the 24-hour baseline
Interventions Gapabentin versus metoclopramide.
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Guttuso 2014 (Continued)
Outcomes Mean per cent change from baseline to study endpoint in daily PUQE score. Mean per cent change from
baseline to study endpoint in individual PUQE score, daily oral nutrition scores, days of hospital admission,
NVPQOLquestionnaire, and relief score; need for repeat IV hydration or hospital admission for hyperemesis;
per cent of participants choosing to continue with experimental therapy, per cent of participants downgrading
from an answer of 3-5 at Baseline to 1-2 at study endpoint, maternal side effects and pregnancy outcomes,
mean per cent change in laboratory values, mean per cent change from baseline to days 26-28 in daily PUQE
and NVPQOL scores, mean satisfaction questionnaire scores day 28, per cent of participants downgrading
from an answer of 3-5 at baseline to 1-2 at day 28 on the HGPTC questionnaire
Starting date June 2014.
Contact information Thomas Guttuso, Jr MD: tguttuso@buffalo.edu
Notes Currently recruiting.
Koren 2014
Trial name or title A multicenter trial of the efficacy and safety of Diclegis® for nausea and vomiting of pregnancy in pregnant
adolescents
Methods Randomized controlled trial.
Participants Pregnant women ages 12-17 between 7-14 weeks’ gestation suffering from nausea and vomiting of pregnancy
with a PUQE score >= 6
Interventions Diclegis 2 tablets at bedtime, increasing to 4 tablets as needed, for 14 days, versus placebo
Outcomes Nausea and vomiting of pregnancy severity from baseline to day 15 using PUQE score and Global Assessment
of Well-being scores, severity and occurrences of maternal adverse events
Starting date February 2014.
Contact information Gideon Koren,MD- Hospital for Sick Children, 555 University Avenue, Toronto ON Canada, M5G-1X8
Notes Currently recruiting.
Mehrolhasani 2012
Trial name or title Comparison of Demitron and promethazine in treatment of hyperemesis gravidarum
Methods Randomized controlled trial.
Participants Pregnant women with gestation of 20 weeks or less, suffering from dehydration due to nausea and vomiting
Interventions Demitron 8 mg intramuscular every eight hours for 48 hours versus promethazine 25 mg intramuscular every
eight hours for 48 hours
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Mehrolhasani 2012 (Continued)
Outcomes Nausea and vomiting at 48 hours determined by a questionnaire, adverse drug reactions
Starting date April 2011.
Contact information Yasamin Mehrolhasani(MD)- yasamin m@yahoo.com
Notes Recruitment completed, authors contacted for results.
Mitchell-Jones 2014
Trial name or title Hyperemesis in Pregnancy (HIP)Trial: Inpatient versus outpatientmanagement of severe nausea and vomiting
in pregnancy
Methods Randomized controlled trial.
Participants Pregnant women < 20 weeks gestation with symptoms of hyperemesis gravidarum and at least 1+ ketonuria,
excluding women with another medical condition that may induce nausea and vomiting, diabetes. Potassium
< 3.2, sodium < 130, or abnormal liver or thyroid function tests
Interventions Rapid outpatient rehydration versus inpatient standard care.
Outcomes Daily PUQE score, eating and drinking score, well-being score, weight, and blood test results, repeat atten-
dance and admissions, weight change at 7 days, number of days of IV fluids needed, number of women still
taking antiemetics 1 week after discharge, costs of treatment
Starting date 1/3/2014
Contact information Nicola Mitchell-Jones
Chelsea and Westminster Hospital
369 Fulham Road
London
SW10 9NH
United Kingdom
nicola.mitchell-jones@chelwest.nhs.uk
Notes Currently recruiting.
HG: hyperemesis gravidarum
HGPTC: Hyperemesis Gravidarum Pregnancy Termination Consideration
IV: intravenous
NVPQOL: Health-Related Quality of Life for Nausea and Vomiting during Pregnancy
PUQE: pregnancy-unique quantification of emesis and nausea
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D A T A A N D A N A L Y S E S
Comparison 1. Acupuncture and acupressure vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of women requiring
additional antiemetics
1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.08, 0.50]
2 Spontaneous abortion 1 57 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.05, 5.03]
3 Preterm birth less than 37 weeks 1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.01, 2.26]
4 Stillbirth and neonatal death 1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.04, 8.30]
5 Decision to terminate the
pregnancy
1 57 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.18, 2.95]
6 Quality of life: anxiodepressive
symptomatology
1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.73, 1.40]
Comparison 2. Acupuncture vs metoclopramide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction or cessation in nausea 1 81 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.79, 2.49]
2 Reduction or cessation in
vomiting
1 81 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.92, 2.48]
Comparison 3. Acupunture vs Western medicine (Phenobarbital)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete recovery 1 60 Risk Ratio (M-H, Fixed, 95% CI) 6.75 [2.69, 16.94]
2 Obvious effects 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.07, 1.52]
3 Effects showed 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.98]
4 Ineffective 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.44]
5 Total effective rate 1 60 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [1.40, 3.05]
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Comparison 4. Acupunture vs Chinese medicine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete recovery 1 60 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [3.06, 26.51]
2 Obvious effects 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.05, 0.84]
3 Effects showed 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.57]
4 Ineffective 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.60]
5 Total effective rate 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.19, 2.17]
Comparison 5. Chinese medicine vs Western medicine (Phenobarbital)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete recovery 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.18, 3.07]
2 Obvious effects 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.69, 4.00]
3 Effects showed 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.37, 4.21]
4 Ineffective 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.43, 1.30]
5 Total effective rate 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.79, 2.08]
Comparison 6. Muscle relaxation and pharmacotherapy vs only pharmacotherapy alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical Global Improvement
score
1 30 Mean Difference (IV, Fixed, 95% CI) -0.54 [-1.04, -0.04]
Comparison 7. Midwife-led outpatient care vs routine care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PUQE 1 31 Mean Difference (IV, Fixed, 95% CI) -0.70 [-3.17, 1.77]
2 Hours of hospital admission 1 53 Mean Difference (IV, Fixed, 95% CI) -33.2 [-46.91, -19.
49]
3 Decision to terminate the
pregnancy
1 53 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [0.12, 67.96]
4 Spontaneous miscarriage 1 53 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.15, 6.34]
5 Small for gestational age 1 53 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.26, 7.96]
6 Economic cost 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.28, 3.87]
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Comparison 8. Holistic assessment with standard care vs standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PUQE 1 200 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.10, 0.70]
2 Quality of life: social functioning 1 198 Mean Difference (IV, Fixed, 95% CI) 2.0 [-6.70, 10.70]
3 Quality of life: client satisfaction 1 189 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.90, 0.90]
Comparison 9. Dextrose saline vs normal saline rehydration
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hours of hospital admission 1 203 Mean Difference (IV, Fixed, 95% CI) -5.0 [-10.78, 0.78]
Comparison 10. Pyridoxine vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of episodes of emesis 1 66 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.40, 1.40]
2 Days of hospital admission 1 92 Mean Difference (IV, Fixed, 95% CI) 0.80 [0.08, 1.52]
3 Hospital readmission 1 78 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [0.85, 3.71]
4 Weight change (kg) 1 52 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.93, 0.93]
5 Interventions side effects:
dizziness
1 66 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.85, 3.26]
6 Interventions side effects:
headaches
1 66 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.52, 3.42]
7 Interventions side effects:
diarrhea
1 66 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 71.07]
8 Interventions side effects:
palpitations
1 66 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.22, 4.60]
9 Interventions side effects: dry
mouth
1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.49, 1.38]
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Comparison 11. Metoclopramide vs ondansetron
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severity of nausea 1 83 Mean Difference (IV, Fixed, 95% CI) 1.70 [-0.15, 3.55]
2 Severity of vomiting 1 83 Mean Difference (IV, Fixed, 95% CI) -0.10 [-1.63, 1.43]
3 Intervention side effects: felt
drowsy
1 160 Risk Ratio (M-H, Fixed, 95% CI) 2.4 [1.23, 4.69]
4 Intervention side effects: dry
mouth
1 160 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [1.10, 5.11]
5 Intervention side effects: unable
to sleep
1 160 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.50, 3.28]
6 Intervention side effects: felt
dizzy
1 160 Risk Ratio (M-H, Fixed, 95% CI) 2.33 [0.94, 5.77]
7 Intervention side effects: diarrhea 1 160 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [0.49, 164.46]
8 Intervention side effects:
headache
1 160 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.54, 2.79]
9 Intervention side effects:
palpitations
1 160 Risk Ratio (M-H, Fixed, 95% CI) 2.5 [0.50, 12.51]
10 Intervention side effects: skin
rash
1 160 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 15.71]
11 Intervention side effects:
dystonia
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Quality of life 1 160 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.83, 0.03]
Comparison 12. Hydrocortisone vs metoclopramide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospital readmission 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.00, 1.28]
2 Need for enteral or parenteral
nutrition
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.72]
Comparison 13. Metoclopramide vs promethazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life 1 149 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.22, 1.22]
2 Intervention side effects: unable
to sleep
1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.40, 1.53]
3 Intervention side effects: dry
mouth
1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.62, 1.34]
4 Intervention side effects: diarrhea 1 143 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.32, 5.99]
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5 Intervention side effects:
headache
1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.47, 1.38]
6 Intervention side effects:
palpitations
1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.25, 1.46]
7 Intervention side effects: skin
rash
1 143 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.32, 5.99]
8 Intervention side effects: drowsy 1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.56, 0.87]
9 Intervention side effects: felt
dizzy
1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.34, 0.69]
10 Intervention side effects:
dystonia
1 146 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.11, 0.90]
Comparison 14. Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Days of hospital admission 1 50 Mean Difference (IV, Fixed, 95% CI) -1.10 [-2.07, -0.13]
2 Hospital readmission 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.29]
3 Women requiring additional
antiemetics
1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.17]
4 Congenital anomalies 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Preterm birth 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.17]
6 Decision to terminate the
pregnancy
1 50 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 70.30]
Comparison 15. Ondansetron vs promethazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Days of hospital admission 1 30 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.39, 1.39]
2 Intervention side effect: sedation 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 0.94]
Comparison 16. Corticosteroids vs promethazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe nausea 48 hours 1 80 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [1.08, 3.72]
2 Severe nausea 17th day 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.58, 1.15]
3 Episodes of vomiting 48 hours 1 80 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.33, 27.63]
4 Episodes of vomiting 17th day 1 78 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.21, 4.65]
5 Therapy failure in 2 days 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.28, 8.04]
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6 Hospital readmission 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.53]
7 Number of women requiring
additional antiemetics
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.28, 8.04]
8 Stillbirth and neonatal death 1 40 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.52]
9 Preterm birth 1 40 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.52]
10 Decision to terminate the
pregnancy
1 40 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.52]
11 Intevention side effects:
abdominal pain 48 hours
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.07, 1.55]
12 Intervention side effects:
abdominal pain 3-10 days
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.00]
13 Intervention side effects:
drowsiness 48 hours and 3-10
days
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.00, 1.32]
14 Became completely or partially
well 48 hours
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.47, 0.95]
15 Became completely or partially
well 17th day
1 78 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.95, 2.92]
Comparison 17. Corticosteroids vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Days of hospital admission 1 110 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.70, 0.10]
2 Hospital readmission 4 269 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.50, 0.94]
3 Pregnancy complications 1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.26, 1.47]
4 Spontaneous abortion 1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.11, 3.70]
5 Stillbirth and neonatal death 2 134 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.15, 3.34]
6 Congenital abnormalities 1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.73]
7 Low birthweight 1 110 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.46, 4.00]
8 Small-for-gestational age 1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.21]
9 Preterm birth 2 134 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.31, 3.28]
10 Intervention side effects 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.06, 11.20]
11 Women requiring additional
antiemetic drugs
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.26, 1.17]
12 Decision to terminate the
pregnancy
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.45]
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Comparison 18. ACTH vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction or cessation in
nausea/vomiting
1 32 Mean Difference (IV, Fixed, 95% CI) 0.60 [-1.65, 2.85]
2 Weight gain (kg) 1 32 Mean Difference (IV, Fixed, 95% CI) 1.0 [0.34, 1.66]
3 Hospital readmission 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.16, 6.25]
4 Spontaneous abortion 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.64]
5 Preterm birth 1 32 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.57]
Analysis 1.1. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 1 Number of women
requiring additional antiemetics.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 1 Number of women requiring additional antiemetics
Study or subgroup
AP or APr
stimulation Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Habek 2004 4/21 14/15 100.0 % 0.20 [ 0.08, 0.50 ]
Total (95% CI) 21 15 100.0 % 0.20 [ 0.08, 0.50 ]
Total events: 4 (AP or APr stimulation), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.49 (P = 0.00048)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours AP or APr stim Favours placebo
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Analysis 1.2. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 2 Spontaneous abortion.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 2 Spontaneous abortion
Study or subgroup
AP or APr
stimulation Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2006 1/29 2/28 100.0 % 0.48 [ 0.05, 5.03 ]
Total (95% CI) 29 28 100.0 % 0.48 [ 0.05, 5.03 ]
Total events: 1 (AP or APr stimulation), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours AP or APr stim Favours placebo
Analysis 1.3. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 3 Preterm birth less than
37 weeks.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 3 Preterm birth less than 37 weeks
Study or subgroup
AP or APr
stimulation Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2006 0/23 2/13 100.0 % 0.12 [ 0.01, 2.26 ]
Total (95% CI) 23 13 100.0 % 0.12 [ 0.01, 2.26 ]
Total events: 0 (AP or APr stimulation), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours AP or APr stim Favours placebo
92Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 4 Stillbirth and neonatal
death.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 4 Stillbirth and neonatal death
Study or subgroup
AP or APr
stimulation Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2006 1/23 1/13 100.0 % 0.57 [ 0.04, 8.30 ]
Total (95% CI) 23 13 100.0 % 0.57 [ 0.04, 8.30 ]
Total events: 1 (AP or APr stimulation), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours AP or APr stim Favours placebo
Analysis 1.5. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 5 Decision to terminate the
pregnancy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 5 Decision to terminate the pregnancy
Study or subgroup
AP or APr
stimulation Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2006 3/29 4/28 100.0 % 0.72 [ 0.18, 2.95 ]
Total (95% CI) 29 28 100.0 % 0.72 [ 0.18, 2.95 ]
Total events: 3 (AP or APr stimulation), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours AP or APr stim Favours placebo
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Analysis 1.6. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 6 Quality of life:
anxiodepressive symptomatology.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 6 Quality of life: anxiodepressive symptomatology
Study or subgroup
AP or APr
stimulation Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Habek 2004 17/21 12/15 100.0 % 1.01 [ 0.73, 1.40 ]
Total (95% CI) 21 15 100.0 % 1.01 [ 0.73, 1.40 ]
Total events: 17 (AP or APr stimulation), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours AP or APr stim Favours placebo
Analysis 2.1. Comparison 2 Acupuncture vs metoclopramide, Outcome 1 Reduction or cessation in nausea.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 2 Acupuncture vs metoclopramide
Outcome: 1 Reduction or cessation in nausea
Study or subgroup Acupuncture Metoclopramide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Neri 2005 19/43 12/38 100.0 % 1.40 [ 0.79, 2.49 ]
Total (95% CI) 43 38 100.0 % 1.40 [ 0.79, 2.49 ]
Total events: 19 (Acupuncture), 12 (Metoclopramide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Metoclopramide Favours Acupuncture
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Analysis 2.2. Comparison 2 Acupuncture vs metoclopramide, Outcome 2 Reduction or cessation in
vomiting.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 2 Acupuncture vs metoclopramide
Outcome: 2 Reduction or cessation in vomiting
Study or subgroup Acupuncture Metoclopramide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Neri 2005 24/43 14/38 100.0 % 1.51 [ 0.92, 2.48 ]
Total (95% CI) 43 38 100.0 % 1.51 [ 0.92, 2.48 ]
Total events: 24 (Acupuncture), 14 (Metoclopramide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Metoclopramide Favours Acupuncture
Analysis 3.1. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 1 Complete
recovery.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 1 Complete recovery
Study or subgroup Acupunture Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 27/30 4/30 100.0 % 6.75 [ 2.69, 16.94 ]
Total (95% CI) 30 30 100.0 % 6.75 [ 2.69, 16.94 ]
Total events: 27 (Acupunture), 4 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 4.07 (P = 0.000047)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favors Phenobarbital Favours Acupuncture
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Analysis 3.2. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 2 Obvious effects.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 2 Obvious effects
Study or subgroup Acupunture Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 2/30 6/30 100.0 % 0.33 [ 0.07, 1.52 ]
Total (95% CI) 30 30 100.0 % 0.33 [ 0.07, 1.52 ]
Total events: 2 (Acupunture), 6 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Acupunture Favours Phenobarbital
Analysis 3.3. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 3 Effects showed.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 3 Effects showed
Study or subgroup Acupunture Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 0/30 4/30 100.0 % 0.11 [ 0.01, 1.98 ]
Total (95% CI) 30 30 100.0 % 0.11 [ 0.01, 1.98 ]
Total events: 0 (Acupunture), 4 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Acupunture Favours Phenobarbital
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Analysis 3.4. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 4 Ineffective.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 4 Ineffective
Study or subgroup Acupunture Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 1/30 16/30 100.0 % 0.06 [ 0.01, 0.44 ]
Total (95% CI) 30 30 100.0 % 0.06 [ 0.01, 0.44 ]
Total events: 1 (Acupunture), 16 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 2.78 (P = 0.0055)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Acupunture Favours Phenobarbital
Analysis 3.5. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 5 Total effective
rate.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 5 Total effective rate
Study or subgroup Acupunture Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 29/30 14/30 100.0 % 2.07 [ 1.40, 3.05 ]
Total (95% CI) 30 30 100.0 % 2.07 [ 1.40, 3.05 ]
Total events: 29 (Acupunture), 14 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00024)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Phenobarbital Favours Acupuncture
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Analysis 4.1. Comparison 4 Acupunture vs Chinese medicine, Outcome 1 Complete recovery.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 4 Acupunture vs Chinese medicine
Outcome: 1 Complete recovery
Study or subgroup Acupunture Chinese Medicine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 27/30 3/30 100.0 % 9.00 [ 3.06, 26.51 ]
Total (95% CI) 30 30 100.0 % 9.00 [ 3.06, 26.51 ]
Total events: 27 (Acupunture), 3 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.99 (P = 0.000067)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Chinese Medicine Favours Acupuncture
Analysis 4.2. Comparison 4 Acupunture vs Chinese medicine, Outcome 2 Obvious effects.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 4 Acupunture vs Chinese medicine
Outcome: 2 Obvious effects
Study or subgroup Acupunture Chinese Medicine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 2/30 10/30 100.0 % 0.20 [ 0.05, 0.84 ]
Total (95% CI) 30 30 100.0 % 0.20 [ 0.05, 0.84 ]
Total events: 2 (Acupunture), 10 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Acupunture Favours Chinese Medicine
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Analysis 4.3. Comparison 4 Acupunture vs Chinese medicine, Outcome 3 Effects showed.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 4 Acupunture vs Chinese medicine
Outcome: 3 Effects showed
Study or subgroup Acupunture Chinese Medicine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 0/30 5/30 100.0 % 0.09 [ 0.01, 1.57 ]
Total (95% CI) 30 30 100.0 % 0.09 [ 0.01, 1.57 ]
Total events: 0 (Acupunture), 5 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Acupuncture Favours Chinese Medicine
Analysis 4.4. Comparison 4 Acupunture vs Chinese medicine, Outcome 4 Ineffective.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 4 Acupunture vs Chinese medicine
Outcome: 4 Ineffective
Study or subgroup Acupunture Chinese Medicine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 1/30 12/30 100.0 % 0.08 [ 0.01, 0.60 ]
Total (95% CI) 30 30 100.0 % 0.08 [ 0.01, 0.60 ]
Total events: 1 (Acupunture), 12 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Acupunture Favours Chinese Medicine
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Analysis 4.5. Comparison 4 Acupunture vs Chinese medicine, Outcome 5 Total effective rate.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 4 Acupunture vs Chinese medicine
Outcome: 5 Total effective rate
Study or subgroup Acupunture Chinese Medicine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 29/30 18/30 100.0 % 1.61 [ 1.19, 2.17 ]
Total (95% CI) 30 30 100.0 % 1.61 [ 1.19, 2.17 ]
Total events: 29 (Acupunture), 18 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Chinese Medicine Favours Acupuncture
Analysis 5.1. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 1 Complete
recovery.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 1 Complete recovery
Study or subgroup Chinese Medicine Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 3/30 4/30 100.0 % 0.75 [ 0.18, 3.07 ]
Total (95% CI) 30 30 100.0 % 0.75 [ 0.18, 3.07 ]
Total events: 3 (Chinese Medicine), 4 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Phenobarbital Favours Chinese Medicine
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Analysis 5.2. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 2 Obvious
effects.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 2 Obvious effects
Study or subgroup Chinese Medicine Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 10/30 6/30 100.0 % 1.67 [ 0.69, 4.00 ]
Total (95% CI) 30 30 100.0 % 1.67 [ 0.69, 4.00 ]
Total events: 10 (Chinese Medicine), 6 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Chinese Medicine Favours Phenobarbital
Analysis 5.3. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 3 Effects
showed.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 3 Effects showed
Study or subgroup Chinese Medicine Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 5/30 4/30 100.0 % 1.25 [ 0.37, 4.21 ]
Total (95% CI) 30 30 100.0 % 1.25 [ 0.37, 4.21 ]
Total events: 5 (Chinese Medicine), 4 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Chinese Medicine Favours Phenobarbital
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Analysis 5.4. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 4 Ineffective.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 4 Ineffective
Study or subgroup Chinese Medicine Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 12/30 16/30 100.0 % 0.75 [ 0.43, 1.30 ]
Total (95% CI) 30 30 100.0 % 0.75 [ 0.43, 1.30 ]
Total events: 12 (Chinese Medicine), 16 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Chinese Medicine Favours Phenobarbital
Analysis 5.5. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 5 Total
effective rate.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 5 Total effective rate
Study or subgroup Chinese Medicine Phenobarbital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mao 2010 18/30 14/30 100.0 % 1.29 [ 0.79, 2.08 ]
Total (95% CI) 30 30 100.0 % 1.29 [ 0.79, 2.08 ]
Total events: 18 (Chinese Medicine), 14 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Phenobarbital Favours Chinese Medicine
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Analysis 6.1. Comparison 6 Muscle relaxation and pharmacotherapy vs only pharmacotherapy alone,
Outcome 1 Clinical Global Improvement score.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 6 Muscle relaxation and pharmacotherapy vs only pharmacotherapy alone
Outcome: 1 Clinical Global Improvement score
Study or subgroup Muscle relaxation Pharmacotherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gawande 2011 15 1.46 (0.52) 15 2 (0.85) 100.0 % -0.54 [ -1.04, -0.04 ]
Total (95% CI) 15 15 100.0 % -0.54 [ -1.04, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Muscle relaxation Favours Pharmacotherapy
Analysis 7.1. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 1 PUQE.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 1 PUQE
Study or subgroup Midwife-led care Routine care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McParlin 2008 18 6.2 (2.3) 13 6.9 (4.1) 100.0 % -0.70 [ -3.17, 1.77 ]
Total (95% CI) 18 13 100.0 % -0.70 [ -3.17, 1.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours midwife-led care Favours routine care
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Analysis 7.2. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 2 Hours of hospital
admission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 2 Hours of hospital admission
Study or subgroup
Midwife-
led
outpatient Routine care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McParlin 2008 27 13.3 (26.8) 26 46.5 (24.1) 100.0 % -33.20 [ -46.91, -19.49 ]
Total (95% CI) 27 26 100.0 % -33.20 [ -46.91, -19.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.75 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours midwife-led care Favours routine care
Analysis 7.3. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 3 Decision to terminate
the pregnancy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 3 Decision to terminate the pregnancy
Study or subgroup Midwife-led care Routine care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McParlin 2008 1/27 0/26 100.0 % 2.89 [ 0.12, 67.96 ]
Total (95% CI) 27 26 100.0 % 2.89 [ 0.12, 67.96 ]
Total events: 1 (Midwife-led care), 0 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours midwife-led care Favours routine care
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Analysis 7.4. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 4 Spontaneous
miscarriage.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 4 Spontaneous miscarriage
Study or subgroup Midwife-led care Routine care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McParlin 2008 2/27 2/26 100.0 % 0.96 [ 0.15, 6.34 ]
Total (95% CI) 27 26 100.0 % 0.96 [ 0.15, 6.34 ]
Total events: 2 (Midwife-led care), 2 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Midwife-led care Favours Routine care
Analysis 7.5. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 5 Small for gestational
age.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 5 Small for gestational age
Study or subgroup Midwife-led care Routine care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McParlin 2008 3/27 2/26 100.0 % 1.44 [ 0.26, 7.96 ]
Total (95% CI) 27 26 100.0 % 1.44 [ 0.26, 7.96 ]
Total events: 3 (Midwife-led care), 2 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 6 Economic cost.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 6 Economic cost
Study or subgroup Midwife-led care Routine care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McParlin 2008 3/13 4/18 100.0 % 1.04 [ 0.28, 3.87 ]
Total (95% CI) 13 18 100.0 % 1.04 [ 0.28, 3.87 ]
Total events: 3 (Midwife-led care), 4 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Holistic assessment with standard care vs standard care, Outcome 1 PUQE.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 8 Holistic assessment with standard care vs standard care
Outcome: 1 PUQE
Study or subgroup Holistic assessment Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fletcher 2015 93 7.6 (3.2) 107 7.8 (3.3) 100.0 % -0.20 [ -1.10, 0.70 ]
Total (95% CI) 93 107 100.0 % -0.20 [ -1.10, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Holistic assessment with standard care vs standard care, Outcome 2 Quality of
life: social functioning.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 8 Holistic assessment with standard care vs standard care
Outcome: 2 Quality of life: social functioning
Study or subgroup Holistic assessment Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fletcher 2015 93 34.7 (30.8) 105 32.7 (31.6) 100.0 % 2.00 [ -6.70, 10.70 ]
Total (95% CI) 93 105 100.0 % 2.00 [ -6.70, 10.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Holistic assessment with standard care vs standard care, Outcome 3 Quality of
life: client satisfaction.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 8 Holistic assessment with standard care vs standard care
Outcome: 3 Quality of life: client satisfaction
Study or subgroup Holistic Assessment Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fletcher 2015 88 25.3 (4.9) 101 25.8 (4.9) 100.0 % -0.50 [ -1.90, 0.90 ]
Total (95% CI) 88 101 100.0 % -0.50 [ -1.90, 0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Dextrose saline vs normal saline rehydration, Outcome 1 Hours of hospital
admission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 9 Dextrose saline vs normal saline rehydration
Outcome: 1 Hours of hospital admission
Study or subgroup Dextrose Saline Normal Saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tan 2013 102 43 (21) 101 48 (21) 100.0 % -5.00 [ -10.78, 0.78 ]
Total (95% CI) 102 101 100.0 % -5.00 [ -10.78, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours dextrose saline Favours normal saline
Analysis 10.1. Comparison 10 Pyridoxine vs placebo, Outcome 1 Number of episodes of emesis.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 1 Number of episodes of emesis
Study or subgroup Pyridoxine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tan 2009 33 1.9 (2.4) 33 1.4 (1.1) 100.0 % 0.50 [ -0.40, 1.40 ]
Total (95% CI) 33 33 100.0 % 0.50 [ -0.40, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Pyridoxine vs placebo, Outcome 2 Days of hospital admission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 2 Days of hospital admission
Study or subgroup Pyridoxine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tan 2009 47 3.9 (2.3) 45 3.1 (1) 100.0 % 0.80 [ 0.08, 1.52 ]
Total (95% CI) 47 45 100.0 % 0.80 [ 0.08, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Pyridoxine vs placebo, Outcome 3 Hospital readmission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 3 Hospital readmission
Study or subgroup Pyridoxine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2009 15/40 8/38 100.0 % 1.78 [ 0.85, 3.71 ]
Total (95% CI) 40 38 100.0 % 1.78 [ 0.85, 3.71 ]
Total events: 15 (Pyridoxine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 Pyridoxine vs placebo, Outcome 4 Weight change (kg).
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 4 Weight change (kg)
Study or subgroup Pyridoxine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tan 2009 27 -0.8 (1.9) 25 -0.8 (1.5) 100.0 % 0.0 [ -0.93, 0.93 ]
Total (95% CI) 27 25 100.0 % 0.0 [ -0.93, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 Pyridoxine vs placebo, Outcome 5 Interventions side effects: dizziness.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 5 Interventions side effects: dizziness
Study or subgroup Pyridoxine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2009 15/33 9/33 100.0 % 1.67 [ 0.85, 3.26 ]
Total (95% CI) 33 33 100.0 % 1.67 [ 0.85, 3.26 ]
Total events: 15 (Pyridoxine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 10.6. Comparison 10 Pyridoxine vs placebo, Outcome 6 Interventions side effects: headaches.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 6 Interventions side effects: headaches
Study or subgroup Pyridoxine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2009 8/33 6/33 100.0 % 1.33 [ 0.52, 3.42 ]
Total (95% CI) 33 33 100.0 % 1.33 [ 0.52, 3.42 ]
Total events: 8 (Pyridoxine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 10.7. Comparison 10 Pyridoxine vs placebo, Outcome 7 Interventions side effects: diarrhea.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 7 Interventions side effects: diarrhea
Study or subgroup Pyridoxine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2009 1/33 0/33 100.0 % 3.00 [ 0.13, 71.07 ]
Total (95% CI) 33 33 100.0 % 3.00 [ 0.13, 71.07 ]
Total events: 1 (Pyridoxine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 10.8. Comparison 10 Pyridoxine vs placebo, Outcome 8 Interventions side effects: palpitations.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 8 Interventions side effects: palpitations
Study or subgroup Pyridoxine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2009 3/33 3/33 100.0 % 1.00 [ 0.22, 4.60 ]
Total (95% CI) 33 33 100.0 % 1.00 [ 0.22, 4.60 ]
Total events: 3 (Pyridoxine), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 10.9. Comparison 10 Pyridoxine vs placebo, Outcome 9 Interventions side effects: dry mouth.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 10 Pyridoxine vs placebo
Outcome: 9 Interventions side effects: dry mouth
Study or subgroup Pyridoxine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2009 14/33 17/33 100.0 % 0.82 [ 0.49, 1.38 ]
Total (95% CI) 33 33 100.0 % 0.82 [ 0.49, 1.38 ]
Total events: 14 (Pyridoxine), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Metoclopramide vs ondansetron, Outcome 1 Severity of nausea.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 1 Severity of nausea
Study or subgroup Metoclopramide Ondansetron
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kashifard 2013 34 5.1 (3.4) 49 3.4 (5.2) 100.0 % 1.70 [ -0.15, 3.55 ]
Total (95% CI) 34 49 100.0 % 1.70 [ -0.15, 3.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours metoclopramide Favours ondansetron
Analysis 11.2. Comparison 11 Metoclopramide vs ondansetron, Outcome 2 Severity of vomiting.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 2 Severity of vomiting
Study or subgroup Metoclopramide Ondansetron
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kashifard 2013 34 4.7 (3.5) 49 4.8 (3.5) 100.0 % -0.10 [ -1.63, 1.43 ]
Total (95% CI) 34 49 100.0 % -0.10 [ -1.63, 1.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Metoclopramide vs ondansetron, Outcome 3 Intervention side effects: felt
drowsy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 3 Intervention side effects: felt drowsy
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 24/80 10/80 100.0 % 2.40 [ 1.23, 4.69 ]
Total (95% CI) 80 80 100.0 % 2.40 [ 1.23, 4.69 ]
Total events: 24 (Metoclopramide), 10 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Metoclopramide vs ondansetron, Outcome 4 Intervention side effects: dry
mouth.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 4 Intervention side effects: dry mouth
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 19/80 8/80 100.0 % 2.38 [ 1.10, 5.11 ]
Total (95% CI) 80 80 100.0 % 2.38 [ 1.10, 5.11 ]
Total events: 19 (Metoclopramide), 8 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 11.5. Comparison 11 Metoclopramide vs ondansetron, Outcome 5 Intervention side effects:
unable to sleep.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 5 Intervention side effects: unable to sleep
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 9/80 7/80 100.0 % 1.29 [ 0.50, 3.28 ]
Total (95% CI) 80 80 100.0 % 1.29 [ 0.50, 3.28 ]
Total events: 9 (Metoclopramide), 7 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 11.6. Comparison 11 Metoclopramide vs ondansetron, Outcome 6 Intervention side effects: felt
dizzy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 6 Intervention side effects: felt dizzy
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 14/80 6/80 100.0 % 2.33 [ 0.94, 5.77 ]
Total (95% CI) 80 80 100.0 % 2.33 [ 0.94, 5.77 ]
Total events: 14 (Metoclopramide), 6 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
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Analysis 11.7. Comparison 11 Metoclopramide vs ondansetron, Outcome 7 Intervention side effects:
diarrhea.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 7 Intervention side effects: diarrhea
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 4/80 0/80 100.0 % 9.00 [ 0.49, 164.46 ]
Total (95% CI) 80 80 100.0 % 9.00 [ 0.49, 164.46 ]
Total events: 4 (Metoclopramide), 0 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 11.8. Comparison 11 Metoclopramide vs ondansetron, Outcome 8 Intervention side effects:
headache.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 8 Intervention side effects: headache
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 11/80 9/80 100.0 % 1.22 [ 0.54, 2.79 ]
Total (95% CI) 80 80 100.0 % 1.22 [ 0.54, 2.79 ]
Total events: 11 (Metoclopramide), 9 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 11.9. Comparison 11 Metoclopramide vs ondansetron, Outcome 9 Intervention side effects:
palpitations.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 9 Intervention side effects: palpitations
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 5/80 2/80 100.0 % 2.50 [ 0.50, 12.51 ]
Total (95% CI) 80 80 100.0 % 2.50 [ 0.50, 12.51 ]
Total events: 5 (Metoclopramide), 2 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 11.10. Comparison 11 Metoclopramide vs ondansetron, Outcome 10 Intervention side effects: skin
rash.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 10 Intervention side effects: skin rash
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 1/80 1/80 100.0 % 1.00 [ 0.06, 15.71 ]
Total (95% CI) 80 80 100.0 % 1.00 [ 0.06, 15.71 ]
Total events: 1 (Metoclopramide), 1 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 11.11. Comparison 11 Metoclopramide vs ondansetron, Outcome 11 Intervention side effects:
dystonia.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 11 Intervention side effects: dystonia
Study or subgroup Metoclopramide Ondansetron Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abas 2014 0/80 0/80 Not estimable
Total (95% CI) 80 80 Not estimable
Total events: 0 (Metoclopramide), 0 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 11.12. Comparison 11 Metoclopramide vs ondansetron, Outcome 12 Quality of life.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 11 Metoclopramide vs ondansetron
Outcome: 12 Quality of life
Study or subgroup Metoclopramide Ondansetron
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abas 2014 80 8.3 (1.6) 80 8.7 (1.1) 100.0 % -0.40 [ -0.83, 0.03 ]
Total (95% CI) 80 80 100.0 % -0.40 [ -0.83, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Hydrocortisone vs metoclopramide, Outcome 1 Hospital readmission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 12 Hydrocortisone vs metoclopramide
Outcome: 1 Hospital readmission
Study or subgroup Hydrocortisone Metoclopramide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bondok 2006 0/20 6/20 100.0 % 0.08 [ 0.00, 1.28 ]
Total (95% CI) 20 20 100.0 % 0.08 [ 0.00, 1.28 ]
Total events: 0 (Hydrocortisone), 6 (Metoclopramide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Hydrocortisone vs metoclopramide, Outcome 2 Need for enteral or
parenteral nutrition.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 12 Hydrocortisone vs metoclopramide
Outcome: 2 Need for enteral or parenteral nutrition
Study or subgroup Hydrocortisone Metoclopramide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bondok 2006 0/20 1/20 100.0 % 0.33 [ 0.01, 7.72 ]
Total (95% CI) 20 20 100.0 % 0.33 [ 0.01, 7.72 ]
Total events: 0 (Hydrocortisone), 1 (Metoclopramide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 13.1. Comparison 13 Metoclopramide vs promethazine, Outcome 1 Quality of life.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 1 Quality of life
Study or subgroup Metoclopramide Promethazine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tan 2010 73 7.6 (2.2) 76 7.1 (2.3) 100.0 % 0.50 [ -0.22, 1.22 ]
Total (95% CI) 73 76 100.0 % 0.50 [ -0.22, 1.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 Metoclopramide vs promethazine, Outcome 2 Intervention side effects:
unable to sleep.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 2 Intervention side effects: unable to sleep
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 12/70 16/73 100.0 % 0.78 [ 0.40, 1.53 ]
Total (95% CI) 70 73 100.0 % 0.78 [ 0.40, 1.53 ]
Total events: 12 (Metoclopramide), 16 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Metoclopramide vs promethazine, Outcome 3 Intervention side effects: dry
mouth.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 3 Intervention side effects: dry mouth
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 28/70 32/73 100.0 % 0.91 [ 0.62, 1.34 ]
Total (95% CI) 70 73 100.0 % 0.91 [ 0.62, 1.34 ]
Total events: 28 (Metoclopramide), 32 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 Metoclopramide vs promethazine, Outcome 4 Intervention side effects:
diarrhea.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 4 Intervention side effects: diarrhea
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 4/70 3/73 100.0 % 1.39 [ 0.32, 5.99 ]
Total (95% CI) 70 73 100.0 % 1.39 [ 0.32, 5.99 ]
Total events: 4 (Metoclopramide), 3 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 13.5. Comparison 13 Metoclopramide vs promethazine, Outcome 5 Intervention side effects:
headache.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 5 Intervention side effects: headache
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 17/70 22/73 100.0 % 0.81 [ 0.47, 1.38 ]
Total (95% CI) 70 73 100.0 % 0.81 [ 0.47, 1.38 ]
Total events: 17 (Metoclopramide), 22 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 13.6. Comparison 13 Metoclopramide vs promethazine, Outcome 6 Intervention side effects:
palpitations.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 6 Intervention side effects: palpitations
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 7/70 12/73 100.0 % 0.61 [ 0.25, 1.46 ]
Total (95% CI) 70 73 100.0 % 0.61 [ 0.25, 1.46 ]
Total events: 7 (Metoclopramide), 12 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 13.7. Comparison 13 Metoclopramide vs promethazine, Outcome 7 Intervention side effects: skin
rash.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 7 Intervention side effects: skin rash
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 4/70 3/73 100.0 % 1.39 [ 0.32, 5.99 ]
Total (95% CI) 70 73 100.0 % 1.39 [ 0.32, 5.99 ]
Total events: 4 (Metoclopramide), 3 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 13.8. Comparison 13 Metoclopramide vs promethazine, Outcome 8 Intervention side effects:
drowsy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 8 Intervention side effects: drowsy
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 41/70 61/73 100.0 % 0.70 [ 0.56, 0.87 ]
Total (95% CI) 70 73 100.0 % 0.70 [ 0.56, 0.87 ]
Total events: 41 (Metoclopramide), 61 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
Test for subgroup differences: Not applicable
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Analysis 13.9. Comparison 13 Metoclopramide vs promethazine, Outcome 9 Intervention side effects: felt
dizzy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 9 Intervention side effects: felt dizzy
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 24/70 52/73 100.0 % 0.48 [ 0.34, 0.69 ]
Total (95% CI) 70 73 100.0 % 0.48 [ 0.34, 0.69 ]
Total events: 24 (Metoclopramide), 52 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 4.03 (P = 0.000056)
Test for subgroup differences: Not applicable
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Analysis 13.10. Comparison 13 Metoclopramide vs promethazine, Outcome 10 Intervention side effects:
dystonia.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 13 Metoclopramide vs promethazine
Outcome: 10 Intervention side effects: dystonia
Study or subgroup Metoclopramide Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tan 2010 4/70 14/76 100.0 % 0.31 [ 0.11, 0.90 ]
Total (95% CI) 70 76 100.0 % 0.31 [ 0.11, 0.90 ]
Total events: 4 (Metoclopramide), 14 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 1 Days of hospital admission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 1 Days of hospital admission
Study or subgroup
Parenteral
fluid+diazepam
Parenteral
fluid alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ditto 1999 25 4.5 (1.9) 25 5.6 (1.6) 100.0 % -1.10 [ -2.07, -0.13 ]
Total (95% CI) 25 25 100.0 % -1.10 [ -2.07, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 2 Hospital readmission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 2 Hospital readmission
Study or subgroup
Parenteral
fluid+diazepam
Parenteral
fluid alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ditto 1999 1/25 6/25 100.0 % 0.17 [ 0.02, 1.29 ]
Total (95% CI) 25 25 100.0 % 0.17 [ 0.02, 1.29 ]
Total events: 1 (Parenteral fluid+diazepam), 6 (Parenteral fluid alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 3 Women requiring additional antiemetics.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 3 Women requiring additional antiemetics
Study or subgroup
Parenteral
fluid+diazepam
Parenteral
fluid alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ditto 1999 1/25 2/25 100.0 % 0.50 [ 0.05, 5.17 ]
Total (95% CI) 25 25 100.0 % 0.50 [ 0.05, 5.17 ]
Total events: 1 (Parenteral fluid+diazepam), 2 (Parenteral fluid alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 14.4. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 4 Congenital anomalies.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 4 Congenital anomalies
Study or subgroup
Parenteral
fluid+diazepam
Parenteral
fluid alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ditto 1999 0/25 0/25 Not estimable
Total (95% CI) 25 25 Not estimable
Total events: 0 (Parenteral fluid+diazepam), 0 (Parenteral fluid alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 14.5. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 5 Preterm birth.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 5 Preterm birth
Study or subgroup
Parenteral
fluid+diazepam
Parenteral
fluid alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ditto 1999 1/25 2/25 100.0 % 0.50 [ 0.05, 5.17 ]
Total (95% CI) 25 25 100.0 % 0.50 [ 0.05, 5.17 ]
Total events: 1 (Parenteral fluid+diazepam), 2 (Parenteral fluid alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 14.6. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 6 Decision to terminate the pregnancy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 6 Decision to terminate the pregnancy
Study or subgroup
Parenteral
fluid+diazepam Parenteral fluid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ditto 1999 1/25 0/25 100.0 % 3.00 [ 0.13, 70.30 ]
Total (95% CI) 25 25 100.0 % 3.00 [ 0.13, 70.30 ]
Total events: 1 (Parenteral fluid+diazepam), 0 (Parenteral fluid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 15.1. Comparison 15 Ondansetron vs promethazine, Outcome 1 Days of hospital admission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 15 Ondansetron vs promethazine
Outcome: 1 Days of hospital admission
Study or subgroup Ondansetron Promethazine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sullivan 1996 15 4.47 (2.3) 15 4.47 (1.5) 100.0 % 0.0 [ -1.39, 1.39 ]
Total (95% CI) 15 15 100.0 % 0.0 [ -1.39, 1.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 Ondansetron vs promethazine, Outcome 2 Intervention side effect: sedation.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 15 Ondansetron vs promethazine
Outcome: 2 Intervention side effect: sedation
Study or subgroup Ondansetron Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sullivan 1996 0/15 8/15 100.0 % 0.06 [ 0.00, 0.94 ]
Total (95% CI) 15 15 100.0 % 0.06 [ 0.00, 0.94 ]
Total events: 0 (Ondansetron), 8 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 16.1. Comparison 16 Corticosteroids vs promethazine, Outcome 1 Severe nausea 48 hours.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 1 Severe nausea 48 hours
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 20/40 10/40 100.0 % 2.00 [ 1.08, 3.72 ]
Total (95% CI) 40 40 100.0 % 2.00 [ 1.08, 3.72 ]
Total events: 20 (Prednisolone), 10 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 16.2. Comparison 16 Corticosteroids vs promethazine, Outcome 2 Severe nausea 17th day.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 2 Severe nausea 17th day
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 22/39 27/39 100.0 % 0.81 [ 0.58, 1.15 ]
Total (95% CI) 39 39 100.0 % 0.81 [ 0.58, 1.15 ]
Total events: 22 (Prednisolone), 27 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 16.3. Comparison 16 Corticosteroids vs promethazine, Outcome 3 Episodes of vomiting 48 hours.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 3 Episodes of vomiting 48 hours
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 3/40 1/40 100.0 % 3.00 [ 0.33, 27.63 ]
Total (95% CI) 40 40 100.0 % 3.00 [ 0.33, 27.63 ]
Total events: 3 (Prednisolone), 1 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 16.4. Comparison 16 Corticosteroids vs promethazine, Outcome 4 Episodes of vomiting 17th day.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 4 Episodes of vomiting 17th day
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 3/39 3/39 100.0 % 1.00 [ 0.21, 4.65 ]
Total (95% CI) 39 39 100.0 % 1.00 [ 0.21, 4.65 ]
Total events: 3 (Prednisolone), 3 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 16.5. Comparison 16 Corticosteroids vs promethazine, Outcome 5 Therapy failure in 2 days.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 5 Therapy failure in 2 days
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Safari 1998 3/20 2/20 100.0 % 1.50 [ 0.28, 8.04 ]
Total (95% CI) 20 20 100.0 % 1.50 [ 0.28, 8.04 ]
Total events: 3 (Prednisolone), 2 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 16.6. Comparison 16 Corticosteroids vs promethazine, Outcome 6 Hospital readmission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 6 Hospital readmission
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Safari 1998 0/17 5/17 100.0 % 0.09 [ 0.01, 1.53 ]
Total (95% CI) 17 17 100.0 % 0.09 [ 0.01, 1.53 ]
Total events: 0 (Prednisolone), 5 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
Test for subgroup differences: Not applicable
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Analysis 16.7. Comparison 16 Corticosteroids vs promethazine, Outcome 7 Number of women requiring
additional antiemetics.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 7 Number of women requiring additional antiemetics
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Safari 1998 3/20 2/20 100.0 % 1.50 [ 0.28, 8.04 ]
Total (95% CI) 20 20 100.0 % 1.50 [ 0.28, 8.04 ]
Total events: 3 (Prednisolone), 2 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 16.8. Comparison 16 Corticosteroids vs promethazine, Outcome 8 Stillbirth and neonatal death.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 8 Stillbirth and neonatal death
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Safari 1998 1/20 0/20 100.0 % 3.00 [ 0.13, 69.52 ]
Total (95% CI) 20 20 100.0 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (Prednisolone), 0 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 16.9. Comparison 16 Corticosteroids vs promethazine, Outcome 9 Preterm birth.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 9 Preterm birth
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Safari 1998 1/20 0/20 100.0 % 3.00 [ 0.13, 69.52 ]
Total (95% CI) 20 20 100.0 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (Prednisolone), 0 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 16.10. Comparison 16 Corticosteroids vs promethazine, Outcome 10 Decision to terminate the
pregnancy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 10 Decision to terminate the pregnancy
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Safari 1998 1/20 0/20 100.0 % 3.00 [ 0.13, 69.52 ]
Total (95% CI) 20 20 100.0 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (Prednisolone), 0 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 16.11. Comparison 16 Corticosteroids vs promethazine, Outcome 11 Intevention side effects:
abdominal pain 48 hours.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 11 Intevention side effects: abdominal pain 48 hours
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 2/40 6/40 100.0 % 0.33 [ 0.07, 1.55 ]
Total (95% CI) 40 40 100.0 % 0.33 [ 0.07, 1.55 ]
Total events: 2 (Prednisolone), 6 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours prednisolone Favours promethazine
Analysis 16.12. Comparison 16 Corticosteroids vs promethazine, Outcome 12 Intervention side effects:
abdominal pain 3-10 days.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 12 Intervention side effects: abdominal pain 3-10 days
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 0/40 4/40 100.0 % 0.11 [ 0.01, 2.00 ]
Total (95% CI) 40 40 100.0 % 0.11 [ 0.01, 2.00 ]
Total events: 0 (Prednisolone), 4 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 16.13. Comparison 16 Corticosteroids vs promethazine, Outcome 13 Intervention side effects:
drowsiness 48 hours and 3-10 days.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 13 Intervention side effects: drowsiness 48 hours and 3-10 days
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 0/40 6/40 100.0 % 0.08 [ 0.00, 1.32 ]
Total (95% CI) 40 40 100.0 % 0.08 [ 0.00, 1.32 ]
Total events: 0 (Prednisolone), 6 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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Analysis 16.14. Comparison 16 Corticosteroids vs promethazine, Outcome 14 Became completely or
partially well 48 hours.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 14 Became completely or partially well 48 hours
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 20/40 30/40 100.0 % 0.67 [ 0.47, 0.95 ]
Total (95% CI) 40 40 100.0 % 0.67 [ 0.47, 0.95 ]
Total events: 20 (Prednisolone), 30 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 16.15. Comparison 16 Corticosteroids vs promethazine, Outcome 15 Became completely or
partially well 17th day.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 16 Corticosteroids vs promethazine
Outcome: 15 Became completely or partially well 17th day
Study or subgroup Prednisolone Promethazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ziaei 2004 20/39 12/39 100.0 % 1.67 [ 0.95, 2.92 ]
Total (95% CI) 39 39 100.0 % 1.67 [ 0.95, 2.92 ]
Total events: 20 (Prednisolone), 12 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
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Analysis 17.1. Comparison 17 Corticosteroids vs placebo, Outcome 1 Days of hospital admission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 1 Days of hospital admission
Study or subgroup Corticosteroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Yost 2003 56 1.9 (0.9) 54 2.2 (1.2) 100.0 % -0.30 [ -0.70, 0.10 ]
Total (95% CI) 56 54 100.0 % -0.30 [ -0.70, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 17.2. Comparison 17 Corticosteroids vs placebo, Outcome 2 Hospital readmission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 2 Hospital readmission
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson-Piercy 2001 5/12 8/12 13.7 % 0.63 [ 0.29, 1.36 ]
Duggar 2001 1/14 4/25 4.9 % 0.45 [ 0.06, 3.61 ]
Yost 2003 19/56 19/54 33.2 % 0.96 [ 0.58, 1.61 ]
Tabatabaii 2008 15/48 28/48 48.1 % 0.54 [ 0.33, 0.87 ]
Total (95% CI) 130 139 100.0 % 0.69 [ 0.50, 0.94 ]
Total events: 40 (Corticosteroids), 59 (Placebo)
Heterogeneity: Chi2 = 2.91, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours corticosteroids Favours placebo
Analysis 17.3. Comparison 17 Corticosteroids vs placebo, Outcome 3 Pregnancy complications.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 3 Pregnancy complications
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yost 2003 7/56 11/54 100.0 % 0.61 [ 0.26, 1.47 ]
Total (95% CI) 56 54 100.0 % 0.61 [ 0.26, 1.47 ]
Total events: 7 (Corticosteroids), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 17.4. Comparison 17 Corticosteroids vs placebo, Outcome 4 Spontaneous abortion.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 4 Spontaneous abortion
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yost 2003 2/56 3/54 100.0 % 0.64 [ 0.11, 3.70 ]
Total (95% CI) 56 54 100.0 % 0.64 [ 0.11, 3.70 ]
Total events: 2 (Corticosteroids), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 17.5. Comparison 17 Corticosteroids vs placebo, Outcome 5 Stillbirth and neonatal death.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 5 Stillbirth and neonatal death
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson-Piercy 2001 1/12 3/12 85.5 % 0.33 [ 0.04, 2.77 ]
Yost 2003 1/56 0/54 14.5 % 2.89 [ 0.12, 69.55 ]
Total (95% CI) 68 66 100.0 % 0.70 [ 0.15, 3.34 ]
Total events: 2 (Corticosteroids), 3 (Placebo)
Heterogeneity: Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 17.6. Comparison 17 Corticosteroids vs placebo, Outcome 6 Congenital abnormalities.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 6 Congenital abnormalities
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yost 2003 0/56 1/54 100.0 % 0.32 [ 0.01, 7.73 ]
Total (95% CI) 56 54 100.0 % 0.32 [ 0.01, 7.73 ]
Total events: 0 (Corticosteroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 17.7. Comparison 17 Corticosteroids vs placebo, Outcome 7 Low birthweight.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 7 Low birthweight
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yost 2003 7/56 5/54 100.0 % 1.35 [ 0.46, 4.00 ]
Total (95% CI) 56 54 100.0 % 1.35 [ 0.46, 4.00 ]
Total events: 7 (Corticosteroids), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours corticosteroids Favours placebo
Analysis 17.8. Comparison 17 Corticosteroids vs placebo, Outcome 8 Small-for-gestational age.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 8 Small-for-gestational age
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson-Piercy 2001 1/12 1/12 100.0 % 1.00 [ 0.07, 14.21 ]
Total (95% CI) 12 12 100.0 % 1.00 [ 0.07, 14.21 ]
Total events: 1 (Corticosteroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 17.9. Comparison 17 Corticosteroids vs placebo, Outcome 9 Preterm birth.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 9 Preterm birth
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nelson-Piercy 2001 2/12 4/12 42.4 % 0.50 [ 0.11, 2.23 ]
Yost 2003 7/56 4/54 57.6 % 1.69 [ 0.52, 5.44 ]
Total (95% CI) 68 66 100.0 % 1.01 [ 0.31, 3.28 ]
Total events: 9 (Corticosteroids), 8 (Placebo)
Heterogeneity: Tau2 = 0.27; Chi2 = 1.58, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 17.10. Comparison 17 Corticosteroids vs placebo, Outcome 10 Intervention side effects.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 10 Intervention side effects
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duggar 2001 1/14 1/11 100.0 % 0.79 [ 0.06, 11.20 ]
Total (95% CI) 14 11 100.0 % 0.79 [ 0.06, 11.20 ]
Total events: 1 (Corticosteroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 17.11. Comparison 17 Corticosteroids vs placebo, Outcome 11 Women requiring additional
antiemetic drugs.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 11 Women requiring additional antiemetic drugs
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson-Piercy 2001 5/12 9/12 100.0 % 0.56 [ 0.26, 1.17 ]
Total (95% CI) 12 12 100.0 % 0.56 [ 0.26, 1.17 ]
Total events: 5 (Corticosteroids), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 17.12. Comparison 17 Corticosteroids vs placebo, Outcome 12 Decision to terminate the
pregnancy.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 17 Corticosteroids vs placebo
Outcome: 12 Decision to terminate the pregnancy
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson-Piercy 2001 0/12 1/12 100.0 % 0.33 [ 0.01, 7.45 ]
Total (95% CI) 12 12 100.0 % 0.33 [ 0.01, 7.45 ]
Total events: 0 (Corticosteroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 18.1. Comparison 18 ACTH vs placebo, Outcome 1 Reduction or cessation in nausea/vomiting.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 18 ACTH vs placebo
Outcome: 1 Reduction or cessation in nausea/vomiting
Study or subgroup ACTH Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ylikorkala 1979 16 9.4 (3.4) 16 8.8 (3.1) 100.0 % 0.60 [ -1.65, 2.85 ]
Total (95% CI) 16 16 100.0 % 0.60 [ -1.65, 2.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 18.2. Comparison 18 ACTH vs placebo, Outcome 2 Weight gain (kg).
Review: Interventions for treating hyperemesis gravidarum
Comparison: 18 ACTH vs placebo
Outcome: 2 Weight gain (kg)
Study or subgroup ACTH Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ylikorkala 1979 16 2.5 (0.9) 16 1.5 (1) 100.0 % 1.00 [ 0.34, 1.66 ]
Total (95% CI) 16 16 100.0 % 1.00 [ 0.34, 1.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours ACTH
143Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 18.3. Comparison 18 ACTH vs placebo, Outcome 3 Hospital readmission.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 18 ACTH vs placebo
Outcome: 3 Hospital readmission
Study or subgroup ACTH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ylikorkala 1979 2/16 2/16 100.0 % 1.00 [ 0.16, 6.25 ]
Total (95% CI) 16 16 100.0 % 1.00 [ 0.16, 6.25 ]
Total events: 2 (ACTH), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 18.4. Comparison 18 ACTH vs placebo, Outcome 4 Spontaneous abortion.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 18 ACTH vs placebo
Outcome: 4 Spontaneous abortion
Study or subgroup ACTH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ylikorkala 1979 1/16 1/16 100.0 % 1.00 [ 0.07, 14.64 ]
Total (95% CI) 16 16 100.0 % 1.00 [ 0.07, 14.64 ]
Total events: 1 (ACTH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 18.5. Comparison 18 ACTH vs placebo, Outcome 5 Preterm birth.
Review: Interventions for treating hyperemesis gravidarum
Comparison: 18 ACTH vs placebo
Outcome: 5 Preterm birth
Study or subgroup ACTH Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ylikorkala 1979 1/16 0/16 100.0 % 3.00 [ 0.13, 68.57 ]
Total (95% CI) 16 16 100.0 % 3.00 [ 0.13, 68.57 ]
Total events: 1 (ACTH), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Cochrane Complementary and Alternative Therapies Field Register search
Searched by the Information Specialist (20 September 2014) and then via The Cochrane Register of Studies (CRSO) (20 December
2015)
(pregnan* OR antenatal OR prenatal) AND (nause* OR sickness OR vomit* OR emesis OR hyperemisis OR antiemetic)
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Rupsa C Boelig: contact person and guarantor of review, drafted initial protocol and final review, reviewed articles for inclusion,
conducted data extraction and quality analysis.
Vincenzo Berghella: helped to initiate this review, edited protocol, provided both methodological and clinical perspective.
Anthony J Kelly: helped to initiate this review, provided both methodological and clinical perspective, reviewed discrepancies in articles
of inclusion, data extraction, and quality analysis.
Steven J Edwards: provided methodological perspective.
Samantha J Barton: providedmethodological perspective, reviewed articles for inclusion, conducted data extraction and quality analysis.
Gabriele Saccone: conducted data analysis/meta-analysis and constructed accompanying figures and tables.
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Anthony J Kelly:none known.
Steve J Edwards: none known.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We edited one of our primary outcomes from ’Reduction or cessation in nausea/vomiting’ to ’Severity, reduction or cessation in nausea/
vomiting’ because it was found that this was often what was reported.
We edited one of our secondary outcomes from ’Number of antiemetics required’ to ’Number of women requiring additional antiemet-
ics,’ again because this outcome was more often reported than number of antiemetics.
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